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ABSTRACT 
 
Neuropeptides, as one largest category of cell-to-cell signaling molecules, play a 
regulatory role in a range of physiological and behavioral functions within an 
organism, such as reproduction, feeding, metabolism regulation, learning and memory. 
They act as neurotransmitters, neuromodulators, peptide hormones and trophic factors. 
They are differentially processed, modified, expressed and distributed, resulting in a 
wide range of chemical forms and quantities in different tissues and time points. 
Therefore, it is not an easy task to achieve a complete understanding of neuropeptides 
in the human brain. Fortunately, as there are a variety of well-conserved 
neurochemical pathways within simpler animal models, these studies can provide 
insights and address fundamental questions in the human brain. A number of model 
organisms that are commonly used in neuroscience have been explored. For example, 
the flatworm (Schmidtea mediterranea) provides understanding of regeneration and 
reproduction, while the comb jelly (Pleurobrachia pileus), as the earliest branching in 
extant animals, is an excellent model for investigating animal evolution.  
The ability to characterize peptides in a complex sample depends on the available 
of suitable tools. Mass spectrometry (MS), coupled to liquid chromatography (LC) 
and assisted by appropriate sampling protocols, has been successfully applied to 
unambiguously characterize neuropeptides and their post-translational modifications. 
No individual MS instrument and approach work well for a majority of samples. 
Therefore, we used multiple MS platforms with either electrospray ionization (ESI) or 
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matrix-assisted laser desorption/ionization (MALDI) and selected several instruments 
to study peptide of interest in different animal models. We used and optimized three 
distinct LC-MS-based approaches. One is a non-targeted approach, which integrates 
LC-MS with bioinformatics, and analyzes the complement of peptides (termed 
peptidomics), with sample sizes ranging from whole animals to single organs or 
tissues. Another is a targeted approach, which focuses on specific peptides that have 
been implicated in a defined physiological or behavioral function. The third is a 
quantitative approach that compares the difference of peptide levels between two 
samples arising from different behavioral stages, application of drugs or chemicals, 
and arising through gene knockouts.  
We used these approaches combined with molecular and genomic information to 
advance our knowledge of neuropeptides. More specifically, we characterized the 
peptidomes in the flatworm, the comb jelly and the sea slug, from samples ranging 
from whole animals to tissues; we sequenced the human insulin ectopically expressed 
in the fruit fly, and we detected a putative alarin peptide in the human cell line which 
requires further verification; we confirmed peptide level changes as a function of 
genetic manipulations in the mouse tissues. Our knowledge of neuropeptides 
throughout the Metazoa has been enhanced based on these results.  
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CHAPTER 1 
INTRODUCTION AND RESEARCH OVERVIEW 
 
1.1 Background 
A complete understanding of human brain is perhaps impossible. One way to 
make progress is to break this task into smaller and simplified pieces and analyze 
them individually, which are then combined together for a global picture. A joint 
effort from a variety of areas, such as molecular biology, biochemistry, analytical 
chemistry and behavioral studies, is a viable approach. In the Sweedler group, we are 
continuously developing and implementing a variety of analytical techniques to 
determine cell-to-cell signaling molecules, such as amino acids, serotonin, peptides 
and nitric oxide. We are interested in not only their chemical structures, but also 
temporal, spatial and quantitative information. These techniques have been applied to 
a wide range of animal models, including the sea slug (Aplysia californica), snail 
(Lymnaea stagnalis), flatworm (Schmidtea mediterranea), honey bee (Apis mellifera), 
song bird (Taeniopygia guttata), mouse (Mus musculus), and rat (Rattus norvegicus), 
to understand their nervous systems at molecular levels.  
 My dissertation research emphasizes the investigation and understanding of 
neuropeptides in a variety of model organisms. This has been achieved by selectively 
utilizing four liquid chromatography-mass spectrometry (LC-MS) platforms, and 
developing and optimizing a range of analytical approaches. One is a non-targeted 
approach, which is a comprehensive analysis of peptides, termed peptidomics, with 
 2
sample sizes ranging from whole animals to single organs or tissues. Another is a 
targeted approach, which usually focuses on a specific peptide that has been 
implicated in a defined physiological or behavioral function. The third is a 
quantitative approach that compares the difference of peptide levels between two 
samples arising from different behavioral stages, application of drugs or chemicals, 
and arising through gene knockouts. These approaches, combined with genome 
sequencing, bioinformatics, and molecular biology, advance our knowledge of 
neuropeptides in many organisms.  
 To set a foundation for the following chapters, we introduce below the three 
major areas of the dissertation: neuropeptides, the model organisms and the MS-based 
techniques.  
 
1.2 Introduction to Neuropeptide 
Neuropeptides are cell-to-cell signaling molecules that are synthesized in nerve 
cells or peripheral organs [26, 36, 58]. They act as neurotransmitters, 
neuromodulators, hormones, and trophic factors [27, 53, 58], and modulate diverse 
physiological and behavioral functions within an organism, such as learning and 
memory (dynorphins, galanin) [44], pain [34, 45, 56], feeding (neuropeptide Y and 
galanin) [25, 30], metabolism regulation (insulin) [28], and drug addiction (dynorphin) 
[55].  
Neuropeptides are initially expressed as large protein precursors in the rough 
endoplasmic reticulum (ER). The preprohormone contains a signal peptide at the 
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N-terminus, which is recognized by signal recognition particle, is cleaved off and 
guides the precursor to the rough ER. The precursor is then transported to the 
trans-Golgi, where a number of processing enzymes acts as endopeptidases to cleave 
the precursor. The first described and so called classical pathway involves the 
cleavage at mono- or dibasic sites by prohormone convertases, and the removal of 
C-terminal basic residues by carboxypeptidase D/E (Figure 1.1). Other cleavages and 
then called non-classical cleavages. Some of the peptides are further 
post-translationally modified, which often influence their bioactivity via increased 
stability toward enzymatic degradation or altered binding affinity to receptors [1, 12]. 
One of the most important PTMs is amidation, which occurs at the C-terminus of the 
peptide sequence after glycine removal and accounts for half of all known bioactive 
neuropeptides [26]. Another common PTM, N-terminal pyroglutamate, is formed by 
the cyclization of glutamine or glutamate [20], while disulfide bond is formed by 
linking the thiol groups from two cysteines [16]. Other PTMs of peptides include 
acetylation [43], methylation [48], oxidation [46], and sulfation [48]. As a result, 
neuropeptides are generated to have a wide range of masses, a variety of PTMs, and 
distinct sequences with multiple charge states, which could not be accurately 
predicted from the protein precursor unless measuring them.  
Furthermore, the peptidases employed for prohormones processing may be 
differentially expressed in cells or tissues [4-6], during various developmental stages 
[7] or upon stimulation. Therefore, peptides could be differentially processed, 
modified, expressed and distributed, resulting in a wide range of chemical forms and 
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quantities at different regions or time points. For example, the transient expression of 
somatostatin in many central nervous systems and substance P in spinal guiding 
neurons were demonstrated during early developmental stages [26]. In addition, a 
single prohormone may encode multiple bioactive neuropeptides, with each having 
distinct functions. On the other hand, different peptides with resembling structures 
may share similar functions. Therefore, it is necessary to distinguish the sequence and 
PTMs of each peptide in a specific animal, location or time point, to facilitate further 
functional studies.  
 
1.3 Introduction to Model Organisms 
To succeed in neuroscience investigations, one needs to not only develop 
cutting-edge technologies, but also select the right model organisms. It is true that 
human brains have distinct organization from other organisms (e.g. insects, slugs, 
jellyfish). However, the majority of neurochemical pathways are surprisingly 
well-conserved across metazoan, such as synthesis, release, and some catabolism 
pathways. Therefore, simpler biological models (e.g. sea slug, flatworm) are utilized 
to provide more straightforward answers and valuable insights to many fundamental 
and complex neuroscience questions related to human brain function. The recognition 
and selection of these models leads to the initiation of genome sequencing projects, 
which in turn greatly facilitate the biological research and understanding of individual 
model organisms. The neuropeptide investigation, based on but not directly deduced 
from these sequenced genomes, takes a step forward to characterize the sequence, 
 5
post-translational modifications, expression and biological functions of neuropeptides. 
Six model organisms, Pleurobrachia pileus, Aplysia californica, Schmidtea 
mediterranea, Drosophila melanogaster, Mus musculus, and Homo sapiens, were 
explored in my dissertation and will be described individually. 
1.3.1 Pleurobrachia pileus 
Ctenophores, commonly known as comb jellies, are marine animals living mostly 
in the open ocean. Ctenophores are distinct by using their comb rows as primary 
means of locomotion, in addition to passive drift. Pleurobrachia, the sea gooseberry, 
is one of the most common ctenophore species. Ctenophore attracts people’s attention 
in many aspects. From an evolutionary point of view, phylogenomic study provided a 
high statistical support for ctenophore as the earliest branching in extant animals, 
which justifies it as a good model to study animal evolution [47]. Their crystal clear 
embryos make the observation and investigation of fertilization, cell cycle or division 
possible. In addition, they could grow into the characteristic cydippid stage, a 
miniature adult, within less than 24 h after fertilization and release into water, and 
thus it is an ideal system for exploring adult regeneration and wound healing.  
1.3.2 Aplysia californica 
The sea slug, Aplysia californica, is a well-established neurobiological model, 
and has been successfully used by Eric Kandel and others to study fundamentals of 
learning and memory [31, 32]. Aplysia has a simple neuronal network with large and 
easily accessible neurons ranging from 5 μm to 500 μm. This allows the examination 
of neuronal architecture at defined compartments and single cell levels, which could 
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be linked to specific neuron activity or stereotyped behaviors. The similarity of many 
biochemical pathways between Aplysia and mammals also demonstrates the 
significance in evolutionary and developmental biology.  
1.3.3 Schmidtea mediterranea 
Planarians are freshwater flatworms, and members of the phylum Platyhelminthes. 
Planarians have a remarkable regeneration capability, and could regenerate into a 
complete worm from a lateral fragment 1/279th, the size of the original worm [41]. 
This is attributed to the presence of neoblasts, highly undifferentiated cells, across the 
body of adult planarian. More interestingly, when starved, these animals degrow by 
losing cells, rather than shrinking cell size. Schmidtea mediterranea was selected as a 
model system from thousands of planarian species, due to its diploid, a small genome 
size, robust regeneration and the availability of both sexual and asexual strains [54]. 
While sexual animals need to cross-fertilize to reproduce, asexual animals undergo 
transverse fission. Considering the degree of conservation between planarian and 
humans, the investigation on regeneration and tissue homeostasis could contribute to 
human biology [54]. In addition, planarian sits as the basal members of the bilateria in 
the evolution tree of the metazoan, and has key anatomical features (e.g. central 
nervous system, mesoderm) as platforms for evolutionary studies of higher organisms 
[42].  
1.3.4 Drosophila melanogaster 
The fruit fly, Drosophila melanogaster, is one of the most studied and genetically 
well-known eukaryotic organisms. Its frequent use is mainly because it is easy to care 
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for, quickly breeds and lays numerous eggs, even in a lab environment. Thus, several 
generations can be investigated in a short period of time. The availability of its 
complete genome since 2000, and powerful genetic approaches in a long history 
greatly promote its widely use in biological research, such as genetics, physiology and 
evolution. More importantly, there is genetic similarity between fruit flies and 
mammals: a recognizable match between three fourths of known human disease genes 
and fruit fly genome [49], and mammal homologs found for 50% fly proteins. This 
justifies the use of Drosophila as a genetic model for a number of human diseases (e.g. 
Parkinson's, Alzheimer's, diabetes). 
1.3.5 Mus musculus 
Mouse, Mus musculus, is the most commonly used animal model and genetically 
modified lab mammal in laboratory research. It is due to the following reasons: they 
are small and relatively easy to maintain, and proliferate fast; its high degree of 
homology to humans makes it a key model for understanding human genome and 
many complex traits, such as many diseases; a variety of strains has been established 
through inbred, outbred and transgenic modifications; and many molecular genetic 
tools are also available [24].  The completion of genome sequencing project for 
mouse in 2002 [62], together with the comparative mapping between mouse and 
human, has expanded studies on mouse genetics, which sheds light on human 
research. 
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1.3.6 Homo sapiens 
Humans, homo sapiens, are the only living species in the Homo genus. The first 
draft for human genome was published by the international Human Genome 
Sequencing Consortium in 2001 [52], which was completed in 2003 [35]. Human 
genome is composed of more than three billion nucleotides and about 20,000 protein 
coding genes, more complex than the models used in this dissertation and less 
complex than other animals. One research tool to aid human research involves 
primary human cell cultures, a tool that has become well used in academic research, 
as well as in biopharmaceutical industry. More than 200 cell types in humans have 
been selected and cultured for research purposes, including the keratinocyte cell line, 
which has been used in this dissertation.  
 
1.4 Introduction to Liquid Chromatography 
The complexity of biological samples and wide dynamic range of peptides 
present a challenge for peptide investigation. One solution is to utilize liquid 
chromatography (LC) to fractionate samples and reduce sample complexity prior to 
MS analysis. Two types of LC separation mechanism have been successfully applied: 
one is based on the hydrophobicity using reverse phase (RP) columns, while the other 
requires the presence of charges for binding and effective separation on strong cation 
exchange (SCX) columns. A sequential use of these two LC systems provides a more 
thorough separation for complex samples [21, 22, 51, 61]. This dissertation focuses on 
the identification of endogenous peptides, which do not contain C-terminal basic 
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residues. Therefore, without the presence of fixed charges, SCX does not provide the 
resolution of the components and thus RP was selected as the major tool to separate 
endogenous peptides. Considering the typical size and sequence of these peptides, 
C18 column is usually the choice for an efficient fractionation.  
In order to elute a wide range of peptides from a column in a reasonable time, a 
solvent gradient is generated by mixing water and the appropriate organic solvent. 
Methanol and acetonitrile are the most common organic solvents for peptide studies. 
Methanol hydrogen bonding and hydrophilicity are useful; a higher percentage of 
methanol is required to elute peptides which facilitates solvent evaporation when 
using electrospray ionization (ESI). On the other hand, the higher viscosity of 
water/methanol mixture needs to be considered as it creates a high pressure in the LC 
column for a given flow rate [23]. To aid the generation of positively charged 
peptides in ESI source, certain acids, such as formic acid (FA) and acetic acid (AA), 
are added to the solvent to provide an acidic environment with pH ~5. While for 
creating negative peptides, ammonium acetate and ammonium formate are usually 
supplied with a pH ~9. Furthermore, separation efficiency and selectivity could be 
improved by adding ion-pairing reagents into the solvent systems, with FA, AA, 
trifluoroacetic acid (TFA), and heptafluorobutyric acid (HFBA) as most common 
ones [19]. While HFBA and TFA are excellent choices for better LC separation, FA 
and AA have less effect on ion suppression in ESI. Previous studies indicated that a 
low concentration of TFA (e.g. 0.02%) could provide a good balance for the 
performance of LC and MS [19]. A multidimensional RP separation of peptides could 
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be developed by employing different columns, organic solvents (methanol vs 
acetonitrile), or different ion-pairing additives (e.g., FA vs HBFA).  
 
1.5 Introduction to Mass Spectrometry 
Mass spectrometry (MS) has been applied to the discovery of numerous peptides 
in a variety of animal models [18, 36]. It is an analytical platform, which ionizes and 
generates charged molecules/fragments and then measures mass-to-charge ratios (m/z) 
to determine their masses or chemical structures. For many measurement approaches 
such as sequencing, one does not need an understanding of the instrumental details.  
However, no individual MS instrument and approach work well for a majority of 
samples and so one needs some basic knowledge of when individual approaches work 
well (or fail). In this dissertation, we have utilized multiple MS platforms, including 
electrospray ionization (ESI)-ion trap (IT) MS (Bruker HCTultra), matrix-assisted 
laser desorption/ionization (MALDI)-time of flight (TOF) MS (Bruker ultraflex and 
ultrafleXtreme), and ESI-quadrupole-time of flight (Q-TOF) MS (Water Premier, and 
Bruker 4G maXis). The selection of instrument depends different factors, such as the 
characteristics of peptide of interest (e.g., structure, mass, etc), and the goal for 
identification or quantitation. Therefore, a number of approaches have been developed 
to characterize peptides in complex biological samples. Here, we will briefly 
introduce the ion sources, mass analyzers, fragmentation and quantitation for these 
MS platforms, with detailed information elaborated in later chapters.  
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1.5.1 Ion sources 
The introduction of MALDI and ESI in the late 1980s revolutionized the field of 
peptide and protein discovery [15, 33, 60], which was recognized by the Nobel Prize 
for Chemistry to Koichi Tanaka and John Fenn in 2002. These are two types of 
ionization mechanisms, which transfer the analytes of interest into gas phase and 
ionize them.  
In MALDI, a matrix absorbs UV laser beam, and thus is vaporized, carrying with 
it some of the analyte.  It is ionized and also ionizes analyte molecules in a way that 
minimizes thermal heating and hinders their fragmentation. Commonly used matrices 
for peptides are α-cyano-4-hydroxycinnamic acid (CHCA), 2,5-dihydroxy benzoic 
acid (DHB), and sinapinic acid (SA) [9]. While CHCA is suitable for smaller peptides, 
SA is mainly for large peptides/proteins with DHB in-between. After mixing matrix 
and analyte solutions in a molar ratio of typically 10,000:1, it is spotted onto a target 
plate and dried for MALDI analysis. There are a number of advantages using MALDI. 
First, it has excellent detection limits; when using modern instruments, attomole 
levels of peptides can be characterized. Second, accurate mass (e.g. several ppm) and 
high resolution (e.g. ~40,000) are achieved with proper calibration and instrumental 
parameters. There is no theoretical upper mass limit for proteins. Third, it has 
relatively high tolerance towards small molecule contaminants (e.g., salt, detergent), 
and thus the data quality is less likely to be influenced with poor quality samples. 
Lastly, it is a rapid measurement, and because such a small fraction of the sample is 
used, it allows the samples on the target to be reanalyzed if necessary. The generation 
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of mostly +1 charge peptide simplifies the data analysis process as well. However, 
two drawbacks need to be considered: one is the signal suppression due to the 
competition among various analytes with differential ionization capability; the other is 
the ability to characterize analytes at the lower mass range because of interference of 
MS peaks from the matrix. MALDI is oftentimes combined with TOF mass analyzer, 
but can also be combined with other mass analyzers.  
In ESI, the sample dissolved in a polar and volatile solvent, elutes from a 
capillary with a high voltage between the capillary tip and the nozzle. The liquid exits 
the capillary and forms a stable Taylor cone. In the electrospray process, the droplts 
evaporate until they reach a critical size where a coulombic explosion occurs, and the 
charged ions are then directed to the inlet. A warm flow of nebulizer gas facilitates the 
shrinkage of the ejected droplets. While in the positive mode, a trace of formic acid or 
acetic acid in the solution helps the protonation, ammonia solution or a negative 
volatile amine can be added to aid deprotonation in the negative mode. ESI is distinct 
from MALDI in many characteristics. First, it usually generates multiple charged 
peptides, and the exact charge state depends on the chemical properties of peptides 
(e.g., size, the number and position of charge amino acids) and the solvent used [9]. 
The mass analyzers used with ESI tend to be more efficient for tandem MS 
measurements.  Second, ESI works with sample volumes well suited for coupling to 
small volume LC separations. Third, signal suppression of the sort occurring in 
MALDI is less prominent in ESI, and thus peptides with a wider dynamic range of 
concentrations could be handled. Fourth, ESI has been coupled to a variety of mass 
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analyzers, such as ion trap (IT), quadrupole (Q), quadrupole-time of flight (Q-TOF), 
and Fourier-transform ion cyclotron resonance (FTICR). On the other hand, the 
presence of detergent and salt interferes the spraying process and impact the 
sensitivity of ESI, and thus LC is usually employed before ESI for complex biological 
samples.  
1.5.2 Mass analyzers 
Following ionization, mass analyzers generate information on analyte ions 
according to their mass to charge ratio (m/z). Three types of mass analyzers are 
utilized in this dissertation, ion trap (IT), time-of-flight (TOF), and quadrupole-time 
of flight (Q-TOF).  
In ion trap, ions are accelerated and focused by a series of focusing devices, such 
as octopoles and lens, and then enter the trap through an opening in the electrode (e.g., 
the endcap electrode, ring electrode). Ions above a certain m/z are then trapped when 
applying a constant radiofrequency (RF) amplitude at a low voltage. Helium gas in 
the trap not only acts as a collision gas to generate ion fragments in the MS/MS mode, 
but also helps maintain ions to the center of the trap for enhanced sensitivity and mass 
resolution. The MS spectra could be obtained by ejecting ions out of the trap in an 
order of m/z, resulting from either the mass-selective instability or resonance as RF 
increases. For the ion selection step in MS/MS mode, a supplementary RF could be 
supplied to maintain a narrow m/z range while ejecting most of the ions. Therefore, IT 
MS usually has a higher MS/MS sensitivity, although relatively low mass accuracy 
and resolution. In addition, by controlling the number of ions in the trap by an ion 
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gate, the space charging issue in IT could be minimized [9]. 
Since its first introduction in 1946 [57], the TOF mass analyzer has been widely 
employed, and is well-suited for pulsed ion sources like MALDI. Through 
acceleration in an electrical field, ions have the same kinetic energy, but different 
velocities depending on the mass to charge ratio. The time for the ion to reach the 
detector within a defined distance is measured, which can be translated into m/z. The 
initial velocity of the ejected ion could affect the resolution of a TOF analyzer. This 
can be compensated by the introduction of an ion reflector, where ions could be 
adjusted to the same kinetic energy by penetrating into different depths in the 
electrostatic field [11, 37].  
Q-TOF is one of the most common hybrid mass spectrometers with orthogonal 
acceleration into the TOF section. When equipped with a reflector, high mass 
resolution could be achieved. In MS mode, the quadrupole acts only as a focusing 
device with TOF as a mass analyzer. In MS/MS mode, the quadrupole is used for ion 
selection and fragmentation, and ions are analyzed by TOF with high resolving power.  
1.5.3 Tandem MS 
Tandem MS, known as MS/MS, includes multiple steps of MS selection and 
analysis with fragmentation occurring in-between. It has been widely applied to 
peptide sequencing and PTM identification. It can be accomplished in two ways: one 
uses sequential mass spectrometers separated in space, such as TOF; the other uses a 
single mass spectrometer, with multiple separation steps occurring over time, such as 
IT. The fragmentation of peptides could happen at multiple positions along the 
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backbone, including Cα-C, C-N, and N-Cα, which results in six types of fragment 
ions; for proteins and peptides, the fragment ions are named by a nomenclature that 
recognizes where the peptide backbone has been cleaved, so the ions are named via as 
shown in Figure 1.2: an, bn, cn, xn, yn, and zn.[2, 50]  
The approaches employed for MS/MS determine which types of fragment ions 
are generated. One major approach for MS/MS is collision-induced dissociation 
(CID), which is based on the collision between parent ions and an inert gas (e.g. He, 
Ar). The types of daughter ions generated depend on the sequence, the collision 
energy, and the number of charges [14]. Low energy CID (<100 eV), often used in 
ESI-IT and ESI-Q-TOF, cleaves the amide bonds (C-N) and generates series of bn, and 
yn ions [29], as well as some neutral losses. High energy CID (keV range), used in 
MALDI-TOF, cleaves at Cβ-Cγ and generates dn and wn ions [14]. However, CID 
often has a preference for the cleavage sites, and some labile PTMs could be lost 
during fragmentation. Therefore, two other approaches, electron capture dissociation 
(ECD) and electron transfer dissociation (ETD), have been developed and 
implemented [59, 63]. They induce the cleavage of the N-Cα bond and generate cn, 
and zn ions, which is independent of the peptide sequence and size. Liable PTMs, such 
as phosphorylation and sulfonation, are also reserved [38].  
1.5.4 Quantitation 
While it is important to identify peptides, quantitative information obtained from 
MS studies can be beneficial. Here, absolute quantitation refers to the measurement of 
the mass or concentration of a peptide and relative quantitation refers to determining 
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changes in level between two or more treatments.  To achieve absolute quantitation 
by MS, standards of the peptides, or those containing heavy stable isotopes (e.g., 2H, 
13C, 15N, or 18O) are added to samples. However, this requires known standards and so 
is expensive and low throughput. The other way is to utilize MS to obtain a relative 
ratio of a peptide from two different samples. For example, one sample is labeled with 
a light stable isotope, and another is labeled with a heavy stable isotope, which are 
then combined and analyzed together by MS or MS/MS. This labeling approach is 
based on the mass difference created via differential labeling. Another option is to 
skip the labeling processes, and directly and individually analyze each sample by MS 
for comparison. It replies on the linear relationship between the MS intensity and the 
amount of analyte. This approach simplifies the sampling processes, minimizes the 
sample loss, and is suitable for quantifying peptides in lower abundance, but does 
require higher quality MS instruments to assure that multiple peaks do not overlap. A 
variety of MS platforms have been applied to quantify peptides, such as ESI-Q-TOF, 
MALDI-TOF, and ESI-IT [3, 7, 8, 10, 13, 39, 40]. 
 
1.6 Dissertation Overview 
This dissertation presents a number of projects with an overarching goal to 
identify and quantify neuropeptides in complex biological samples. Chapter 2 is an 
overview of recent MS-based approaches, with emphasis on those that could provide 
temporal, spatial and quantitative information, and thus may lead to a set of peptides 
with higher potential to participate in cell-to-cell signaling. Some of these approaches 
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were utilized in the following chapters.  
Chapter 3 and 4 presents MS-based quantitative approaches to compare peptide 
level difference between two samples. In chapter 3, eight well-designed standard 
mixtures with four replicates each were examined on three types of MS platforms, 
including ESI-IT, MALDI-TOF, and ESI-Q-TOF MS. By optimizing parameters 
during data acquisitions and selectively choosing the appropriate charge states for 
quantitation during data analysis, all three instruments could accurately quantify 
peptides with a wide dynamic range of concentrations up to 1200 fold. Two of the 
instruments, MALDI-TOF, and ESI-Q-TOF MS, were selected for quantifying 
biological samples in chapter 4, considering the low abundance of peptides and 
complexity in these biological samples. As a result, 24 peptides from either mice 
spinal cords or striata showed significant level change between wide-type and 
knock-out Endothelin Converting Enzyme-2 (ECE-2) mice. Therefore, the role of 
ECE-2 as a non-classical processing enzyme in vivo has been demonstrated.  
Chapter 5 and 6 illustrate two neuropeptidomics studies on whole model 
organisms, flatworm (Schmidtea mediterranea) and comb jelly (Pleurobrachia pileus), 
respectively. These studies utilized the non-targeted approach, a combination of 
MS-based techniques and bioinformatics for genome-wide characterization of 
peptides. As a result, a database of 51 prohormones was experimentally confirmed 
with five of them discovered via de novo sequencing of MS/MS spectra, and a total of 
142 peptides from 40 prohormones were identified by MS in Schmidtea mediterranea. 
Preliminary studies on Pleurobrachia pileus compiled a database of 58 putative 
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prohormones/proteins, based on which 62 peptides were identified by MS. A list of 
promising de novo tags may lead to a more complete prohormone/protein database in 
Pleurobrachia. These studies generated a relatively complete library of peptides in 
these two model organisms, with Schmidtea mediterranea so far having the highest 
prohormone coverage across metazoa.  
Chapter 7 presents another neuropeptidomics study focusing on specific regions 
in Aplysia californica. The investigation of atrial gland, an exocrine organ with 
reproductive and pheromone activity, not only identified a number of egg-laying and 
atrial gland related hormones, but also discovered three unexpected peptides with 
intrachain disulfide bond derived from B3-5 precursor, which is a promising target to 
explore its pheromone activity. In addition, the connectives in Aplysia, tracts for 
transporting neuropeptides, were collected and investigated, which produces a list of 
peptides that are transported and hence have the potential to be bioactive.  
Chapter 8 and 9 focuses on the identification of one specific peptide each, with 
the peptides implicated to play a role in cell-to-cell signaling. We employed 
Drosophila melanogaster and cell cultures from Homo sapiens in chapter 8 and 9 
respectively. The chemical structure of human insulin ectopically expressed in 
Drosophila has been characterized by MS. It is identical to the structural of human 
insulin with the presence of three disulfide bonds and also expressed at high levels, 
which opens the door to utilize Drosophila as a model to produce large amounts of 
peptides. Alarin has been implicated to participate in food intake and regulate body 
weight in rats. Here we developed sampling protocols and MS-based approach to 
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concentrate low abundance of alarin from human culturing media, and detected a 
putative alarin peptide, which hopefully leads to clarification of its chemical structure 
by analyzing more samples.  
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1.8 Figures 
 
 
 
 
Figure 1.1 Classical and non-classical neuropeptide processing steps. Image was 
adpated from [17] with permission from Springer © 2005.  
 
 
 
 
Figure 1.2 Nomenclature for fragment ions. Image was adapted from [50] with 
permission from John Wiley & Sons, Inc. © 1984.  
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CHAPTER 2 
NEW MASS SPECTROMETRIC APPROACHES  
FOR UNCOVERING NEUROPEPTIDES  
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contributions to the manuscript, and Stephanie C. Baker for the final editing. The 
project described was supported by the National Institute on Drug Abuse under 
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2.2 Introduction  
Neuropeptides, a broad class of structurally diverse cell-to-cell signaling 
molecules, are involved in a myriad of biological processes. Synthesized as protein 
precursors, they undergo complex enzymatic processing, are packaged into vesicles, 
and can be transported long distances to their cellular release sites. A number of 
prediction programs are available that help identify cell-to-cell signaling peptides by 
predicting prohormone cleavage sites [32]. However, because the final bioactive 
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peptide products are determined by the particular enzymes present and the order in 
which they act, and because they vary in a brain- and context-specific manner, it is 
difficult to confirm final products without measuring them. As one example, the 
cleavage of prohormones at basic amino acid (lysine and arginine) sites is common, 
but only a fraction of such sites are actually cleaved [32]. Although prediction 
methods are useful, oftentimes empirically measuring the peptide presence using mass 
spectrometry (MS)-based methods is required.  
 MS, assisted by separation techniques such as liquid chromatography (LC), 
offers the capability to fractionate and characterize complex samples to determine 
their chemical constituents. Since one of its first successes in characterizing 
thyrotropin-releasing hormone [4], MS characteristics have advanced dramatically, 
leading to recent discoveries of large numbers of brain peptides in a number of animal 
models [12, 24]. In addition to being used to unambiguously identify and characterize 
neuropeptides and their posttranslational modifications in complex biological 
systems—without previous knowledge of the peptide sequences—MS can also 
provide information about neuropeptide level changes under various physiological 
conditions. Furthermore, recent advances in localization and imaging approaches have 
been combined with several MS platforms to reveal the distribution of neuropeptides 
in tissue slices and even whole animals.  
No single method works equally well for all samples. Instruments vary in their 
analytical capabilities; thus, selecting the appropriate MS platform depends on a 
number of factors. These may include the characteristics of the peptides of interest 
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(e.g., peptide charge states, mass range of detection), the experimental goals (e.g., 
peptide identification, quantification, or distribution), and the number of samples to be 
examined. Several MS technologies are available: electrospray ionization (ESI), 
quadrupole-time of flight (Q-TOF), ion trap (IT), matrix-assisted laser 
desorption/ionization (MALDI)-TOF, Fourier transform ion cyclotron resonance 
(FT-ICR), and others [2, 24].  
When measuring peptides in a brain sample, one typically characterizes hundreds 
of peptides. Which ones are neuropeptides and what are the other peptides present? 
While prohormones often encode multiple peptides, only a portion of these peptides 
are involved in cell-to-cell signaling. It has been suggested that the other peptides 
provide charge neutrality during acidification of the dense core vesicle, aid in correct 
folding and disulfide bond formation of their corresponding prohormones, and even 
participate in receptor localization. Another important point is that only a fraction of 
the peptides in a vesicle are expected to be bone fide neuropeptides. Contributing to 
the complexity of peptide measurements, one typically obtains a snapshot of 
prohormone processing (peptide formation), storage, and degradation. Thus one can 
expect that the final products, as well as the processing intermediates and degradants, 
will be present in the sample. Keep in mind also that the tissue isolation process may 
lead to further degradation or other changes in the peptide forms. 
Consequently, a peptidome measurement can result in long lists of peptides, only 
a fraction of which are involved in cell-to-cell signaling (and hence, only a fraction of 
which are neuropeptides). One can design sampling protocols to obtain information 
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on function, transport, release, distribution, and changes in abundance based on 
treatments. In this chapter, we provide an overview of various MS-based approaches 
for uncovering neuropeptides by following their dynamics from transport to release, 
and from localization to heterogeneity, as well as their level changes based on 
physiological perturbations. The sample types range from single cells to whole 
animals. These measurements allow one to focus on specific sets of peptides based on 
their form, release, and level change or distribution, information that advances 
neuropeptide research. 
 
2.3 MS-based Neuropeptide Discovery 
2.3.1 Peptide Transport Studies 
Among the numerous peptides identified by MS, only a subset are expected to be 
transported long distances such as from a soma down nerves, and it is this subset of 
transported brain peptides that is more likely to function in cell-to-cell signaling. The 
ability to isolate subcellular structures associated with the transport process (vesicles) 
or release (synapses) results in fractions containing specific sets of peptides, thereby 
facilitating the identification of the localized neuropeptides. These transport studies 
can address questions such as: Which neuropeptides are transported? Which 
endogenous neuropeptides are cleaved and generated in vesicles via in vivo events? 
A number of approaches are available to examine these issues. One option is to 
ligate living nerve tissue between the central nervous system and periphery so that the 
ends of the nerve can be sampled after a suitable delay. Increased peptide levels can 
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be observed at the nerve end towards the peptide source and reduced levels from the 
end located towards the destination of the peptides. A simple technique is to place the 
entire nerve onto a sample plate for the direct measurement of peptides by MALDI 
MS [23]. Alternatively, the nerve sample can be homogenized in peptide extraction 
solutions, such as acidified acetone, acidified methanol or HCl [35]. The resulting 
solution contains a variety of peptides that were being transported when the nerve was 
isolated. These samples oftentimes are subjected to several clean-up steps (e.g., 
desalting) or separation by LC or other techniques, before identification by MS. 
Another option is to isolate individual neurons for direct analysis via MALDI MS; 
this allows one to discriminate peptide patterns among soma, dendrites, and axons [19, 
29] and thus determine which peptides are transported.  
Another intriguing approach is to look for peptide packaging by isolating vesicles, 
such as large dense core vesicles, or to isolate specific locations such as synaptosomes. 
Typically after tissue or brain isolation, secretory vesicles are separated and collected 
through differential and sucrose density gradient centrifugations [13], while synaptic 
components are enriched by subcellular fractionation [27]. These processes reduce the 
chemical complexity of the samples by concentrating the more abundant molecules in 
these fractions. The fractions are then homogenized in extraction solutions to recover 
peptides, followed by separation and MS identification. A variety of MS-platforms 
have been used to detect and sequence the peptides from these subcellular 
compartments, or to create sets of peptides determined to likely play a role in 
cell-to-cell communication [13, 16, 27]. As another example, vesicles and 
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synaptosomes from a region of interest have been isolated before and after a treatment 
(e.g., morphine administration); the changes in peptide levels determined by MS 
reflect the effects of the treatment [27]. Techniques used to accomplish these 
measurements are detailed later (see Peptide Quantification). 
2.3.2 Peptide Release Studies 
Cell-to-cell signaling peptides must be released from the cell under a stimulation 
condition in order to affect other cells. Which peptides are released, what are their 
forms on release, and under what conditions are they released? For example, upon 
various stimulations, the posterior lobe of the pituitary releases hormones such as 
oxytocin and vasopressin, while the anterior pituitary secretes other growth and 
reproductive hormones. The integration of MS measurements with in vitro and in vivo 
sampling approaches allows the characterization of peptide release; several examples 
of measuring peptide release are discussed below. 
In vitro sampling of release has been reported using tissues from individual 
neurons and neuronal clusters in invertebrates [15] and from mammalian brain slices 
[14]. The stimulation and releasate collection are performed in vitro or ex vivo and the 
releasate profiles typically characterized by off-line MALDI-TOF MS. Once released, 
the peptides are diluted by orders of magnitude as they diffuse into the cellular media. 
A number of techniques have been developed to improve neuropeptide recovery and 
to provide spatial information on the location of release. By use of a solid-phase 
extraction (SPE) material embedded within pipettes or micrometer-sized beads to 
collect releasates, as shown in Figure 2.1A, the peptides are collected and 
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concentrated before their measurement. After desalting with water rinses, peptide 
analytes are eluted from the SPE material or beads for subsequent MS analysis. 
Because of its high sensitivity and tolerance for impurities, MALDI MS is often used 
for these measurements. In MALDI MS, the eluents are co-crystallized with a matrix 
(e.g., alpha-cyano-4-hydroxycinnamic acid), ionized with a laser, and the resultant 
ions analyzed by the appropriate mass analyzer. MALDI MS requires minimal sample 
preparation due to its high tolerance for salts and other background molecules. This 
approach provides high quality mass profiles, allowing one to measure multiple 
released peptides, as well as their posttranslational modifications (Figure 2.1B). 
Because of these characteristics, MALDI MS has been widely implemented in peptide 
release studies [14, 15, 18]. Furthermore, by collection of releasates from various 
locations using these beads (Figure 2.1C), or over a time course (Figure 2.1D), spatial 
and temporal information is added to the chemical release profiles. To improve the 
detectability of this approach for specific peptide categories, several SPE collection 
columns have been developed, such as a micron-scale porous polymer monolithic 
column, which provides both high binding capacity and spatial resolution [18].  
Microdialysis is a well-used brain sampling technique that has been combined 
with MS and other separation techniques to examine the extracellular fluid of animals 
in vivo, including brain tissues and the cerebrospinal fluid [26, 28]. A microdialysis 
probe can be used both to collect endogenous compounds (e.g., peptides) and 
administer exogenous substances, such as drugs, directly and locally into the tissue 
regions of interest. The system includes a pump to perfuse the probe with a 
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physiological salt solution (perhaps with a drug) while the device collects compounds 
that diffuse from the extracellular space across the membrane; the heart of the 
approach is the semi-permeable membrane that allows molecules smaller than a 
selected size to be sampled (Figure 2.2A). To provide optimum sampling efficiency, 
the probe needs to be carefully designed (e.g., the membrane material and size), and 
the experimental parameters well controlled (e.g., the composition of the perfusion 
fluid, the perfusion flow rate, temperature) [26]. As shown in Figure 2.2B, the probe 
can be placed in a freely moving animal to monitor intracerebral neuropeptide release 
[16]. SPE materials have also been incorporated into probes in order to further 
concentrate and/or desalt the releasates before MS analysis. MS enables mass spectral 
comparisons between samples collected before, during and after the application of the 
selected stimuli, or over a specific time course, or at different tissue locations, all of 
which provide insights into the temporal and spatial chemistry occurring in vivo. 
While accurate mass measurements are useful, more confident identifications require 
tandem MS capabilities. Because the number of peptides that can be fragmented by 
MS over a specific time-period is limited, hyphenating MS to small-volume 
separations reduces sample complexity, yielding larger numbers of peptides that are 
identified via tandem MS. The combination of chemical, temporal and spatial 
information on peptides that can be revealed by MS-based approaches, demonstrate 
the power of this technology as a discovery tool. For example, the peptide little SAAS 
is released from the suprachiasmatic nucleus at one time of day and directly affects 
circadian phase at that time of day [14]. 
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2.3.3 Peptide Localization and Distribution Studies 
Peptides often have sparse and highly localized distributions that change during 
development, treatment, and in some cases, even during specific behaviors. Methods 
that provide localization details are valuable to understanding peptide function and in 
fact, optical imaging via microscopy has established that peptides have complex 
distributions within the brain. The caveat with microscope-based imaging is that 
selective and specific probes are often required to image specific peptides. By contrast, 
mass spectrometry imaging (MSI), which combines mass spectrometric approaches 
with imaging technologies, does not require preselection or labeling of analytes. It has 
been used to examine a range of biological tissues, and provides both chemical and 
spatial information for known and unknown molecules, including neuropeptides [5, 9]. 
Another advantage of MSI compared with traditional microscopy is that the 
distribution of a wide range of compounds can be obtained in a single experiment. 
The direct analysis of tissue samples and the minimal sample preparation 
requirements are also beneficial. Figure 2.3 illustrates a typical MSI procedure, from 
sample preparation to data analysis. Experimental animals are selected and the regions 
of interest (e.g., brain, spinal cord, nerves) are isolated and dissected out under 
physiological conditions. A slice of tissue is sectioned via a cryostat and then placed 
onto a MALDI target plate, incorporating additional sample preparation steps as 
needed, e.g., sample stretching to improve spatial resolution [34]. After matrix 
application, mass spectra are acquired in an ordered array of positions across the 
sample. Selected ion images of neuropeptides are reconstructed by plotting the MS 
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signal intensities with the x, y coordinates of each spot. Peak assignments are made 
either by mass-matching or via subsequent tandem MS. The localization of tens to 
hundreds of peptides can be imaged at spatial resolutions from the low micron to 
hundreds of microns size range, depending on the instrumental and protocol figures of 
merit. 
Obtaining quality images of peptides with MSI relies heavily on choosing the 
appropriate sample preparation protocols, selected according to sample type, mass 
range of interest, and desired spatial resolution and sensitivity. Several measurement 
approaches can be considered, such as stigmatic imaging [1], oversampling [20], and 
stretched sampling [34]. Because each MS platform provides unique capabilities, 
choosing the right system is also important. MALDI MS is well suited for imaging 
peptides with a wide range of masses at spatial scales from single cells [29] to whole 
animals [21], while secondary ion mass spectrometry, or SIMS imaging is often used 
to study peptides with lower molecular weight masses (usually less than 700 Da) at 
higher spatial resolution [34]. Other ionization techniques, such as ESI and desorption 
electrospray ionization, or DESI, are alternative approaches [33]. 
2.3.4 Single-cell Neuropeptide Studies 
Neurons are heterogeneous cells with distinct chemical compositions and 
functions, even among adjacent cells. With optimized sample preparation protocols 
and appropriate MS platforms, individual larger neurons can be interrogated [19, 22, 
30, 31]; however, such measurements are not common. Because the neuropeptide 
complement varies in a cell-specific fashion, the analysis of single cells tends to 
 36
reduce sample complexity and prevent the dilution of a specific neuropeptide with 
contents from nearby cells. Therefore, neuropeptides present at high local levels but 
low global abundances are more easily detected.  
Many single-cell analyses utilize MALDI MS; as mentioned previously, it is 
tolerant of salts. It is also tolerant of lipids, compatible with solid samples, has 
excellent detection limits, and requires minimal sample preparation. An overview of 
single-cell MALDI MS is illustrated in Figure 2.4. After animal dissection and 
single-cell isolation under physiological conditions, single cells are positioned onto 
the target plate and an appropriate MALDI matrix is applied. This approach has 
successfully been used to assay large invertebrate neurons to mammalian cells, with 
cell sizes ranging from several to hundreds of microns [30]. These approaches are 
becoming higher throughput, capable of identifying rare novel neuropeptides, and 
placing the resulting information into the context of the specific functions of 
individual neurons, and of following the cell-specific changes of peptide levels 
resulting from disease and exposure to drugs [31]. 
2.3.5 Peptide Quantitation 
Details about which peptides are present within a brain region or tissue, including 
how these peptides are affected by the administration of drugs, gene knockout, or 
behavioral changes [12], advances our understanding of peptide function. Quantitative 
peptidomic approaches that use MS-based methodologies allow us to compare 
changes in the relative amounts of many peptides simultaneously. There are several 
common MS-based approaches for quantifying peptides that use isotopic labeling [3, 
 37
7, 8, 11, 25] and label-free methods [10]; the general procedures are illustrated in 
Figure 2.5. For isotopic labeling, the extracts from control and experimental samples 
are labeled with either light or heavy labeling reagents, which create labeled peptides 
with the same structure but a mass difference. Suitable isotopic labeling reagents 
should provide high reactivity and efficient labeling, stably labeled peptides during 
sample preparation and MS measurement, the co-elution of differentially labeled 
peptides from commonly used LC columns, and a mass difference large enough for 
peak recognition and differentiation; these characteristics help ensure more 
reproducible and accurate results. Two types of “universal” reagents are widely 
employed for peptide labeling: one targets the N-terminus and the ε-amino group of 
lysine residues (e.g., succinic anhydride and trimethylammoniumbutyryl), and the 
other targets the C-terminus (e.g., methanol) [12]. After labeling, samples are 
combined and simultaneously measured, with the MS instrument allowing the 
“identical” peptides to be differentiated; the difference in peptide abundance is 
quantified by determining the ratio of differentially labeled peaks in the same mass 
spectra (Figure 2.5C).  
Label-free measurements require fewer sample preparation steps after peptide 
extraction, and the samples are individually analyzed using LC–MS to obtain separate 
mass spectra for comparison (Figure 2.5B). Since this approach handles samples 
separately throughout the process, it is essential to maintain experimental consistency 
during peptide extraction and sample preparation, and to carefully select the proper 
MS platform and parameters to obtain reproducible and comparable results. While 
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label-free quantification tends to work well for quantifying peptides in the 
smallest-volume samples and peptides in low abundance with no theoretical limitation 
to the number of samples being compared, labeling approaches combine the samples 
at an earlier stage and thus may provide a more accurate quantification. The current 
availability of labeling reagents for quantitative peptidomics allows a comparison of 
up to four samples [3, 25], but the development of optimized reagents may lead to the 
ability to label more samples in parallel. Both labeling and label-free approaches have 
been successfully applied to investigate the correlation of peptide level changes in 
examining foraging behavior in honey bees [3] and the effects of drug exposure [7, 11] 
and food deprivation and exercise [8] in mice. We expect such peptide studies to 
continue. 
 
2.4 Conclusions and Future Perspectives 
Significant advances in the integration of MS measurement methods with various 
sampling techniques have combined to collect dynamic, temporal and spatial 
information for neuropeptidomics research. As a result, the number of peptides 
discovered from a range of model organisms has dramatically increased over the past 
decade, shedding light on potential neuropeptides in the context of their biological 
environments. The emergence of more advanced MS platforms capable of 
unambiguous peptide identification, lower detection limits, higher information content 
and higher throughput, in concert with the continuous development of more localized 
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and activity-dependent sampling techniques, will further advance our understanding 
of these important cell-to-cell signaling molecules. 
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2.6 Figures 
 
 
Figure 2.1 MS-based approaches for collecting peptide release from brain slices. (A) 
Solid phase extraction pipette sampling allows the spatially resolved collection of 
released peptides and their subsequent characterization via MALDI-TOF MS. CHCA 
is alpha-cyano-4-hydroxycinnamic acid. (B) MALDI-TOF MS characterization of 
releasates before (upper panel) and after (lower panel) simulation. Peptide peaks are 
labeled as (a) to (o) and identified in the original work [14]. (C) Spatially resolved 
release of arginine vasopressin (AVP) peptide from a brain slice was performed by 
placing individual beads onto the slice, and then removing them for subsequent MS 
characterization; the beads were placed on four regions -- suprachiasmatic nucleus 
(SCN), supraoptic nucleus (SON), anterior hypothalamic nucleus (AHP), and optic 
tract (OT). (D) Temporal release of five endogenous peptides over a time course of 24 
h. The inset shows the release of AVP at 4 hour intervals. CT is circadian time. Figure 
adapted from [14] with permission from National Academy of Sciences, USA © 2008. 
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Figure 2.2 Microdialysis used for the in vivo collection of releasates from a behaving 
animal. (A) Microdialysis probe (on the left) and a schematic representation (on the 
right). The magnified membrane region demonstrates the net diffusion of analytes 
(open circles) into the probe, and the net diffusion of the perfusate containing stimuli 
or other substances (closed circles) to the extracellular space (Figure adapted and 
modified from [6] with permission from Springer © 2007). (B) An animal in the cage 
during microdialysis with a U-shaped probe. Figure adapted from [17] with 
permission from Elsevier © 2001.  
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Figure 2.3 Schematic of MS imaging protocols. Figure adapted and modified from [9] 
with permission from Springer © 2010.  
 
 
 
 
Figure 2.4 Overview of single-cell MALDI MS. (A) Cell isolation and sample 
preparation. (B) The MALDI ionization process. A typical mass spectrum of a single 
bag cell neuron from Aplysia californica is shown. (C) A cultured neuron with matrix 
crystals. Figure adapted from [22] with permission from Elsevier © 2000. 
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Figure 2.5 Neuropeptide quantification workflow with representative mass spectra 
shown. (A) Labeling approach from sample preparation and succinic anhydride 
labeling to LC–MS data analysis. (B) Label-free approach from sample preparation to 
LC–MS data analysis. (C) MS spectra of bradykinin standards differentially labeled 
with succinic anhydride (molecular weight = 1059.55 with masses 1159.62 (labeled 
with hydrogen)/1163.66 (labeled with deuterium) after labeling; charge state +2). The 
measured ratio is within 4% of the expected ratio, 2:1. Figure adapted and modified 
from [35] with permission from Springer © 2011. 
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CHAPTER 3 
METHOD VALIDATION: RELATIVE QUANTITATION OF 
NEUROPEPTIDES OVER A THOUSAND-FOLD  
CONCENTRATION RANGE 
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3.2 Introduction 
Neuropeptides are cell-to-cell signaling molecules that have diverse regulatory 
and behavioral functions within biological systems, with the functional effect of a 
specific neuropeptide dependent on its chemical form. Neuropeptides are initially 
expressed as a prohormone which then undergoes a large number of enzymatic 
 48
processing steps in the cell to produce final bioactive peptides [20, 27, 34]. The final 
forms of neuropeptides depend on the particular enzymes present in the tissue and the 
order the enzymes process the prohormones. Therefore, a large number of 
neuropeptides differing in sequence and post-translational modifications (PTMs) are 
produced within a specific brain region. Furthermore, the peptidases responsible for 
prohormones processing may be differentially expressed in tissues [19, 38, 39] or 
during development [49], resulting in peptides that are differentially expressed, 
modified, cycled, and distributed. Because of this, the specific form and quantity of a 
neuropeptide vary at different regions, upon release, and/or among developmental 
stages, and the dynamic range of neuropeptides spans many orders of magnitude. 
These challenges, as well as its low abundance and the surrounding of complex 
biological matrices, have spawned the field of neuropeptidomics [3, 29, 34, 41]. 
While one aspect of neuropeptidomics involves characterizing the peptides present 
[21, 34] or released [2, 23, 24] from a nervous system, oftentimes, one requires 
quantitative information on neuropeptide level changes arising from different 
behavioral states, gene knockouts, exposure to chemicals or drugs, and so forth [7, 13, 
14, 16, 17, 40, 44]. Because of the large sample dynamic range and other issues, 
quantitation for neuropeptidomics is still challenging.  
One can quantify peptides in several ways, with perhaps the two most common 
MS-based approaches being categorized as label-free [16, 25, 26, 31, 46] and isotopic 
labeling [7, 13, 14, 40, 44]. Other less common but promising approaches include 
spectral counting that counts the number of times specific peptides are detected [35, 
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36, 45, 50], standard addition [40] and approaches using MS to read a surface with the 
bound peptide on it [32].   
Most label-free methods rely on the linear relationship between the intensity of 
MS signal and the amount of analyte [8]. They directly compare analyte levels with 
fewer sample handling steps; as each step involves reagent delivery and transfers, 
fewer steps implies less sample losses. Therefore, label-free quantitation tends to 
work well for smaller-volume samples and peptides in low abundance. This approach 
also produces less complex samples to analyze compared to labeling approaches as 
differentially labeled samples are not needed. The minimal sample loss and the lower 
matrix interference also suggest that label-free approach have a higher coverage of 
quantified peptides [4]. In addition, by running each sample in parallel on the 
instruments, there is no limitation in theory to the number of samples that can be used 
for MS comparison. However, these approaches compares peptide levels from 
different MS runs and so has larger systematic errors and tends to have poorer 
quantitation accuracy than the labeling approach [4, 8]. 
The isotopic labeling approach combines the differentially labeled samples 
together and compares their peptide level differences in a single MS or LC-MS run. 
This removes run to run differences in the separation/mass spectrometry. As a minor 
point, isotopic labeling approach for peptidomic studies creates multiple tagged 
molecules for each peptide (that are distinguishable via mass differences in MS or 
MS/MS modes [8, 21, 34], making the samples more complex.  Overall, isotopic 
labeling tends to provide a higher accuracy of quantitation than label-free approaches 
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[4].  
  A variety of studies have been conducted on peptide quantitation through isotopic 
labeling and MS [5, 7, 9-15, 28, 30, 40, 44, 47, 48] The labeling reagents that are 
commonly employed for peptide quantitation of biological samples are H-/D- forms 
of acetic anhydride [10, 11], succinic anhydride (SA) [7, 10, 40, 48], and 
4-trimethylammoniumbutyryl (TMAB) [9, 13]. These reagents react with the primary 
amines, label the free N-termini of peptides as well as the side chain of any internal 
lysine residues, and thus generate differentially labeled peptides with a mass 
difference of several daltons for differentiation and comparison. Some additional 
labels have also been developed and tested in peptide/protein standards, such as urea, 
formaldehyde [1, 15, 18, 28, 43]. In addition, previous efforts have been made to 
validate the labeling approach. Several studies have investigated the abilities of 
isotope labels and MS to accurately quantify a single peptide standard or digests from 
a single protein over a concentration range of up to two orders of magnitude [1, 5, 15, 
28]. Other studies prepared mixtures of peptide standards with each peptide having 
the same concentration, labeled them differentially, and combined in a molar ratio 1:1 
[12, 15] or ratios ranging from 4:1 to 1:4 [11]. After these steps, the quantitation 
accuracy of these peptide mixtures by MS platforms has been validated.  
Given these well-performed validations, what else is needed?  The examples 
above tend to be in mixtures that do not mimic the large dynamic range of peptides 
present in a biological sample where peptides that are present span many orders of 
magnitude.  Do these labeling schemes provide accurate quantitative results when 
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there are peptides spanning 3 or more orders of magnitude?  Are there specific MS 
platforms better suited to such samples and what data acquisition and analysis 
approaches work best?  Here we investigate different MS platforms for quantifying a 
number of isotopically labeled neuropeptides with a range of concentrations and ratios 
from 12:1 to 1:12, in mixtures with a peptide concentration range over three orders of 
magnitude (within each mixture). We selected H4/D4- succinic anhydride as the 
labeling reagent because of its high labeling efficiency, stable labeling of peptides 
throughout sample preparation and measurement on all used MS platforms, the 4 Da 
difference between H/D- labeled peptides to distinguish the isotopologue clusters of 
the labeled and unlabeled forms of the peptide, and the co-elution of differentially 
labeled peptides from reverse-phase columns [21]. While we expect the other labels to 
generate similar results, this will need to be confirmed. Our peptide quantitation was 
performed on three MS platforms that have been previously employed for peptide 
quantitation [5, 7, 40], including UPLC-ESI-Q-TOF MS, CapLC-ESI-IT MS, and 
MALDI-TOF MS. The results demonstrated that among three platforms, 
CapLC-ESI-IT MS was the most robust for quantifying peptides accurately over a 
wide concentration range. However, by adjusting the data acquisition to assure that 
the peptide signals reach a threshold, as well as some other manipulations, the quality 
of the results was greatly increased, which allows the other two systems to obtain the 
same dynamic range performance. There are other parameters than dynamic range; for 
example, MALDI MS was able to quantify the peptide ratios at lower concentrations 
than the other tested platforms. 
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3.3 Experimental 
3.3.1 Chemicals 
Chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise 
stated. The peptide standards for MALDI-TOF calibration were from Bruker 
Daltonics (Billerica, MA). Milli-Q water was filtered by a Milli-Q 119 filtration 
system (Millipore, Bedford, MA, USA). HPLC-grade solvents were purchased from 
Thermo Fisher (Fair Lawn, NJ, USA). 
3.3.2 Sample preparation and isotopic labeling  
Five neuropeptide standards, (bradykinin1-7, NPSSFVRIamide, bradykinin, 
angiotensin I, and neurotensin) as shown in Table 3.2 were individually dissolved to 
concentrations varying from 1 μM to 100 μM. They were mixed together to generate 
eight different peptide mixtures with each having the five peptides at various 
concentrations/ratios. 
Each pair of samples were labeled with 4M either H4-SA or D4-SA dissolved in 
DMSO, after a pH adjustment of each sample to ~9 using phosphate buffer (1 M, 
pH=9.5), or 1 M NaOH if needed. The samples were then vortexed, centrifuged, and 
incubated at room temperature for 15 min, followed by a pH readjustment with 1 M 
NaOH to ~9. The whole procedure repeated 6 times for better labeling efficiency. 
After the last round of labeling and pH adjustment, 2.5 M glycine was added, and the 
incubation lasted for an hour to remove excess free labels. The pH adjustment and 
addition of 2 M hydroxylamine in DMSO were followed to remove labels from 
tyrosine, serine and threonine residues of peptides. After the combination of H- and 
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D- labeled samples, PepClean C18 spin columns (Pierce, Rockford, IL) were applied 
here to desalt the samples, and the peptides were then eluted by 70% aqueous 
acetonitrile solution. Following the removal of the organic solvent in a SpeedVac 
concentrator (Thermo Scientific, San Jose, CA), the samples with 20 μl each were 
ready for MS analysis.  
As a result, four different samples (Sample 1–4) were prepared with various 
expected ratios of H/D-labeled peptides (12:1, 8:1, 4:1, 2:1, 1:1, 1:2, 1:4, 1:8, 1:12) 
and the final peptide concentrations ranging from ~250 nM to 300 μM, producing 
peptide concentration difference up to 1200 fold (Table 3.1). Each sample was labeled 
in a forward and a reverse direction (Table 3.1): the combination of H-SA labeled 
mixture-X and D-SA labeled mixture-Y as a forward label, and the combination of 
D-SA labeled mixture-X and H-SA labeled mixture-Y as a reverse label. In addition, 
each sample had four labeling replicates, which resulted in a total of 32 samples for 
peptide quantitation on each MS platform.  
3.3.3 MS analysis  
The three MS platforms were used for quantitative peptidomic studies: a UPLC 
system coupled to an electrospray ionization quadrupole time-of-flight 
(UPLC-ESI-Q-TOF MS) (Premier, Waters, Milford, MA), a capillary LC (Micromass, 
Manchester, UK) coupled to ESI ion trap (CapLC-ESI-IT MS) (Bruker Daltonics 
HCTultra, Billerica, MA), and Matrix assisted laser desorption/ionization 
(MALDI)-TOF MS (Bruker Daltonics UltrafleXtreme, Billerica, MA). While 1 μl of 
samples directly injected into CapLC-ESI-IT MS, they needed to be diluted 
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differently for each platform, ~30 fold for UPLC-ESI-Q-TOF MS and 100 fold for 
MALDI-TOF MS, to generate a suitable concentration range for MS platforms. 
For the UPLC-ESI-Q-TOF MS platform, a reversed phase C18 nanoAcquity 
column (Waters, Milford, MA) separated the sample using a mixture of solvent A 
(100% water with 0.1% formic acid (FA)) and solvent B (100% acetonitrile (ACN) 
with 0.1% FA). The 90 min gradient for LC system was generated as follows: 1% 
solvent B in 0-30min (isocratic); 1-50% solvent B in 30-60 min (linear); 50-90% 
solvent B in 60-65min (linear); 90-1% solvent B in 65-70 min (linear); 1% solvent B 
in 70-90 min (isocratic). Only MS spectra were collected with a scan range of m/z 
300-2000.  
For the CapLC-ESI-IT MS, the samples were separated on a reversed phase C18 
CapLC system (Micromass, Manchester, UK). The solvent gradient was generated by 
mixing solvent A (95% water and 5% ACN containing 0.1% FA and 0.01% 
trifluoroacetic acid (TFA)) and solvent B (aqueous 95% ACN containing 0.1% FA and 
0.01% TFA). The 55 min gradient for LC system was created as follows: 3-25% 
solvent B in 0-10 min (linear); 25-50% solvent B in 10-40 min (linear); 50%-80% 
solvent B in 40-43 min (linear); 80% solvent B in 43-45 min (isocratic); 80%-3% 
solvent B in 45-48 min (linear); 3% solvent B in 48-55 min (linear). Data was 
acquired for a MS scan range of m/z 300-2000.  
For the MALDI-TOF MS platform, 0.5 µl of sample was spotted onto a stainless 
steel MALDI plate (Bruker Daltonics, Billerica, MA), with 0.5 µl of either saturated 
2,5-dihydroxybenzoic acid (DHB) or alpha-cyano-4-hydroxycinnamic acid (CHCA) 
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as matrices. Three technical replicates were collected for each spot with every spectra 
comprised of 10 acquisitions of 100 laser shots.  
3.3.4 MS data analysis 
The identification of peptide peaks were performed by a combination of charge 
state, mass match, and LC retention time. The mass difference between H- and D- 
labeled peptides with +1 charge state is 4 Da, and with +2 charge is 2 Da. For the data 
acquired by UPLC-ESI-Q-TOF MS and CapLC-ESI-IT MS, the extracted ion 
chromatography was created for both light and heavy labeled peptides, and the mass 
spectra across the entire elution period for both peaks were summed for quantitation. 
The intensities of most abundant isotopic peaks for either H- or D- labeled peptides 
were used for ratio calculations. For the data acquired by MALDI-TOF MS, after the 
identification of differentially labeled peptides, the most abundant isotopic peaks were 
used for ratio calculations.  
 
3.4 Results and Discussion 
3.4.1 Experimental design 
We designed a set of peptide mixtures and experiments to determine under what 
conditions (e.g. MS platforms, ratios, data acquisition and analysis, etc.) we can 
perform relative quantitation of neuropeptides from a mixture. Our set of samples 
represents variations of neuropeptide sequences, post-translational modifications 
(PTMs), and concentrations. Each sample contains a mixture of five representative 
neuropeptide standards, which have masses spread across 500-2000 Da (Table 3.2), a 
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mass range suitable for peptide detection by all three MS platforms. Two out of these 
five neuropeptides are modified by amidation or pyroglutamylation, two common 
PTMs present in neuropeptides. These samples also have expected ratios of 
differentially labeled peptides varying from 12:1 to 1:1 to 1:12, and involved peptide 
concentrations from 250 nM to 300 μM. For the best performance, we diluted the 
samples before analysis: 30 fold (~8 nM to 10 μM) and 100 fold (2.5 nM to 3 μM). 
Such mixtures represent an important range of the physiological concentrations of 
neuropeptides, which spans from the micromolar to femtomolar [22, 33]. Furthermore, 
in order to allow comparisons between different samples, only one of the parameters, 
either the ratio of differentially labeled peptides or the peptide concentration, was 
modified when designing comparable sample mixtures. To account for variations 
during sample preparation and instrumental fluctuation, four technical replicates were 
labeled in parallel, and samples were also labeled in both forward and reverse 
directions. In this way, the effects of various factors on peptide quantitation have been 
addressed. 
3.4.2 Peptide quantitation 
By using succinic anhydride to label each of the five peptides (Table 3.1) in the 
mixtures, MS peaks are 100 Da (H-SA) or 104 Da (D-SA) heavier than the parent 
peaks (Figure 3.1). The results indicate that greater than 99% of the peptides in our 
mixtures were labeled regardless of concentrations of the other peptides in the 
mixtures.  This is because of the more than 1000-fold excess of labeling reagent to 
peptide (Figure 3.1).  Our results also demonstrate the stability of the labeled 
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peptides during storage and analysis with all three MS platforms. These are 
prerequisites for our follow-up studies.  
The ratio of peak intensities of H- or D- labeled peptides in MS spectra was 
compared to the theoretical ratio. A 20% error in the peptide ratios was used as the 
cutoff as this value is oftentimes used as an accuracy threshold for bioassays and has 
been used in a number of studies to validate isotopic labeling approaches [1, 6, 28]. 
When the observed ratio of isotopically labeled peptides is within 20% of the 
expected ratio, the quantification is considered to be a success.  
3.4.2.1 CapLC-ESI-IT MS 
One microliter of each of the eight peptide mixtures (with four replicates for each 
mixture) was assayed.  Each was injected into CapLC-ESI-IT MS, the MS spectra 
across the entire elution time for all H- and D-labeled peptides were summed, and the 
ratios were calculated using their most abundant isotopic peaks. The representative 
MS spectra of two such peptides, bradykinin 1-7 or bradykinin, are presented in 
Figure 3.2 A-B, and the ratios of differentially labeled peptides are within 2% of the 
expected ratios 1:1 and 1:2. The representative data of the ratios and concentrations 
for the five peptides in two mixtures are shown in Figure 3.2 C-D, with peptide 
mixture 1-F having a concentration range from 0.25 µM to 100 µM (400 fold range), 
and peptide mixture 2-F from 0.25 µM to 300 µM (1200 fold difference). Sample 1-F 
and sample 2-F have the same expected ratios for the five peptides but different 
concentrations. The observed average ratio of these differentially labeled peptides was 
within 20% of the expected ratio, even for peptides (e.g. Angiotensin I) with the 
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highest expected ratio of 12:1 (Figure 3.2 C-D). Over this range, the peptides levels 
did not change the observed quantitation accuracy (Figure 3.2 C-D), and the same for 
changing only ratios (data not shown). For peptides with an expected ratio of 1:1, the 
relative error for the observed ratio was typically less than 10%.  Since this platform 
generated one predominant charge state (either +1 or +2 charge) for each peptide, 
peptides with only one charge state were quantified here (Figure 3.2).  In summary, 
the CapLC-ESI-IT MS allowed us to obtain quantitative data for most and the results 
are consistent between the forward and reverse labeling (data not shown).  
3.4.2.2 UPLC-ESI-Q-TOF MS 
The ESI-Q-TOF MS platform is widely employed in quantitative peptidomics of 
various biological samples [1, 7, 12], partially because of its high mass resolution and 
mass accuracy. The nano-scale UPLC-ESI-Q-TOF MS requires lower amount of 
samples to be injected than the CapLC-ESI-IT MS and we diluted the samples ~30 
fold. Our initial analysis of these samples demonstrated a narrow linear range ~50 
fold and some inconsistency among multiple charge states of the same peptide. In 
order to understand this, we selected one mixture, Sample 4-R, made a serial dilution 
series, and then injected one microliter of eight dilutions into UPLC-ESI-Q-TOF MS 
to seek ways for improved quantitative results. Our results suggest that if the MS 
signals for the peptides being measured fall within the linear region of the detector of 
UPLC-ESI-Q-TOF MS (ideally from Log (MS Intensity) 2 to 4), the ratios of 
H/D-labeled peptides are mostly within the 20% threshold, even for peptides with 
high ratios (e.g., Bradykinin with expected ratio 8:1 in Series 6~8 (+1 charge), and in 
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Series 1~4 (+2 charge)) (Figure 3.3 A-B). On the other hand, if the peptide signal 
does not produce an MS signal within the linear range (e.g. detector saturation), the 
difference of peptide levels are distinguished but underestimated (e.g. Bradykinin in 
Series 5-8 (+2 charge)) (Figure 3.3 B). The representative MS spectra of H- or D- 
labeled bradykinin (+1 and +2 charge states) are shown in Figure 3.3 C-D. For 
isotopically labeled peptide pairs with a ratio of 1:1, no significant difference was 
observed, even if the detector was saturated (Figure 3.3 E-H).  
Often peptides with multiple charge states are generated by ESI, and so we 
commonly observed +1 and +2 charge states. We investigated the measurement 
accuracy for both charge states. The comparison between Figure 3.3A and 3.3B 
suggests that MS signals within the linear region is required for either +1 or +2 
charged peptides to be accurately quantified. Interestingly, the MS intensities of 
peptide with different charge states vary.  Often the +2 charge peptide has a much 
higher MS signal than +1 charge peptide, with a two order of magnitude difference 
observe in many cases (Figure 3.3 A-B and G-H).  It appears that the peptide with +2 
charge usually saturates the detector before the same peptide with +1 charge. We take 
advantage of this for our samples by selecting ions with the appropriate charge state to 
quantify. As a result of this, the observed ratios for all the peptides are within 20% of 
the expected values. Compared to previous studies showing that ESI-Q-TOF MS has a 
linear range below 100 fold for quantitation [37], our approaches successfully 
quantified peptide mixtures with a concentration range of >1000-fold (Figure 3.4). 
Peptides in the low femtomole range were successfully quantified on 
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UPLC-ESI-Q-TOF MS (Figure 3.3 B Series-1).  
3.4.2.3 MALDI-TOF MS 
One key advantage of MALDI-TOF MS, compared to other MS platforms, is that 
it requires much lower amount of samples to analyze, and could detect peptide at 
attomole levels. Therefore, we diluted our samples 100 fold for MALDI-TOF MS, 
spotted 0.5 µl diluted samples with either DHB or CHCA as matrices on the MALDI 
target, and made a comparison among the samples. Ten acquisitions of MS signals 
were obtained uniformly across a single sample spot and added together for 
quantitation purposes.  
Our initial results suggested that without any optimization, MALDI was able to 
differentiate peptide levels, and was able to do this for even the lowest level peptides, 
but may only provide accurate quantitation for peptides with concentration difference 
about 20 fold or less (data not shown), which is similar result to previous reports [28, 
42]. However, by selecting appropriate data acquisition protocols, the effective 
dynamic range of MALDI-TOF is improved. First, we make sure that the higher 
abundance peptides do not saturate the detector. Saturation of the MALDI-TOF MS 
detector is easily identified, and often times it could be simply fixed by modifying the 
MS parameters (e.g. laser power). In addition, we required the peak intensity of 
peptides to be above a certain S/N threshold, and optimized the acquisition parameters 
(e.g. laser power) to make sure the lower concentration peaks met this threshold 
requirement even for the peptides at the lowest abundance.  
Our data using DHB as matrix after the optimization of data acquisitions are 
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shown in Table 3.3. For most of the peptides, the observed ratios are within 20% of 
the theoretical ratios. However, the dynamic range for MALDI-TOF MS is sample 
dependent. For sample 4-R, MALDI-TOF MS accurately quantified peptides over a 
range of ~1200 fold from 2.5 pM to 3000 pM. With sample 2-F and same 
concentration range, peptides could be accurately quantified over a range of ~250 fold 
from 12.5 pM to 3000 pM. But for sample 1-F, accurate quantitation of peptides could 
only be obtained over a range of ~20 fold from 62.5 pM to 1000 pM.   
Notably, two types of peptides were harder to quantify by MALDI-TOF MS. One 
is the peptide pair with a high expected ratio (Table 3.3 FVRIamide and Angiotensin I 
in Sample 1-F), and the other type is peptides in low abundance that generate low MS 
signals (Table 3.3 Bradykinin and Neurotensin in Sample 2-F). The combined 
situation generally results in an observed ratio of the differentially labeled peptides 
larger than the expected ratio (Table 3.3 FVRIamide and Angiotensin I in Sample 1-F, 
and Neurotensin in Sample 2-F). It may be due to more prominent effects of ion 
suppression of one labeled peptide by another. However, the observed ratio still 
correctly reflects the actual 1:1 ratio, even if the peptide is at a low level (Table 3.3 
Angiotensin I in Sample 4-R, and Bradykinin 1-7 in Sample 2-F).  
It is also worth mentioning that, if we want to obtain relatively accurate 
quantitation of one specific peptide in very low abundance, instrumental parameters 
could be adjusted or optimized just for the peptide of interest to obtain MS signals 
above the threshold while not saturating the detector. One single MS acquisition, 
instead of several summed spectra across the sample, is enough to achieve good 
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quantitation accuracy. As shown in Figure 3.5, the accuracy for low abundance 
FVRIamide and Angiotensin I are 7% and 3% respectively after optimization and 
single MS acquisition, while previous results without such adjustments reported larger 
errors, 106% and 76% respectively (Table 3.3 Sample 1-F). This could only be 
obtained for peptides above low femtomole level, the limit of quantitation (LOQ) of 
our MALDI-TOF MS platform. 
What are the effects of the MALDI matrix used?  Besides DHB, we tested the 
other common matrix CHCA. As shown in Table 3.4, while the use of DHB led to an 
accurate quantitation of most peptides in Sample 4-R over a concentration range of 
~1200 fold from 2.5 pM to 3000 pM, CHCA was less robust and the percentage of 
error is higher for all five peptides than those by DHB.  As CHCA provides a more 
consistent MS signal across the sample spot [42], we expected better quantitation 
performance.  Perhaps the differentially labeled peptides co-crystallized in both 
DHB and CHCA differently. More importantly, DHB and its sweet spots facilitate the 
enrichment of peptides into a small region, which leads to a more intense MS signal, 
making it easier to meet threshold requirements, and thus providing a wider 
concentration range and a lower LOQ. For most peptides, low femtomole or even 
lower levels of peptides are required when using DHB as matrix for accurate 
quantitation, consistent with previous studies [40]. While MALDI TOF MS is not 
commonly considered to be the ideal instrument for peptide quantitation [42], our 
results suggest that MALDI-TOF MS could differentiate the change of peptide levels. 
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3.5 Conclusions  
By using isotopic labeling approach, the quantitation accuracy of neuropeptide 
measurements over a concentration range greater than >3 orders of magnitude and 
with varying sample complexity was investigated on three different MS platforms. 
The peptide concentrations in the mixtures vary from 250 nM to 300 μM. The 
different MS platforms performed differently. CapLC-ESI-IT MS handles a wide 
dynamic range of peptides with a limit of quantification (LOQ) ~100 fmol. By 
selecting the appropriate charge state to quantify, the dynamic range of accurate 
quantitation on UPLC-ESI-Q-TOF MS has been improved by at least one magnitude 
[37]. Previous studies demonstrated that MALDI-TOF provided quantitative results 
for peptides with relatively narrow concentration range (perhaps less than 2 orders of 
magnitude [28, 42]). By optimizing the acquisition parameters, the ability of MALDI 
to quantify peptides is improved to greater than 1200 fold (although this is  
sample-dependent). MALDI-TOF MS has the lowest LOQ (limit of quantification) 
among the three platforms, and simpler data analysis. The approaches outlined here 
lead to a dynamic range one order of magnitude higher than previously reported for 
isotopic labeling approaches [8]. While it was easiest to quantify peptides close to the 
1:1 ratio, such situations not always encountered in neuropeptide measurements and 
so understanding the limits of the strategies used to measure peptides is important. 
While the approaches shown are important and generalizable, the specifications of the 
specific instruments will have evolved, and so will need to be validated as new 
instrumental platforms evolve. 
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3.7 Figures and Tables 
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Figure 3.1 Representative MS spectra of a peptide mixture by MALDI-TOF MS indicating 
complete peptide labeling by H-/D- succinic anhydride. Each spectrum demonstrates the 
detection of the five standard peptides (Bradykinin 1-7, FVRIamide, Bradykinin, Angiotensin 
I, and Neurotensin) with +1 charge state. Dotted squares indicate the original masses of 
peptides before SA labeling showing complete incorporation of the labels. Broken line 
squares indicate the peaks of H-/D- labeled peptides.  
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Figure 3.2 Representative data for quantitaiton of peptide mixtures by CapLC-ESI-IT MS. 
(A) MS spectra of H- and D- forms of bradykinin 1-7 (+1 charge, MW 756.39) with an 
expected ratio 1:1 and calculated ratio 1.02:1 (2% error). (B) MS spectra of H- and D-forms 
of bradykinin (+1 charge, MW 1059.56) with expected ratio 1:2 and calculated ratio 1:1.97 
(2% error). (C) Sample 1-F with a concentration range of 400 fold (0.25 µM to 100 µM) and 
relative errors ≤ 20% for all peptides. (D) Sample 2-F with a concentration range of 1200 fold 
(0.25 µM to 300 µM) and relative errors ≤ 20% for all peptides. Key: a: bradykinin (+2 
charge); b: bradykinin 1-7 (+1 charge); c: neurotensin (+2 charge); d: FVRIamide (+1 charge);   
e: angiotensin I (+2 charge).  The expected ratio (H/D) is the ratio of H- and D- labeled 
peptides actually in the mixture and the observed Ratio (H/D) is the ratio average observed 
ratios determined from four technical replicates.  Error bars are standard deviations; the 
broken line is the expected 1:1 correlation between observed and expected ratios, and the 
relative error (%) is calculated by (average of observed ratios-expected ratio)/expected ratio.  
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Figure 3.3 UPLC-ESI-Q-TOF MS quantitative analysis of a serial dilution of Sample 4-R (a 
concentration range of 1200 fold). The order for the amount of sample in series 1~8 is 
1<2<3<4<5<6<7<8 (the highest dilution is 10000 times for series-1). (A-B) Comparison of 
the observed ratios of differentially labeled bradykinin standards (expected ratio 8:1) in the 
serial dilution with +1 (a) or +2 (b) charge state. (C-D) A peak pair of differentially labeled 
bradykinin standards (expected ratio 8:1) in one dilution (Series-6) with +1 charge and 
observed ratio 7.59:1 (C) or +2 charge and observed ratio 4.48:1 (D). (E-F) Comparison of 
the observed ratios of differentially labeled Angiotensin I standards (expected ratio 1:1) in the 
serial dilution with +1 (E) or +2 (F) charge state. (G-H) A peak pair of differentially labeled 
Angiotensin I standards (expected ratio 1:1) in one dilution (Series-4) with +1 charge and 
observed ratio 1.01:1 (G) or +2 charge and observed ratio 1.05:1 (H). Exp. ratio indicates the 
expected ratio of H- and D- labeled peptides in the mixture; Obs. Ratio (H/D) indicates the 
observed ratios of H- and D- labeled peptides in the mixture. The broken line square indicates 
that the observed ratio is within 20% of the expected ratio. The solid line indicates the 
expected ratio of H- and D- labeled peptides; The linear region of this MS platform is at best 
from Log (MS intensity) 2 to 4. 
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Figure 3.4 Representative data for quantitation of peptide mixtures by UPLC-ESI-Q-TOF 
MS. (A) Sample 3-R with a concentration range of 300 fold (25 nM to 7.5 µM after 10 times 
dilution) and a relative error ≤ 20%. (B) Sample 4-R with a concentration range of 1200 fold 
(25 nM to 30 µM after 10 times dilution) and a relative error ≤ 20%. Key: a: neurotensin; b: 
FVRIamide; c angiotensin I; d: bradykinin 1-7; e: bradykinin. The expected ratio (H/D) is the 
ratio of H- and D- labeled peptides actually in the mixture and the observed Ratio (H/D) is 
the ratio average observed ratios determined from four technical replicates.  Error bars are 
standard deviations; the broken line is the expected 1:1 correlation between observed and 
expected ratios, and the relative error (%) is calculated by (average of observed 
ratios-expected ratio)/expected ratio.  
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Figure 3.5 MS spectra of Sample 1-F for peptide quantitation via a single acquisition by 
MALDI-TOF MS (a) H- and D- forms of FVRIamide (+1 charge, MW 917.51) with expected 
ratio 8:1 and calculated ratio 8.5:1 (7% error). (b) H- and D-forms of Angiotensin I (+1 
charge, MW 1295.68) with expected ratio 12:1 and calculated ratio 12.4:1 (3% error).  
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Table 3.1 The peptide concentrations and ratios in eight peptide mixturesa 
Forward labeling 
 
Sample 1-F 
 (conc. range of 400 fold) 
Sample 2-F 
 (conc. range of 1200 fold) 
Sample 3-F 
 (conc. range of 300 fold) 
Sample 4-F 
 (conc. range of 1200 fold) 
Peptide  
Final Conc.  
of H/D (µM) 
Final Ratio  
of H/D 
Final Conc. 
of H/D (µM) 
Final Ratio  
of H/D 
Final Conc. 
of H/D (µM) 
Final Ratio  
of H/D 
Final Conc. 
of H/D (µM) 
Final Ratio  
of H/D 
Bradykinin 1-7 12.5/12.5 1:1 1.25/1.25 1:1 1.25/5 1:4 12.5/50 1:4 
FVRIamide 2/0.25 8:1 100/12.5 8:1 25/12.5 2:1 0.5/0.25 2:1 
Bradykinin  6.25/12.5 1:2 0.25/0.5 1:2 0.25/2 1:8 6.25/50 1:8 
Angitensin I 15/1.25 12:1 300/25 12:1 25/25 1:1 1.25/1.25 1:1 
Neurotensin 100/25 4:1 25/6.25 4:1 75/6.25 12:1 300/25 12:1 
Reverse labeling 
 
Sample 1-R 
 (conc. range of 400 fold) 
Sample 2-R  
 (conc. range of 1200 fold) 
Sample 3-R  
  (conc. range of 300 fold) 
Sample 4-R  
  (conc. range of 1200 fold) 
Peptide  
Final Conc.  
of H/D (µM) 
Final Ratio  
of H/D 
Final Conc. 
of H/D (µM) 
Final Ratio  
of H/D 
Final Conc. 
of H/D (µM) 
Final Ratio  
of H/D 
Final Conc. 
of H/D (µM) 
Final Ratio  
of H/D 
Bradykinin 1-7 12.5/12.5 1:1 1.25/1.25 1:1 5/1.25 4:1 50/12.5 4:1 
FVRIamide 0.25/2 1:8 12.5/100 1:8 12.5/25 1:2 0.25/0.5 1:2 
Bradykinin  12.5/6.25 2:1 0.5/0.25 2:1 2/0.25 8:1 50/6.25 8:1 
Angitensin I 1.25/15 1:12 25/300 1:12 25/25 1:1 1.25/1.25 1:1 
Neurotensin 25/100 1:4 6.25/25 1:4 6.25/75 1:12 25/300 1:12 
a There are four samples labeled in a forward direction (Sample 1-F to Sample 4-F), four labeled in a reverse direction (Sample 1-R to Sample 4-R). Sample 1-F and 
Sample 1-R are the same mixture labeled in forward or reverse directions, and the same for the others. Final conc. of H/D indicates the final concentrations for both 
H- and D- labeled peptides in the mixture; Final Ratio of H/D indicates the final ratios of H- and D- labeled peptides in the mixture; 
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Table 3.2 Five peptide standardsa 
Peptide Name Peptide Sequence Theor. Mass (Da) No. of labels 
Theor. Masses (H/D) 
after labeling 
Bradykinin 1-7 RPPGFSP 756.39 1 856.46/860.49 
FVRIamide NPSSFVRIa 917.51 1 1017.58/1021.61 
Bradykinin RPPGFSPFR 1059.56 1 1159.63/1163.66 
Angiotensin I DRVYIHPFHL 1295.68 1 1395.75/1399.78 
Neurotensin pELYENKPRRPYIL 1671.90 1 1771.97/1776.01 
a “p” indicates N-terminal pyroglutamylation; “a” indicates C-terminal amidation.  The theor. mass, 
theoretical monoisotopic mass.  The number of labels are the number of succinic anhydride labels 
covalently bound to the peptide after labeling. Theor. mass (H/D) after labeling indicates the expected 
monoisotopic masses of H- or D- labeled peptides.  
 
 
Table 3.3 Representative data for quantitaiton of peptide mixtures  
by MALDI-TOF MS using DHB as matrix a 
Peptide Name 
Final Conc. of H/D 
after dilution (pM) 
Exp. Ratio of 
H/D 
Ave. Ratio of H/D  
± SD 
Error 
(%) 
Sample 1-F (A concentration range of 400 fold) 
Bradykinin 1-7 125 / 125 1 1.09±0.05 9 
FVRIamide 20 / 2.5 8 16.52±0.32 106 
Bradykinin 62.5 / 125 0.5 0.53±0.02 6 
Angiotensin I 150 / 12.5 12 21.10±1.37 76 
Neurotensin 1000 / 250 4 3.72±0.48 -7 
Sample 2-F (A concentration range of 1200 fold) 
Bradykinin 1-7 12.5 / 12.5 1 0.84±0.03 -16 
FVRIamide 1000 / 125 8 8.49±1.13 6 
Bradykinin 2.5 / 5 0.5 N/A N/A 
Angiotensin I 3000 / 250 12 10.50±0.63 -13 
Neurotensin 250 / 62.5 4 6.08±0.26 52 
Sample 4-R (A concentration range of 1200 fold) 
Bradykinin 1-7 500 / 125 4 5.00±1.24 25 
FVRIamide 2.5 / 5 0.5 0.47±0.04 -6 
Bradykinin 500 / 62.5 8 9.42±0.92 18 
Angiotensin I 12.5 / 12.5 1 1.05±0.12 6 
Neurotensin 250 / 3000 0.083 0.095±0.01 13.5 
a Final conc. of H/D indicates the final concentrations for both H- and D- labeled peptides in the mixture; 
Exp. ratio of H/D indicates the expected ratio of H- and D- labeled peptides in the mixture; Ave. Ratio of 
H/D indicates the average ratios of four technical replicates of a peptide in the mixtures; SD means 
standard deviation; Error (%) is calculated by (average ratio-expected ratio)/expected ratio, and numbers in 
bold are within 20% of expected ratios, and the negative sign indicates the average ratio is lower than the 
expected ratio. Samples were diluted 100 times for MALDI-TOF MS studies.  
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Table 3.4 Representative data for quantitation of peptide mixtures  
using CHCA versus DHB as matrices by MALDI-TOF MSa 
Peptide Name 
Final Conc. of H/D 
after dilution (pM) 
Exp. Ratio 
of H/D 
Ave. Ratio of H/D 
± SD 
Error (%) 
Sample 4-R with CHCA (A concentration range of 1200 fold) 
Bradykinin 1-7 500 / 125 4 6.19±0.36 55 
FVRIamide 2.5 / 5 0.5 0.40±0.03 -20 
Bradykinin 500 / 62.5 8 11.83±1.20 47 
Angiotensin I 12.5 / 12.5 1 0.92±0.07 -8 
Neurotensin 250 / 3000 0.083 0.10±0.01 25 
Sample 4-R with DHB (A concentration range of 1200 fold) 
Bradykinin 1-7 500 / 125 4 5.00±1.24 25 
FVRIamide 2.5 / 5 0.5 0.47±0.04 -6 
Bradykinin 500 / 62.5 8 9.42±0.92 18 
Angiotensin I 12.5 / 12.5 1 1.05±0.12 6 
Neurotensin 250 / 3000 0.083 0.095±0.01 13.5 
a Final conc. of H/D indicates the final concentrations for both H- and D- labeled peptides in the mixture; 
exp. ratio of H/D is the expected ratio of H- and D- labeled peptides in the mixture; Ave. Ratio of H/D 
indicates the average ratios of four technical replicates of a peptide in the mixtures; SD standard deviation; 
error (%) is calculated by (average ratio-expected ratio)/expected ratio, and numbers in bold are within 
20% of expected ratios, and the negative sign indicates the average ratio is lower than the expected ratio; 
samples here were diluted 100 times for MALDI-TOF MS studies. 
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CHAPTER 4 
QUANTITATIVE PEPTIDOMICS OF MICE DEFICIENT IN 
ENDOTHELIN-CONVERTING ENZYME-2 (ECE-2) 
 
4.1 Notes and Acknowledgements 
This chapter was adapted with permission from a portion of the manuscript 
entitled “Mice deficient in endothelin-converting enzyme-2 exhibit abnormal 
responses to morphine and altered peptide levels in the spinal cord” that was 
published by Miller L.K., Hou X., Rodriguiz R.M., Gagnidze K., Sweedler J.V., 
Wetsel W.C., Devi L.A., in Journal of Neurochemistry, 2011;119:1074-85. 
DOI: 10.1111/j.1471-4159.2011.07513.x [16]. Lydia K. Miller, Khatuna Gagnidze 
and Lakshmi A. Devi at Mount Sinai School of Medicine (NY), and Ramona M. 
Rodriguiz and William C. Wetsel at Duke University Medical Center (NC) performed 
the behavioral and biological studies, as well as raising the animals and providing 
mice tissues for our peptidomics work. I am very grateful to Stanislav Rubakhin for 
always being there for me whenever I needed mouse samples. I really appreciate that 
Xian Chen shared with me her peptidomics data in mouse tissues. I would like to 
thank Jonathan V. Sweedler for his insightful advices throughout the project. The data 
presented here focuses on MS-based peptidomics studies using mice spinal cord. My 
contribution to this work was designing and performing MS-related experiments, 
followed by data analysis and interpretation. I also presented additional peptidomics 
studies using mouse brain region—striatum, which has yet to be published. This work 
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was supported by grants from NIH NS026880 and DA0019521 (to L.A.D.), P30 
DA018310 (to J.V.S.). The content is solely the responsibility of the authors and does 
not necessarily represent the official views of NIDA or the National Institutes of 
Health. 
 
4.2 Introduction 
The majority of neuropeptides are synthesized as prepropeptide precursors that 
undergo cleavage to bioactive peptides while transiting from the Golgi apparatus to 
the cell membrane in secretory vesicles. This post-translational processing serves as 
an important regulatory step in peptide synthesis, as the precursor propeptide may be 
processed to different peptides depending upon the peptidases expressed in a 
particular cell [13, 24, 25]. For example, proenkephalin can be ‘classically’ processed 
at dibasic residues by prohormone convertases and carboxypeptidases to yield Met- 
and Leu-enkephalin. Alternatively, this precursor can be ‘non-classically’ processed at 
non-basic residues to yield longer bovine adrenal medulla (BAM) peptides [20, 21, 
25], which exhibit higher analgesic potency relative to enkephalins and can decrease 
morphine tolerance [15, 16]. Alternative processing of peptide precursors could thus 
have important physiological implications.  
Although the endopeptidases (prohormone convertase 1 and 2) and 
carboxypeptideases responsible for classical neuropeptide processing have been 
well-characterized, less is known about the peptidases that cleave at non-classical 
sites [13]. To date, endothelin-converting enzyme-2 (ECE-2) has been suggested as a 
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non-classical neuropeptide processing enzyme based on its biochemical properties, 
tissue distribution, and cleavage-site selectivity [13]. ECE-2 belongs to the Neprilysin 
(NEP) family (M13) of zinc metalloproteases, sharing 59% sequence homology with 
ECE-1 and 37% with NEP. Homology modeling has revealed that the substrate 
binding pocket is well conserved between these enzymes [14]. Despite this fact, 
ECE-2’s distribution and biochemical properties suggests that it plays a unique role in 
neuropeptide processing within the secretory pathway. While ECE-1 and NEP show 
predominant cell-surface expression and are optimally active at neural pH [27, 28, 31], 
ECE-2 is present intracellularly and it exhibits an acidic pH optimum, consistent with 
processing that takes place within the acidic secretory pathway [10, 25, 33]. ECE-2 
also has a restricted neuroendocrine distribution, with relatively high levels in regions 
rich in neuropeptides, such as the hypothalamus, spinal cord, and midbrain [10, 23]. 
In contrast, NEP and ECE-1 show a broad tissue distribution, with highest expression 
in the kidney and liver, respectively [30, 40]. Hence, the distribution and biochemical 
properties of ECE-2 support a unique role in neuropeptide processing.  
ECE-2 was named for its role in generating the potent vasoconstrictor 
endothelin-1 from its precursor big-endothelin-1 [10]. We have shown that ECE-2 
processes a number of neuroendocrine peptides at non-classical sites at acidic pH in 
vitro [19]. Of the 42 peptides screened using mass spectrometry (MS), 10 were found 
to be substrates for ECE-2, including three proenkephalin-derived peptides (i.e. 
peptide E, BAM22 and BAM18), dynorphin B, and substance P. Comparisons of 
these substrates revealed that ECE-2 prefers aromatic or aliphatic residues in the P1’ 
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position (C-terminal aspect of the peptide bond), like ECE-1 and NEP. However, 
ECE-2 can cleave some, but not all substrates of ECE-1 and NEP, indicating there are 
cleavage-site preferences beyond these residues. This ability to cleave selectively at 
non-basic residues further supports the contention that ECE-2 functions as a 
non-classical neuropeptide processing enzyme.  
Recently, a viable and fertile knockout (KO) mouse model has aided investigation 
of ECE-2’s role in vivo. These mice show no gross developmental defects, and 
behavioral analyses have revealed no impairments in sensory or motor functions or 
signs of depressive- or anxiety-like responses [30, 41]. However, we did observe 
impairments in learning and memory, which, together with its relatively high 
expression in the hippocampal dentate gyrus, suggests that ECE-2 may process 
as-yet-unidentified peptides important for mediating these behaviors [30]. 
Alternatively, these deficiencies in learning and memory processes could reflect an 
Alzheimer’s disease-like phenotype, as ECE-2 KO mice show increased amyloid 
b-protein accumulation in the brain [9].  
Owing to the availability of ECE-2 KO mouse, we were able to investigate 
whether ECE-2 serves as a neuropeptide processing enzyme in vivo. The mouse spinal 
cord and brain regions (e.g. striatum and hippocampus) were selected to study, due to 
their high expression levels of both ECE-2 and neuropeptides [23]. We developed a 
multi-stage peptide extraction protocol, and employed multiple MS platforms for 
peptidomics analysis. As a result, we identified a number of previously known and 
unknown neuropeptides, and also found that the levels of some peptides were altered 
 81
in either spinal cord or striatum of ECE-2 KO mice. Our findings support a role of 
ECE-2 in neuropeptide processing in vivo. 
 
4.3 Experimental 
4.3.1 Animals  
Adult age-matched and sex-matched ECE-2 KO mice and wild-type (WT) 
littermate controls were used for these experiments. Animals were generated and 
propagated by heterozygous C57BL6/J-129/SvJ matings at Mount Sinai School of 
Medicine and at Duke University as described [23]. Efforts were made to minimize 
animal suffering, and all experimental procedures were approved by the Institutional 
Animal Care and Use Committees at Mount Sinai School of Medicine and Duke 
University. ARRIVE guidelines were followed. Mice were anesthetized and 
euthanized by CO2 for biochemical experiments. The spinal cords were removed, 
immediately frozen on dry ice, and stored at -80ºC. 
4.3.2 Chemicals 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless 
otherwise stated. The peptide standards for Matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) calibration were obtained from 
Bruker Daltonics (Billerica, MA). 
4.3.3 Peptide Extraction and Isotopic Labeling 
A multistage extraction protocol that allows for efficient extraction of peptides 
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was used [3]. Briefly, spinal cord tissues from three WT or ECE-2 KO mice were 
pre-heated at 90ºC for 1 min to inactivate endogenous enzymes. Samples were then 
partially homogenized in ~5 volumes of deionized water, sonicated for 30 s, and 
heated to 90ºC for 20 min. After centrifugation and supernatant collection, the 
remaining pellets were cooled on ice for 20 min and then fully homogenized two 
times in ~10 volumes of acidified acetone (40:6:1 acetone/water/12M HCl) twice. 
Following sonication, vortexing, and centrifugation, the supernatants were collected. 
The combined two-stage extracts were dried using a SpeedVac concentrator (Thermo 
Scientific, San Jose, CA, USA), and reconstituted in solvent A [95% water and 5% 
acetonitrile (ACN) with 0.1% formic acid (FA) and 0.01% trifluoroacetic acid (TFA)]. 
Prior to tandem MS studies, the samples were filtered through a Microcon centrifugal 
filter with a 10 kDa cutoff (Millipore, Billerica, MA, USA). After pH adjustment to 
~9 using 1 M phosphate buffer or 1 M NaOH if needed, each spinal cord was divided 
into half and labeled with 2 μL of 4 M[H4] or [D4] succinic anhydride (SA) in 
dimethylsulfoxide. After vortexing, centrifugation, and incubation at 22ºC for 15 min, 
the sample pH was readjusted to ~9 with 1 M NaOH. The labeling procedure was 
repeated four times with subsequent pH adjustment. Any excess free labeling was 
quenched by 15 μL of 2.5 M glycine for at least 1 h. The combined isotope-labeled 
samples were then filtered through a 10 kDa Microcon centrifugal filter (Millipore), 
followed by the addition of 15 μL of 2.5 M hydroxylamine solution, as described [4, 
7]. For each replicate, there were two technical replicates: the combination of 
[H4]-SA labeled WT and [D4]-SA labeled ECE-2 KO samples as forward replicates 
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and the combination of [D4]-SA labeled WT and [H4]-SA labeled ECE-2 KO 
samples as reverse replicates. The samples were desalted by PepCleanTM C18 spin 
columns (Pierce, Rockford, IL, USA), and eluted with 70% aqueous ACN solution. 
4.3.4 Peptide Measurement and Identification by Tandem MS 
Extracts were passed through the first stage of fractionation using a microbore 
HPLC system Magic 2000 (Michrom BioResources, Inc., Aubum, CA, USA) 
equipped with a C18 reverse phase column. A 70 min run was conducted at a 20 
μL/min flow rate, with a five-step linear gradient generated by mixing mobile phases 
A (95% water and 5% ACN, 0.1% FA and 0.01% TFA) and B (95% ACN, 5% water, 
0.1% FA and 0.01% TFA) as previously described [8]. Fractions were manually 
collected, and subjected to second-stage liquid chromatography (LC) separation 
coupled to MS.  
Two LC-MS/MS systems were employed for more comprehensive peptide 
identification. The first was a NanoAcquity ultra performance LC (UPLC) system 
(Waters, Milford, MA, USA) equipped with a C18 reverse phase column (75 μm i.d., 
particle size 3 μm, and pore size 100 Å), connected to an electrospray ionization (ESI) 
source and quadrupole time-of-flight (Q-TOF) mass spectrometer (Waters). The 
solvent gradient over a 90 min run was generated by water/ACN with 0.1% FA at a 
flow rate of 400 nL/ min. MS detection of peptides was controlled by MassLynx 4.1 
software (Waters) in a data-dependent manner. The MS/MS precursor ion selection 
was set at four ions of the highest intensity per MS scan, and dynamic exclusion of 
previously fragmented precursor ions was enabled. The mass-to-charge (m/z) ranges 
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for the MS and MS/MS scans were 200–2000 and 50–2000 Da, respectively. The 
second LC-MS/MS system was a capillary HPLC system (Waters, Milford, MA) with 
a C18 reversed-phase column (300 μm i.d., particle size 3 μm, and pore size 100 Å; 
Dionex, Sunnyvale, CA, USA), coupled to an ESI source and ion-trap mass 
spectrometer (HCTUltra-PTM Discovery system, Bruker Daltonics Inc., Billerica, 
MA, USA). The solvent gradient over a 60 min run was generated by water/methanol 
with 0.1% FA at a flow rate of 2.5 μL/min; the Esquire software (Bruker Daltonics 
Inc.) controlled the MS detection of peptides in a data-dependent manner as described 
[8]. The m/z ranges for MS and MS/MS scans were 300–1800 and 50–3000 Da, 
respectively. 
After data collection, the MS/MS spectra were converted to either .pkl or .mgf 
file formats and sequenced automatically against an in-house mouse precursor 
database using the PEAKS Studio 4.5 software (Bioinformatics Solutions, Inc., 
Waterloo, CA, USA). The search parameters for PEAKS were: cleavage sites, 
variable post-translational modifications (including N-terminal pyro-Glu and 
pyro-Gln, acetylation, methylation, phosporylation, C-terminal amidation, and 
disulfide bond), mass tolerance 0.5 Da for the precursor ion, and 0.5 Da for fragments. 
The criteria for peptide assignments include the PEAKS score, mass error, and 
manual verification as described in previous studies [8]. 
4.3.5 Peptide Measurement and Quantitation by MS 
Two mass spectrometric platforms were implemented for peptide quantitation. 
The first was the Waters NanoAcquity UPLC-ESI-Q-TOF instrument described above. 
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The solvents and instrument settings/parameters were the same as those for the 
peptide identification studies, except that the MS spectra were collected from a scan 
range of m/z 200–2000 Da. The second instrument used was an Matrix-assisted laser 
desorption/ionization (MALDI) coupled to TOF mass spectrometer (UltrafleXtreme, 
Bruker Daltonics, Bremen, Germany). For these studies, 0.5 μL of sample was spotted 
onto a Bruker plate with 0.5 μL of saturated 2,5-dihydroxybenzoic acid as the matrix. 
The spectra were acquired across the spot, and comprised of 10 acquisitions with 500 
laser shots for each.  
After identifying the labeled peptide pairs, an extracted ion chromatography from 
the UPLC-ESI-Q-TOF MS scans was created for both light and heavy labeled 
peptides, and the mass spectra across the entire elution period for both peaks were 
summed. For both platforms, the relative abundance of peptides in WT versus ECE-2 
KO mice was determined by the ratio of peak intensities between light and heavy 
labeled peptides. The data were then analyzed by Student’s t-test to identify peptides 
showing statistically significant differences between genotypes. 
 
4.4 Results and Discussion 
4.4.1 Studies on Mouse Spinal Cords  
We first examined the role of ECE-2 in processing the repertoire of spinal cord 
peptides. We extracted the peptides from either WT or KO mouse spinal cords using a 
modified multi-stage extraction protocol optimized for peptide recovery from the 
CNS [3], hot water followed by ice-cooled acidified acetone. To minimize protein 
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degradation and inactivate endogenous enzymes, our samples were pre-heated at 90ºC 
for 1 min, and acidified acetone was ice-cooled before use. For peptide identification, 
we used WT mouse spinal cords and implemented two LC-MS platforms, 
CapLC-ESI-IT MS/MS, and UPLC-ESI-Q-TOF MS/MS. While for peptide 
quantitation, approaches using both UPLC-ESI-Q-TOF MS and MALDI-TOF MS 
were developed and applied to compare WT and KO ECE-2 spinal cords. 
4.4.1.1 Peptide Identification 
By employing two different LC-MS platforms, we identified 10 peptides known 
or presumed to be present in WT spinal cord [17]. Some of these peptides have been 
previously implicated in pain processing and/or opiate responses, such as 
Met-enkephalin, neurokinins A and B, and cholecystokinin (CCK; Table 4.1). Several 
other neuropeptides were discovered in spinal cord as well (Table 4.1): somatostatin, 
which participates in the regulation of growth in vertebrates [15]; little SAAS, which 
has been suggested to involve in circadian rhythms of mice [1]; PEN, which is known 
to inhibit prohormone convertase 1 activity in mice; and secretogranin, which may be 
involved in secretory granule formation and neurotransmitter/hormone release [18]. In 
addition, we detected peptides from non-prohormone-related proteins, such as, a 
number of myelin basic protein (MBP)-related peptides, cytochrome c oxidase, ATP 
synthase, Hemoglobin, etc (Table 4.2).  
In total, 32 peptides were confidently sequenced, with only 4 of them identified 
by both LC-MS platforms. While 9 peptides were characterized only by 
CapLC-ESI-IT MS/MS, 19 only come from UPLC-ESI-Q-TOF MS/MS. Clearly, with 
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the different sequencing capabilities of these two instruments, we were able to greatly 
improve the peptide coverage in spinal cord.  
4.4.1.2 Quantitative Peptidomics 
Changes in ECE-2 KO versus WT spinal cord peptides were quantified by 
differential isotopic labeling followed by analyses on two different MS platforms: 
LC-ESI-Q-TOF MS and MALDI-TOF MS. Typical mass spectra were shown in 
Figure 4.1, and the forward and reverse labeling data agree well with each other. 
Fourteen masses were found to be significantly different between ECE-2 KO and WT 
mice. Five showed a significant increase, whereas nine showed a significant decrease 
in ECE-2 KO spinal cords compared with WT (Table 4.3). Two peptides that showed 
an increase in ECE-2 KO mice were derived from myelin basic protein (MBP). 
Notably, we did not detect significant changes in any of the classically-processed 
peptides that were identified in WT spinal cord (Table 4.1). Collectively, these 
peptidomics results support a role for ECE-2 in the processing of a range of spinal 
cord peptides and/or precursors in vivo. The partially altered peptide levels after the 
knockout of ECE-2 suggested that there may be other enzymes to compensate the role 
of ECE-2 in peptide processing in vivo.  
From an analytical point of view, the use of two instruments again enhances the 
number of peptides that were quantified. Out of the 14 peptides, 11 were quantified 
only by UPLC-ESI-Q-TOF, while 2 were only from MALDI-TOF. Furthermore, a 
peptide (Obs. Mass=1774.5) that was quantified by both instruments shows quite 
consistent results, which verifies our approaches and the accuracy of the results. For 
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the peptides (Obs. Mass=1774.5 and 1777.5) that existed as two charge states (+3 and 
+4), we quantified them separately. Interestingly, the calculated ratios of different 
charge states of the same peptide agree with each other very well, which justifies the 
way we treated this situation.  
4.4.1.3 Discussion 
Two of these peptides that were altered in KO spinal cords were identified to be 
derived from MBP. They have previously been found to be processed at non-classical 
sties in vitro and in vivo by other enzymes, including calpain [27, 34] and cathepsin [2, 
5, 6]. Our results suggest that ECE-2 may have a role in processing MBP in the spinal 
cord since only two MBP-derived peptides showed increases in ECE-2 KO mice 
(implying reduced cleavage within the sequences), although the cleavage site 
preferences of ECE-2 could not be inferred. However, both peptides contain aliphatic 
and/or aromatic residues previously found at P1’ sites of ECE-2 cleavage in vitro 
(namely Ile, Val, Trp, Phe) [19].  
MBP is known to be a cytosolic/nuclear protein, which raises the intriguing 
question as to the compartment in which ECE-2 might process MBPs. MBP has 
recently been shown to exhibit additional subcellular localization such as exosomes. 
Exosomes are small vesicles derived from the endocytic pathway that are responsible 
for the secretion of proteins; release is regulated by potassium or calcium levels [11]. 
Besides playing a role in discarding proteins, exosomes may also allow intercellular 
transport of proteins [22]. Oligodendrocytes have been shown to secrete major myelin 
proteins (such as MBP) through exosomes [14]. Exosomes could therefore be a 
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possible site of MBP processing by ECE-2. Although ECE-2 has been localized to 
endocytic compartments (Miller and Devi, unpublished), its localization in exosomes 
has yet to be investigated. ECE-2’s localization in endosomes also raises the 
possibility that it processes larger proteins (in addition to neuropeptides) in vesicles. 
Work is currently underway to continue to characterize the unidentified peaks 
The difficulty in identifying the majority of the peptides showing altered levels may 
be due to their low abundance, interference by other high abundance proteins in the 
spinal cord (e.g. MBP), and/or the difficulty in fragmenting some peptides and 
generating high quality spectra by MS.  
 
4.4.2 Studies on Mouse Striata  
Besides spinal cord, ECE-2 is also widely expressed in the brain (e.g. striatum, 
hippocampus) [30]. Since our studies on spinal cord are encouraging, we continued to 
investigate changes in the peptide levels in brain regions of ECE-2 KO mice. Here we 
selected mice striatum with the consideration of its high abundance in both ECE-2 and 
neuropeptides. Due to the limited amount of samples, we only employed 
UPLC-ESI-Q-TOF MS/MS for identification purposes. Peptide quantitation was 
performed on both UPLC-ESI-Q-TOF MS and MALDI-TOF MS.  
4.4.2.1 Peptide Identification 
We identified 19 peptides in KO mouse striatum derived from 9 different 
prohormones previously known or with high potential to be bioactive [12, 20], which 
include Procholecystokinin, Proenkephalin-A, ProSAAS, Prosomatostatin, 
 90
Protachykinin-1, Provasoactive intestinal peptide, and Secretogranin 1-3 (Table 4.4). 
Some of these peptides have been previously implicated in mediating the failure of 
central nervous system associated with Parkinson disease through the investigation of 
mouse striatum samples [26]. We also detected 17 peptides from 
non-prohormone-related proteins, including Brain-specific polypeptide PEP-19, 
Clathrin light chain A, Cocaine- and amphetamine -regulated transcript protein, 
Cytochrome c oxidase, Hemoglobin alpha and beta, NADH dehydrogenase, 
Peptidyl-prolyl cis-trans isomerase A, and Synaptosomal-associated protein (Table 
4.5).  
In total, 36 peptides were confidently sequenced by UPLC-ESI-Q-TOF MS/MS. 
More peptides may be characterized if another set of striata, from either ECE-2 WT or 
KO mice, could be studied by other LC-MS platforms, such as our CapLC-ESI-IT 
MS/MS, or FTMS. 
4.4.2.2 Quantitative Peptidomics 
We performed quantitative peptidomics studies on ECE-2 KO versus WT mouse 
striatum via differential isotopic labeling followed by two different MS platforms: 
UPLC-ESI-Q-TOF MS and MALDI-TOF MS. Ten peptides showed significant 
differences between ECE-2 KO and WT mice. Only one indicated a significant 
decrease, while the rest of them showed a significant increase in ECE-2 KO striatum 
compared with WT (Table 4.6). All the peptides quantified in Table 4.6 come from 
UPLC-ESI-Q-TOF MS, since the complexity of the striatum samples makes it 
difficult to quantify peptides by MALDI-TOF without a separation first.  
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Out of the ten peptides, one peptide, little SAAS, that showed an increase in 
ECE-2 KO mice, was identified by our MS/MS studies and derived from ProSAAS. 
The precursors of another three peptides (dynorphin A8 from Prodynorphin, and big 
LEN and PEN-20 from ProSAAS) were characterized in mouse striatum by either 
previous or current studies. Thus, they were assigned tentatively here, and all showed 
an increase in ECE-2 KO mice (Table 4.6). Consistent with spinal cord investigations, 
our findings suggest that ECE-2 plays role in the processing of striatum peptides 
and/or precursors in vivo.  
4.4.2.3 Discussion 
Four peptides either confidently or tentatively assigned indicated an increase in 
ECE-2 KO mice, which suggests the cleavages by ECE-2 in vivo are within their 
sequences (Table 4.6), although the cleavage site preferences of ECE-2 could not be 
inferred. However, all of them contain aliphatic and/or aromatic residues previously 
found at P1’ sites of ECE-2 cleavage in vitro (namely Ile, Leu, Val, Phe) [19] (Table 
4.6). The prior in vitro studies of those four peptides did not notice any cleavage by 
ECE-2 within the sequences, which may be due to some missing components from the 
biological environments [19]. 
Interestingly, three of those peptides, little SAAS, big LEN, and PEN-20, were 
derived from ProSAAS precursor, which has been previously demonstrated to play 
multiple roles in mice, such as inhibition of prohormone convertase (PC) [21], 
regulation of body weight [30], the involvement in fetal neuropeptide processing [24] 
and circadian rhythms [1]. Previous quantitative peptidomics indicated that the loss of 
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PC1/3 affected most of ProSAAS-derived peptides (e.g. Big LEN, Little LEN, Big 
SAAS and Little SAAS) in mouse amygdala and hypothalamus, but not in striatum 
[29]. Another study showed that the absence of PC2 did not change the levels of most 
of these peptides, expect for a small decrease in Big LEN seen in PC2 null striatum 
[32]. Considering the partially altered levels of peptides, it is likely that other enzymes 
(e.g. PC2) compensate for the role of ECE-2 to process ProSAAS-derived peptides in 
the striatum of ECE-2 KO mouse. 
Furthermore, the fourth peptide showing level increase in ECE-2 KO mouse is 
Dynorphin A8. Dynorphins and its precursor are members of the opioid peptide 
family, and have been thought to play a regulatory role in various functional pathways 
and physiological mechanisms, such as learning and memory, pain, stress response, 
depression, etc [26]. The ECE-2 KO mouse demonstrated the impairments in learning 
and memory, and altered pain thresholds and opiate responses (data not shown) [16]. 
Therefore, the level alteration of dynorphin A8 in ECE-2 KO mouse may correlate 
with some of those regulatory or behavioral changes.  
 
4.5 Conclusions and Future Directions 
In the present study, we have investigated the role of the putative non-classical 
processing enzyme ECE-2 in vivo. The results revealed altered levels of a number of 
peptides in the spinal cord and striatum of ECE-2 KO mice, the first such evidence of 
ECE-2 peptide processing in vivo. Our previous findings suggested the learning and 
memory deficits in ECE-2 KO mice [23], and our behavioral studies also observed 
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striking differences in morphine-induced analgesia in ECE-2 KO mice, including 
more rapid development of tolerance and decreased withdrawal responses [16]. Taken 
together, the present results further support an emerging and important role for ECE-2 
in neuropeptide processing and modulating behaviors. 
Work is currently underway to identify the unidentified peaks that showed 
significant differences between ECE-2 KO and WT animals; these results should lead 
to a better understanding of ECE-2 cleavage site preferences. In addition, other brain 
regions (e.g. hippocampus) will continue to be investigated, which may provide a 
better picture of the role of ECE-2 as a neuropeptide processing enzyme in vivo. 
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4.7 Figures and Tables 
 
 
 
 
 
Figure 4.1 Representative mass spectra of succinic anhydride (SA)-labeled peptides 
from mice spinal cord obtained by MS analysis. A). UPLC-ESI-Q-TOF mass spectra 
of a labeled peptide pair (MW 1757.78, charge state +3) after the combination of 
[H4]-SA labeled WT and [D4]-SA labeled KO samples (upper panel), or  [D4]-SA 
labeled WT and [H4]-SA labeled KO samples (lower panel). B).  MALDI-TOF mass 
spectra of a labeled peptide pair (MW 900.42, charge state +1) after the combination 
of [H4]-SA labeled WT and [D4]-SA labeled KO samples (upper panel), or [D4]-SA 
labeled WT and [H4]-SA labeled KO samples (lower panel). Figure adapted from [16] 
with permission from John Wiley & Sons, Inc. © 2011.
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Table 4.1 Neuropeptides identified from wild type mice spinal cord by MS/MS. 
Precursor Peptide name Peptide sequence 
Obs. 
Mass 
Theor. 
Mass 
Error 
(ppm) 
PEAKS 
Score 
IT Q-TOF 
Procholecystokinin 23-32 *QP.VVPAEATDPV.E 996.82 996.51 311 78  X 
Proenkephalin Met-enkephalin KK.YGGFM.KR  573.4 573.23 296 54  X 
Proenkephalin 197-208 KR.SPQLEDEAKELQ.KR  1385.99 1385.67 231 99 X  
ProSAAS little SAAS R.SLSAASAPLVETSTPLRL.RR  1812.66 1812.0 364 99  X 
ProSAAS PEN RR.SVDQDLGPEVPPENVLGALLRV.KR 2316.84 2316.23 263 99  X 
Prosomatostatin Somatostatin 28-14 R.SANSNPAMAPRE.RK 1243.79 1243.56 185 98 X  
Protachykinin A Neurokinin A KR.HKTDSFVGLMa.GKR 1132.54 1132.57 26 45  X 
Protachykinin B Neurokinin B KR.DMHDFFVGLMa.GKR 1209.61 1209.52 74 97 X  
Secretogranin I 588-597 KR.SFARAPQLDL.KR  1117.01 1116.59 376 86  X 
Secretogranin II 569-581 KR.IPVGSLKNEDTPN.R  1382.59 1382.7 80 80 X X 
(.) indicates a cleavage site; (*) indicates the presence of signal peptide before the sequence; “X” indicates the MS/MS platforms used to identify the peptide; Obs. 
mass, observed monoisotopic mass; Theor. mass, theoretical monoisotopic mass; Putative PTM includes C-terminal amidation (“a”). Table adapted from [16] with 
permission from John Wiley & Sons, Inc. © 2011. 
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Table 4.2 Other peptides identified from wild type mice spinal cord by MS/MS 
Precursor Peptide name Peptide sequence 
Obs. 
Mass 
Theor. 
Mass 
Error 
(ppm) 
Score IT Q-TOF 
ATP synthase, subunit F C-terminus D.PKFEVIDKPQS.# 1286.97 1286.69 218 89 X  
Complexin C-terminus D.TVIKYLPGPLQDMFKK.# 1877.04 1877.05 5 98  X 
Cytochrome c oxidase subunit 5a C-terminus L.RPTLNELGISTPEELGLDKV.# 2180.96 2180.17 362 99 X X 
Cytochrome c oxidase subunit 5a C-terminus L.GISTPEELGLDKV.# 1357.11 1356.71 295 99 X  
Hemoglobin alpha C-terminus H.ASLDKFLASVSTVLTSKYR.# 2085.77 2085.15 297 92 X  
Myelin basic protein isoform 4 11-17 R.SKYLATA.S 752.35 752.41 80 91  X 
Myelin basic protein isoform 4 26-33 H.GFLPRHRD.T 996.39 996.53 141 52  X 
Myelin basic protein isoform 4 34-44 D.TGILDSIGRFF.S 1224.65 1224.65 0 99  X 
Myelin basic protein isoform 4 36-44 G.ILDSIGRFF.S 1066.55 1066.58 28 99 X  
Myelin basic protein isoform 4 42-48 G.RFFSGDR.G 883.28 883.43 170 99  X 
Myelin basic protein isoform 4 42-49 G.RFFSGDRG.A 940.49 940.45 43 96  X 
Myelin basic protein isoform 4 89-98 R.TTHYGSLPQK.S 1130.6 1130.57 27 99  X 
Myelin basic protein isoform 4 104-112 R.TQDENPVVH.F 1037.55 1037.48 67 99  X 
Myelin basic protein isoform 4 104-121 R.TQDENPVVHFFKNIVTPR.T 2140.43 2140.11 150 94 X X 
Myelin basic protein isoform 4 109-121 N.PVVHFFKNIVTPR.T  1553.04 1552.89 97 99 X X 
Myelin basic protein isoform 4 128-135 Q.GKGRGLSL.S 786.53 786.47 76 86  X 
Myelin basic protein isoform 4 C-terminus F.SWGGRDSRSGSPMARR.# 1761.99 1761.84 85 85  X 
Myelin basic protein isoform 5 137-146 G.TLSKIFKLGG.R 1062.65 1062.64 9 99  X 
Orphan G protein-coupled Receptor 271-282 A.ILLGVTSLFALL.W  1259.17 1258.79 302 90  X 
Peptidylprolyl isomerase A 2-22 M.(AcetylV)NPTVFFDITADDEPLGRVSF.E 2380.49 2380.16 139 99 X  
Ubiquitin 57-76 (multiple) L.SDYNIQKESTLHLVLRLRGG.(I/M) 2297.75 2298.25 218 97  X 
Thymosin beta-4 8-21 M.SD(AcetylK)PDMAEIEKFDK.S 1693.99 1693.79 118 53 X  
(.) indicates a cleavage site; Pound (#) indicates the end of a precursor sequence; “X” indicates the MS/MS platforms used to identify the peptide; Obs. mass, 
observed monoisotopic mass; Theor. mass, theoretical monoisotopic mass; Putative PTM includes acetylation (“Acetyl”). Table adapted from [16] with permission 
from John Wiley & Sons, Inc. © 2011. 
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Table 4.3 Quantitative peptidomics of mouse spinal cord: comparison of ECE-2 WT and KO mice. 
Precursor Peptide sequence 
Obs.  
Mass 
Theor.  
Mass 
Z #T 
KO : WT  
Ratio±SD (n) 
MS platform 
Unknown  658.18  1 1 0.81±0.09 (3) * LC-ESI-Q-TOF 
Unknown  768.38  2 1 1.25±0.11(3) * LC-ESI-Q-TOF 
Unknown  900.42  1 1 1.74±0.38(3) * MALDI-TOF 
Unknown  1174.52  3 1 0.65±0.10(3) ** LC-ESI-Q-TOF 
Unknown  1174.52  4 1 0.62±0.15(3) * LC-ESI-Q-TOF 
Unknown  1174.57  1 1 0.59±0.17(3) * MALDI-TOF 
Unknown  1423.34  2 2 0.86±0.02(2) * LC-ESI-Q-TOF 
Myelin basic protein N.PVVHFFKNIVTPR.T 1552.36 1552.88 2 2 1.15±0.02(3) ** LC-ESI-Q-TOF 
Unknown  1713.48  4 1 0.78±0.04(3) ** LC-ESI-Q-TOF 
Unknown  1757.63  3 1 0.59±0.17(3) * LC-ESI-Q-TOF 
Myelin basic protein F.SWGGRDSRSGSPMARR.# 1761.47 1761.83 3 1 1.24±0.11(3) * LC-ESI-Q-TOF 
Unknown  1777.52  4 1 0.84±0.07(3) * LC-ESI-Q-TOF 
Unknown  1777.4  3 1 0.84±0.08(3) * LC-ESI-Q-TOF 
Unknown  1990.51  3 2 0.86±0.03(3) ** LC-ESI-Q-TOF 
Unknown  2104.51  3 2 0.86±0.05(3) * LC-ESI-Q-TOF 
Unknown  2298.15  1 2 1.29±0.01(2) ** MALDI-TOF 
Unknown  2367.60  4 1 0.77±0.11(3) * LC-ESI-Q-TOF 
Two peptides (MW 1174.52 or 1777.52/1777.4 in bold) were quantified at different charge states (+3 or +4) by LC-ESI-Q-TOF MS, and the results from two charge 
states are consistent. Peptides were quantified by either LC-ESI-Q-TOF MS or MALDI-TOF MS, with one peptide (MW 1174.52/1174.57 in italic) showing 
consistent quantitation results between two instruments. Two peptides from myelin basic protein were identified by tandem MS. (.) indicates a cleavage site; (#) 
indicates the end of a precursor sequence; (_) highlights amino acids W, F, I and V; Obs. mass, observed monoisotopic mass (after subtraction of the labeling tags); 
Theor. mass, theoretical monoisotopic mass; Z, charge state; #T, number of tags labeling the peptide; WT, wild type; KO, knockout; SD, standard deviation; n, 
number of biological replicates observed for a peptide. Student’s t-test was carried out to determine the statistically significant difference between the peptide level of 
WT and KO mice. ** p<0.01, * p<0.05. Table adapted from [16] with permission from John Wiley & Sons, Inc. © 2011. 
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Table 4.4 Neuropeptides identified from knock out mice striatum by MS/MS. 
Precursor Peptide Sequence 
Obs. 
Mass 
Theor. 
Mass 
Error 
(ppm) 
PEAKS 
Score 
Procholecystokinin RK.APSGRMSVLKNLQSLDPSHRISD.R 2507.79 2507.29 199 89 
Proenkephalin-A KR.YGGFM.R 573.31 573.23 140 99 
Proenkephalin-A KR.YGGFMRSL.KR 929.59 929.44 161 96 
Proenkephalin-A KRY.GGFM.KK 410.24 410.16 195 84 
Proenkephalin-A KR.SPQLEDEAKELQ.KR 1385.89 1385.67 159 99 
Proenkephalin-A KRY.GGFL.KR 392.27 392.21 153 79 
Proenkephalin-A KR.FAESLPSDEEGENYSKEVPEIE.KR 2497.50 2497.10 160 99 
ProSAAS L.LRLPPTLSARPVKEPRSLSAASAPLVETSTPLRL.RR 3624.04 3623.09 262 76 
ProSAAS R.SLSAASAPLVETSTPLRL.RR (Little SAAS) 1812.37 1812.00 204 99 
ProSAAS RR.AVPRGEAAGAVQELARALAHLLEAERQE.R 2955.13 2954.57 190 88 
ProSAAS RRAV.PRGEAAGAVQELARALAHLLEAERQE.R 2784.99 2784.46 190 99 
Prosomatostatin R.SANSNPAMAPRE.RK 1243.76 1243.56 161 89 
Protachykinin-1 KR.HKTDSFVGLMa.GKR 1132.76 1132.57 168 87 
Provasoactive intestinal peptide A.WPLFGPPSVVRLDDRMPFEGAGDPDQVSLKADSDILQNPLAENGTP.Y 4961.36 4960.43 187 66 
Secretogranin-1 A.GAPVEDSQGQTKVGNEKWTEGGGH.SR 2467.73 2467.14 239 74 
Secretogranin-1 R.APQLDL.KR 655.46 655.35 168 99 
Secretogranin-2 KR.IPVGSLKNEDTPN.R 1382.93 1382.70 166 95 
Secretogranin-3 H.pQLDGTPLTAEDIVH.K 1490.53 1490.73 134 63 
Secretogranin-3 L.TAEDIVHKIA.TR 1095.78 1095.59 173 75 
(.) indicates a cleavage site; “X” indicates the MS/MS platforms used to identify the peptide; Obs. mass, observed monoisotopic mass; Theor. mass, theoretical 
monoisotopic mass; Putative PTM includes N-terminal pyroglutamylation (“p”), and C-terminal amidation (“a”).  
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Table 4.5 Other peptides identified from knock out mice striatum by MS/MS 
Precursor Peptide Sequence 
Obs. 
Mass 
Theor. 
Mass 
Error 
(ppm) 
PEAKS 
Score 
Brain-specific polypeptide PEP-19 A.PETERAAVAIQSQFRKFQKKKAGSQS.end 2920.05 2919.57 164 94 
Clathrin light chain A I.SLKQAPLVH.end 991.74 991.58 161 91 
Cocaine- and amphetamine -regulated  
transcript protein 
D.AELQPRALDIYSAVDDASHEK.E 2327.55 2327.14 176 79 
Cytochrome c oxidase sub Va *.(AcetylA)EDIKTKIKNY.K 1363.96 1363.74 161 99 
Cytochrome c oxidase sub Va RRL.NDFASAVRILEV.VK 1332.99 1332.70 218 99 
Hemoglobin alpha S.VSTVLTSKYR.end 1151.79 1152.65 746? 93 
Hemoglobin beta KKV.ADALANAAGHLDDLPGALSALSDLHAHKL.R 2877.07 2876.48 205 99 
Hemoglobin beta L.ASHHPADFTPAVHASLDKFLASVSTVLTSKYR.end 3453.40 3452.78 179 99 
Hemoglobin beta A.SHHPADFTPAVHASLDKFLASVSTVLTSKYR.end 3382.34 3381.75 174 92 
Hemoglobin beta 
V.HASLDKFLA(PhosphoS)VSTVLTSKYR.end or 
 V.HASL(PhosphoD)KFLASVSTVLTSKYR.end 
2302.23 2302.17 26 77 
Hemoglobin beta A.SLDKFLASVSTVLTSKYR.end 2014.57 2014.11 228 99 
NADH dehydrogenase [ubiquinone] 1 alpha  *.(AcetylA)SATRVIQKL.R 1127.87 1127.67 177 99 
Peptidyl-prolyl cis-trans isomerase A L.KHTGPGILSM.A 1039.73 1039.55 173 86 
Peptidyl-prolyl cis-trans isomerase A KH.TGPGLLSM.N 774.55 774.39 207 88 
Peptidyl-prolyl cis-trans isomerase A T.GPGLLSM.A 673.48 673.35 193 69 
Synaptosomal-associated protein (Snap91)\ L.SPSPTPATQSPKKPPAKDPLADLNIKDFL.end 3072.65 3073.27 202 94 
(.) indicates a cleavage site; (*) indicates the presence of signal peptide before the sequence; Obs. mass, observed monoisotopic mass; Theor. mass, theoretical 
monoisotopic mass; Putative PTM includes N-terminal acetylation (“Acetyl”), and phosphorylation (“Phospho”).  
 
 
 
 
 103
 
 
 
Table 4.6 Quantitative peptidomics of mouse striatum: comparison of ECE-2 WT and KO mice. 
Precursor Peptide sequence 
Obs. 
Mass 
Theor. 
Mass 
Z #T 
KO : WT 
Ratio±SD (n) 
MS platform 
Prodynorphin KR.YGGFLRRI.R (Dynorphin A8) 980.97 980.97 2 1 1.37±0.25(3)** LC-ESI-Q-TOF 
Unknown   1281.18 2 1 1.14±0.11(3) * LC-ESI-Q-TOF 
ProSAAS KR.LENPSPQAPARRLLPP.# (Big LEN) 1754.97 1755.64 2 1 1.26±0.17(3) ** LC-ESI-Q-TOF 
ProSAAS R.SLSAASAPLVETSTPLRL.R (Little SAAS) 1811.99 1812.7 2 1 1.23±0.16(3) ** LC-ESI-Q-TOF 
Unknown   1833.76 2 2 2.13±0.82(3) ** LC-ESI-Q-TOF 
Unknown   1890.78 2 2 2.36±0.84(3) *** LC-ESI-Q-TOF 
ProSAAS RR.SVDQDLGPEVPPENVLGALL.R (PEN-20) 2061.05 2061.94 2 1 1.37±0.25(3) * LC-ESI-Q-TOF 
Unknown   2139.99 3 3 0.86±0.10(3) * LC-ESI-Q-TOF 
Unknown   2261.98 3 2 1.45±0.25(3) *** LC-ESI-Q-TOF 
Unknown   2420.34 3 3 1.23±0.14(2) ** LC-ESI-Q-TOF 
One peptide, little SAAS, from ProSAAS was identified by our tandem MS studies. Three peptides in italic were tentatively assigned, since only their precursors 
ProSAAS and Prodynorphin, were characterized in mouse striatum by current or previous studies. (.) indicates a cleavage site; (#) indicates the end of a precursor 
sequence; (_) highlights amino acids F, L, I and V, at the possible P1’ positions; Obs. mass, observed monoisotopic mass (after subtraction of the labeling tags); Theor. 
mass, theoretical monoisotopic mass; Z, charge state; #T, number of tags labeling the peptide; WT, wild type; KO, knockout; SD, standard deviation; n, number of 
biological replicates observed for a peptide. Student’s t-test was carried out to determine the statistically significant difference between the peptide level of WT and 
KO mice. *** p<0.01, ** p<0.05, * p<0.1.  
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CHAPTER 5 
NEUROPEPTIDOMICS OF THE FLATWORM  
 
5.1 Notes and Acknowledgements 
This chapter was modified with permission from a portion of an article entitled 
“Genome-Wide Analyses Reveal a Role for Peptide Hormones in Planarian Germline 
Development”, by Collins J.J., 3rd, Hou X., Romanova E.V., Lambrus B.G.., Miller C.M., 
Saberi A, Sweedler J.V., Newmark P.A., published in PLoS Biology 2010;8:e1000509. 
DOI:10.1371/journal.pbio.1000509 [9]. The data presented here emphasizes the 
MS-based technologies and results of these studies, with other relevant information 
included for better understanding of the significance of this interdisciplinary work. My 
contribution to this work was the identification of prohormones and their peptides by 
LC-MS, from experimental design and performance to data analysis and interpretation.  
 This is an interdisciplinary team effort that included James J. Collins III, Elena V. 
Romanova, Bramwell G. Lambrus, Claire M. Miller, Amir Saberi, Jonathan V. Sweedler, 
and Phillip A. Newmark. I also would like to thank Fang Xie for her help and 
contribution at the initial stage of this project. J.J.C., E.V.R., J.V.S. and P.A.N. conceived 
and designed the project, which set the foundation for the following studies. J.J.C. 
cultured and collected the sexual and asexual planarians for our LC-MS investigation, 
and compiled the in-house prohormone database of planarian. J.J.C., B.G.L., C.M.M. and 
A.S. performed the biological experiments and functional analysis. E.V.R. conducted the 
quantitative peptidomics studies by MALDI-TOF MS. Everybody involved in this project 
made indispensable efforts to analyze the data and interpret the results. J.J.C. and P.A.N. 
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wrote the paper. This work was supported by the National Institutes of Health 
(www.nih.gov) F32 HD062124 and T32 HD007333 (to J.J.C.), P30 DA018310 and R01 
NS031609 (to J.V.S.), R01 HD043403, and the National Science Foundation 
(www.nsf.gov) IOS-0744689 (to P.A.N.). 
 
5.2 Introduction  
Platyhelminthes (flatworms) inhabit a variety of aquatic and terrestrial environments 
and members of the phylum are thought to parasitize most vertebrate species [30]. The 
remarkable ability of flatworms to maintain plasticity in their reproductive cycles is a key 
to their success. As an example, free-living planarian flatworms are capable of 
reproducing sexually as cross-fertilizing hermaphrodites or asexually by transverse 
fission [24]. Some planarian species even maintain the ability to switch between modes 
of sexual and asexual reproduction, resorbing and regenerating their reproductive organs, 
depending on the environmental context [10]. This dynamic regulation of reproductive 
development is not limited to free-living platyhelminths; parasitic flatworms can also 
undergo dramatic changes in their reproductive development in response to external 
stimuli.  
As mentioned in chapter 1, peptide hormones (i.e. neuropeptides) are among the 
most structurally and functionally diverse class of metazoan signaling molecules [53]. In 
vertebrates, a neuroendocrine axis involving peptide hormone signaling between the 
brain and the gonads controls the maturation and long-term maintenance of reproductive 
development and function [15, 49, 51, 53]. A similar role for neuroendocrine signals in 
controlling flatworm reproduction is suggested by studies exploiting the well-known 
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regeneration abilities of planarians. Head amputation (i.e. removal of the brain/cephalic 
ganglia) of sexually reproducing planarians results in regression of the testes [12, 14] to 
their germ cell primordial [55], which re-grow only when cephalic ganglia regeneration is 
complete. These observations suggest that neural signals control the dynamics of 
planarian reproduction. Thus, flatworms may employ peptide-based mechanisms, similar 
to vertebrates, to synchronize their reproductive development, which intrigues our 
interests and the need to uncover those peptides. 
Peptide hormones are processed proteolytically from longer secretory prohormone 
precursors and often require covalent modifications before becoming biologically active 
[17, 53]. As a result of this extensive processing, and because the biologically relevant 
signaling units are encoded by short stretches of amino acid sequence (usually 3–40 
amino acids), predicting genes encoding these molecules represents a major challenge for 
bioinformatics-driven genome annotation. The recent application of bioinformatic 
approaches coupled to mass spectrometry (MS)-based peptide characterization techniques, 
an approach called peptidomics [3, 13, 18], has revolutionized discovery efforts, 
uncovering hundreds of new genes encoding metazoan bioactive peptides. Among 
invertebrates, however, much of this recent progress has been focused on genome-wide 
studies of nematodes [21-23], arthropods [1, 19, 28, 56, 59], and mollusks [29, 40]. Thus, 
little is known of the peptide hormones present in phyla such as Platyhelminthes. Despite 
recent bioinformatic efforts to characterize flatworm peptide-encoding genes [2, 37], only 
three distinct peptides have been characterized extensively at the biochemical level in all 
flatworms [36]. 
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The planarian S. mediterranea represents an ideal model to characterize flatworm 
neuropeptides, which is due to the availability of its sequenced genome [45], as well as a 
wealth of functional genomic tools [42]. Here, we used peptidomic approaches, a 
combination of bioinformatics and MS-base technologies, to characterize the peptide 
hormone complement of S. mediterranea in both sexual and asexual strains. This analysis 
identified 51 genes predicted to encode more than 200 peptides, 142 of which were 
characterized by mass spectrometry. Our quantitative peptidomics studies via label-free 
MS indicate the abundance changes of some peptides after the disruption of prohormone 
convertase (pc2) gene, an enzyme often required for prohormone processing in other 
model organisms. These results demonstrate the utility of S. mediterranea as a model to 
characterize metazoan peptides and set the foundation for further studies on the discovery 
of neuroendocrine signals that could affect flatworm reproductive development.  
 
5.3 Experimental 
5.3.1 Animal Culture 
Sexual and asexual S. mediterranea were maintained at 20°C in 0.75× and 1.0× 
Montjuïc salts, respectively [6]. To minimize non-specific background from gut contents 
after feeding, animals were starved at least 1 wk prior to use. For all experiments with 
sexual S. mediterranea, sexually mature animals (~1 cm in length, unless otherwise 
specified) with a well-developed gonopore were used, unless otherwise specified. 
5.3.2 Chemicals 
All chemicals were supplied by Sigma-Aldrich (St. Louis, MO) unless otherwise 
stated. The peptide standards for Matrix-assisted laser desorption/ionization 
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time-of-flight mass spectrometry (MALDI-TOF MS) calibration were purchased from 
Bruker Daltonics (Billerica, MA). 
5.3.3 Extraction of Peptides 
For LC/MS analysis, peptide extracts were prepared from 80–100 sexual or asexual 
planarians. Whole animals were mechanically homogenized in 8–10 mL of acidified 
acetone (40:6:1 acetone/water/HCl) or acidified methanol (90:9:1 methanol/acetic 
acid/water). After sonication, vortexing, and centrifugation of the homogenate, the 
supernatant was collected and the organic solvent was removed by evaporation in a 
SpeedVac concentrator (Thermo Scientific, San Jose, CA). The supernatant was then 
filtered through a Microcon centrifugal filter with a 10 kDa cutoff (Millipore, Billerica, 
MA), evaluated for peptide content by MALDI-TOF MS sampling of 0.5 µL and 
subjected to sequential separations by HPLC prior to tandem MS for peptide 
identification. 
5.3.4 Peptide Separation and Measurement 
Peptide extracts were fractionated using a microbore HPLC system Magic 2000 
(Michrom BioResources, Inc., Aubum, CA) with a C18 reverse phase column (Dionex, 
1,000 µm i.d., particle size 3 µm, and pore size 100 Å) at a 20 µL/min flow rate over a 70 
min run. A four-step linear solvent gradient was generated by mixing mobile phases A 
(95% water and 5% acetonitrile (ACN), 0.1% formic acid (FA) and 0.01% trifluoroacetic 
acid (TFA), and B (95% ACN, 5% water, 0.1% FA, and 0.01% TFA) as follows: 
5%–10% B in 20 min, 10%–50% B in next 30 min, 50%–80% B in next 10 min, isocratic 
80% B for 5 min, 80%–5% B in 4 min. Fractions were manually collected, evaluated for 
peptide content by MALDI-TOF MS (Ultraflex II, Bruker Daltonics, Bremen, Germany), 
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and subjected to 2nd stage separation using a capillary HPLC system (Waters, Milford, 
MA) equipped with a C18 reverse phase column (Dionex, 300 µm i.d., particle size 3 µm, 
and pore size 100 Å) and coupled to a HCT Ultra ion-trap mass spectrometer via an 
electrospray ionization source (ESI) (Bruker Daltonics, Bremen, Germany). Second stage 
separation parameters were optimized individually for each fraction using either the same 
water/ACN solvent system or water/methanol with 0.1% FA as a counter-ion. Mass 
spectrometric detection of eluting peptides was controlled by the Esquire software 
(Bruker Daltonics, Bremen, Germany) in a data-dependent manner. Tandem MS ion 
precursor selection was limited to 3 ions per min sorted by signal intensity, preferred 
charge state was set to +2, and the active dynamic exclusion of previously fragmented 
precursor ions limited to 2 spectra per minute. The scan m/z ranges for MS and MS/MS 
were 300–1,800 and 50–3,000, respectively. 
5.3.5 Peptide Identification 
For peptide identification, tandem mass spectra were converted to the .mgf file 
format (Mascot generic file) and processed for sequencing automatically using the 
PEAKS Studio 4.5 software (Bioinformatics Solutions, Inc., Waterloo, CA). PEAKS 
generated data were manually inspected and verified. Automatic sequencing was 
performed against an in-house planarian prohormone database using the following search 
parameters: cleavage sites, variable Post-Translational Modifications (PTMs) (including 
N-terminal pyro-Glu and pyro-Gln, C-terminal amidation, and disulfide bond; the 
maximum number of PTMs on a single peptide was set to four), mass tolerance equal to 
0.3 Da for the precursor ion, and 0.5 Da for fragments. 
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Criteria for peptide assignments and prohormone confirmation were based on 
confidence scores generated by PEAKS for each sequenced peptide and detection mass 
error. A PEAKS confidence score is given as a percentage value from 1% to 99% and 
represents the statistical likelihood that an amino acid sequence matches a given MS 
fragmentation spectrum. The PEAKS statistical algorithm considers factors such as signal 
to noise, total intensity, and spectrum tagging (PEAKS Studio Manual 4.5 
http://www.bioinformaticssolutions.com/products/peaks/support/PEAKSStudioManual4
.5.pdf). Our results are based on the current database of 51 prohormones. Our criteria for 
the validation of a prohormone include the identification of at least one peptide from the 
prohormone with a PEAKS score >80% and a mass accuracy ≤300 ppm, or with a score 
of >50% and a mass accuracy within 150 ppm. In addition, we manually verified 
automatic sequencing results, examined prohormone cleavage sites, and evaluated the 
possible PTMs of the identified peptides. A match of at least three consecutive fragments 
in an ion series from manual sequencing to an automatically generated peptide sequence 
was considered sufficient to validate the peptide assignment. As prohormone 
identification increases with the number of detected encoded peptides, we employed high 
identification criteria for the first peptide but allowed lower standards for assignment of 
additional peptides from the same prohormone (PEAKS score >20%, mass accuracy 
≤500 ppm) provided the fragmentation spectrum satisfied manual verification. 
In cases in which a prohormone had already been confirmed by tandem MS, 
occasionally we assigned peptides by mass match with MALDI-TOF-MS data. Such 
assignments were based on a mass-match within 200 ppm to protonated molecular ions of 
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peptides predicted by NeuroPred (http://neuroproteomics.scs.uiuc.edu/neuropred.html) 
[50]. These assignments are tentative since they are not accompanied by sequencing data. 
5.3.6 Comparison of Prohormones from S. mediterranea and Schistosoma 
Translated nucleotide sequences were downloaded either from the Schistosoma 
mansoni FTP server (ftp.sanger.ac.ik/pub/pathogens/Schistosoma/mansoni) or from the 
NCBI taxonomy browser (http://www.ncbi.nlm.nih.gov/Taxonomy/). These sequences 
were then compared to the sequences of MS-confirmed S. mediterranea prohormones 
using BLASTP. NPY-family members were not included in this analysis, although three 
NPY-like proteins have been previously described in Schistosoma [20, 37].  
5.3.7 Analysis of Prohormone Processing Following pc2 RNAi 
To investigate the effect of pc2 RNAi on the proteolytic processing of prohormones, 
peptide profiles were measured by MALDI-TOF MS and compared by principal 
component analysis followed by a t test in tissue extracts prepared from 7 individual 
control and 7 individual RNAi-treated animals. Extracts were prepared by homogenizing 
each specimen in 100 µL of acidified acetone (see above). Following centrifugation at 
14,000× g for 15 min, supernatant was collected, dried in SpeedVac concentrator 
(Thermo Scientific, San Jose, CA), and reconstituted in 30 µL of 0.01% TFA. For 
MALDI-TOF MS analysis, 0.7 µL of each extract was spotted on a stainless steel sample 
holder and co-crystallized with 0.7 µL of freshly prepared concentrated DHB matrix 
(DHB: 2,5-dihydroxybenzoic acid, 50 mg/mL 50% acetone). Three technical replicates 
were sampled for each biological sample, 42 spots total. Positive ion mass spectra were 
acquired manually in 600–6,000 m/z region using a Bruker Ultraflex II mass spectrometer 
(Bremen, Germany) in linear mode with external calibration. For each spot 700 laser 
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shots in 7 acquisitions were accumulated into a sum spectrum representative of a 
replicate. 
For comparison of peptide profiles in control and pc2(RNAi) animals, raw 
MALDI-TOF MS data were loaded into an evaluation version of ClinProTools software 
(Bruker Daltonics, Bremen, Germany) using the following processing parameters: 
convex hull baseline subtraction, baseline flatness 0.2, mass range 1,000–6,000 m/z, 
Savizky-Golay smoothing over 1 m/z width with 11 cycles, data reduction factor of 10, 
null spectra exclusion enabled, recalibration with maximum peak shift of 200 ppm. All 
spectra were normalized to the total ion count (TIC) prior to PCA calculations. Sum 
spectra from technical replicates were grouped into a representative sample spectrum in 
ClinProTools, thus representing a biological replicate for statistical calculations. From 
representative sample spectra a mean spectrum was generated by ClinProTools to reveal 
general peptide features for control and pc2(RNAi) groups. Standard deviation of signal 
intensities among biological replicates was derived for each peak in the group profile. 
Unlimited peak picking on the base of maximal peak intensity and minimal 
signal-to-noise ratio of 6 was done on the mean spectrum representative of each sample 
group in order to take advantage of noise reduction effect due to spectra addition. Peptide 
profiles of mean spectra representative of biological replicates were compared by 
principal component analysis followed by Anderson-Darling (AD) normality test and 
paired Student's t test for peaks showing normal distribution. Peaks not showing a normal 
distribution (pAD≤0.05) were evaluated by the Wilcoxon or Kruskal-Wallis tests, 
respectively [26, 52, 57]. To decrease the number of false positives while computing 
individual peak statistics on highly complex spectra, the Benjamini-Hochberg procedure 
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incorporated into ClinProTool was automatically applied for p value adjustment during 
analysis [11]. 
 
5.4 Results and Discussion 
5.4.1 Prohormone Database Compilation 
We compiled an in-house database with a total of 51 S. mediterranea prohormones 
through three major approaches. First, similarity searches were performed with 
collections of peptides or prohormones from invertebrate species such as Drosophila 
melanogaster, Aplysia californica, Apis mellifera [19], Caenorhabditis elegans [41], and 
various Platyhelminthes [37] with BLAST. Those peptides and prohormones were 
obtained from genome databases (i.e. Wormbase, http://www.wormbase.org), from NCBI, 
or from an online catalog of bioactive peptides (http://www.peptides.be, [31]). Second, 
we analyzed translated S. mediterranea EST [47, 60] and 454 (Roche, Mannheim, 
Germany) sequence data (Y. Wang and P.A. Newmark, unpublished) for sequences that 
possessed characteristics of prohormone genes including multiple dibasic cleavage sites, 
repeating sequences and a signal sequence (www.cbs.dtu.dk/services/SignalP). Third, 
hundreds of sequence tags generated by de novo MS sequencing of unassigned peptides 
were also used as queries for genomic BLAST searches. These lead to the discovery of 
another five novel prohormones, which include spp-3 and its corresponding peptide 
YLINPRLamide, spp-4 (NMNDEFQFRDL), spp-6 (LIDPMTFGYGFSNL), spp-7 
(LIDPMTFGYGFSNL), and spp-12 (NYMDFFGLNGDMQRF). Putative prohormone 
genes identified using these bioinformatics approaches were then used as queries to 
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search the S. mediterranea genome to determine if additional related prohormones existed 
in the genome. 
The presence of these putative prohormone genes was verified by both biological and 
analytical approaches, as shown in Figure 5.1.  Comprehensive whole-mount in situ 
hybridization analyses were performed for each prohormone candidate [9]. The 
post-translational processing of verified prohormones to bioactive peptides was then 
predicted in silico using Neuropred [50], and the sequences of mature peptides were 
confirmed in whole animal tissue extracts from sexual and asexual planarians by 
LC-ESI-IT MS/MS and/or MALDI-TOF MS, the results of which will be presented later 
in this chapter. The putative prohormones uncovered by de novo sequencing approach 
went through the same procedures and were validated. As a result, 51 prohormone genes 
were identified and collected as our in-house S. mediterranea database, and have the 
following characteristics: (1) possessed a signal sequence, (2) possessed basic cleavage 
sites that flanked predicted or MS-confirmed peptides, and (3) were less than 200 amino 
acids in length. All genes were named according to the S. mediterranea genome 
nomenclature guidelines [44] (Table 5.1), and their sequences together with the predicted 
peptides are listed in Table 5.2.  
5.4.2 Peptide Identification  
We performed peptide extraction of whole animals from both sexual and asexual 
strains, and developed and implemented MS-based approaches to uncover peptides on a 
genome-wide scale. 142 peptides from 40 prohormones were characterized (Table 
5.3-5.5), corresponding to ~45% of the distinct peptides predicted from our collection of 
51 prohormone genes (highlighted in Table 5.2). In most cases, MS confirmed multiple 
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distinct peptides from a single prohormone (Table 5.2), and in five prohormones we even 
detected every predicted peptide by MS (Figure 5.2). Our planarian model by far has the 
highest proportion of prohormones discovered among the metazoan. 
There are a number of analytical efforts we have made to achieve such a high 
coverage of prohormones and peptides. We have studied both sexual and asexual 
planarians, and extracted the peptides by two types of solutions, acidified acetone (40:6:1 
acetone/water/12M HCl) and acidified methanol (90:9:1 methanol/acetic acid/water), 
which results in the identification of different subsets of peptides. When it comes to 
separation, not only 1D LC, but also orthogonal 2D LC separation, microbore LC and 
Water/ACN solvent system followed by capillary LC and Water/Methanol, were utilized 
to help reduce the sample complexity for better MS detection. In addition, we took 
advantage of the distinct ionization mechanisms between ESI-IT MS and MALDI-TOF 
MS, and detected peptides that could only be characterized with ease by one of the 
instruments. Figure 5.3 illustrates typical procedures for uncovering prohormones and 
peptides by LC-ESI-IT MS. While most of peptides were identified from the existing 
prohormone database via tandem MS (Figure 5.3 Left), manual and auto de novo 
sequencing of unassigned MS/MS spectra facilitates the refinement of the existing 
prohormone database and thus the identification of more novel peptides (Figure 5.3 
Right).  
The fact that we discovered ~80% of the prohormones in our current database is 
exciting, and the reasons for not detecting the remaining are many folds. It may be due to 
the overall low abundance of these peptides and prohormones for MS characterization, 
their expression at only certain stages of the life cycle, the poor quality of some MS 
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spectra for confident assignments, and instrumental challenges for detecting very small 
and very large peptides. More peptides could potentially be identified by collecting larger 
amount of samples to study, isolating regions with highly localized peptides, 
investigating different developmental stages, and employing LC-MS platforms with 
different sequencing capabilities. 
5.4.2.1 The Identification of Flatworm Prohormones 
This analysis identified genes encoding relatives of all previously characterized 
flatworm neuropeptides (YIRFamide [34], spp-11; FRFamide [33], npp-4; and 
neuropeptide Y-like [35], npy1-11) and provided biochemical validation for 10 
prohormones previously predicted from the S. mediterranea genome [37]. In particular, 
the neuropeptide Y (NPY)-superfamily represents a large family of neuropeptides that 
influence diverse processes in both vertebrate and invertebrate taxa [36, 53, 58]. This 
family is considered to consist of two types of peptides: the NPY-like peptides that 
possess a C-terminal amidated tyrosine (Y) residue and the NPF peptides that possess a 
C-terminal amidated phenylalanine (F) residue [35]. Vertebrate genomes typically encode 
NPY-like peptides [7], whereas invertebrate genomes encode NPF peptides [4, 27, 35]. 
Our studies found that the planarian genome possesses an expanded family of npy genes 
predicted to encode both NPY-like and NPF-like peptides (Table 5.2). Prohormones 
NPY-5, -7, -9, and -10 possess a C-terminal tyrosine residue, similar to vertebrate NPY 
peptides, and prohormones SMED-NPY-1, -2, -3, -4, -6, and -8 contain a C-terminal 
phenylalanine residue, similar to invertebrate NPF peptides. Three of these planarian npy 
genes (npy-1, -4, and -9) have been described previously [5, 37].Our MS studies have 
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identified peptides in S. mediterranea from 7 of them, npy-1, 3, 5, 6, 7, 9 and 10 (Table 
5.3-5.5).  
5.4.2.2 The Identification of Planarian Prohormones 
Our analysis also found that previously characterized, novel planarian genes encode 
peptide prohormones. Homologues of prohormones eye53-1,2 (GB: BK007033 and GB: 
BK007024, respectively) and 1020HH-1,2 (GB: GU295180 and GB:BK007025, 
respectively) from the planarian Dugesia japonica are required for proper visual system 
function following amputation; knockdown animals show no morphological defects after 
injury yet are unable to respond properly to light [25]. These observations, together with 
the identification of neuropeptides from those prohormones via our LC-MS studies, 
suggest a role for peptide signaling in the functional recovery of the planarian nervous 
system following injury. 
5.4.2.3 Prohormones Similar to Other Species 
The planarian genome also encodes peptides with sequence similarities to those from 
other invertebrate taxa, including mollusks (ppp-1, GB:BK007041; ppp-2, 
GB:BK007018; mpl-1, GB: BK007017; mpl-2, GB: BK007016; and, cpp-1, GB: 
BK007012) and arthropods (ppl-1, GB: BK007007).  
5.4.2.4 Neuropeptides with PTMs 
Among the 142 peptides identified, 35 have been post-translationally modified, via 
either N-terminal pyroglutamination or C-terminal amidation. The presence of N-terminal 
pyroglutamate residue can induce conformational changes of the molecule and reduce the 
susceptibility of neuropeptides to degradation by aminopeptidases, which facilitates its 
participation in important biological functions. Similarly, the C-terminal amide has been 
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suggested to play a role in the full biological potency of most amidated peptide hormones 
[38]. Therefore, the presence of PTMs is a structural hallmark of bioactivity, and peptides 
with such modifications are great candidates for further functional tests.  
5.4.3 Differential Expression of Peptides in Sexual and Asexual Planarians  
The planarian S. mediterranea exists as two distinct strains: an asexual strain that 
lacks reproductive organs and propagates exclusively by fission and a sexual strain that 
reproduces as cross-fertilizing hermaphrodites [43]. This dichotomy presents a unique 
opportunity to explore the extent to which peptide hormones are associated with distinct 
reproductive states. Our MS studies demonstrates 27 prohormones were identified in both 
asexual and sexual strains, while 9 were only characterized in asexual animals and 4 only 
in sexual animals (Table 5.3-5.5). The absence of certain prohormones in one of the 
strains found via our MS studies does not necessarily rule out the possibility of their 
presence, and the issues, such as low abundance, could result in the missing MS peaks. 
But the differences at least suggest the abundance variations of certain prohormones 
between sexual and asexual animals, which may correlate with their differential 
reproductive systems. Our whole-mount in situ hybridization analyses indeed reveal 
some expression alterations of several prohormones between sexual and asexual animals, 
and suggest the complexity of the flatworm nervous system [9]. In particular, one of the 
prohormones, npy-8, has been indicated to be only expressed in the nervous system of 
sexually reproducing planarians through our biological and functional studies (data not 
shown) [9]. 
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5.4.4 pc2 Is Required for Proper Prohormone Processing 
pc2 in S. mediterranea are orthologues of prohormone convertase 2 that are 
indispensable in both vertebrate and invertebrate models for the proteolytic processing of 
prohormones to mature neuropeptides [39, 48]. To examine if pc2 is required for 
prohormone processing in planarians, we disrupted pc2 expression using RNAi and 
performed MS to analyze the peptide complement of pc2(RNAi) animals. Consistent with 
pc2 encoding a genuine prohormone convertase, analysis of peptide profiles in planarian 
tissue extracts by MALDI-TOF MS analysis demonstrated that pc2 RNAi resulted in a 
significant decrease in the signal intensity of a specific set of peptides in sexual animals 
(Figure 5.4A and 5.4B). Interestingly, the levels of some peptides were increased 
following pc2(RNAi); whether this alteration reflects a compensatory mechanism for 
regulating peptide levels or an altered threshold of detection for certain peptides caused 
by a global reduction in neuropeptide levels remains to be determined. However, these 
data parallel studies of pc2 knockout mice, in which the abundance of some peptides was 
either increased or decreased [39]. Given that the S. mediterranea genome is predicted to 
encode at least three additional proteins with similarity to prohormone convertases 
(planarian paper), it is possible that compensatory mechanisms are responsible for the 
observed elevation in the levels of some peptides. This redundancy among prohormone 
convertases is also likely to explain why we only observed changes in a subset of 
peptides following pc2 RNAi.  
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5.4.5 Comparative Genomics Identifies Similarities in Peptide Hormones between 
Free-living and Parasitic Flatworms  
Related flatworms of the genus Schistosoma currently infect over 200 million people 
worldwide [8]. Because of their complicated life cycles, schistosomes are not readily 
amenable to the types of large-scale biochemical analyses that we have employed to 
characterize the planarian peptidome. As an indirect means of biochemically validating 
peptide sequences from these animals, we compared our MS-validated prohormones with 
predicted proteins from the genomes of the trematodes Schistosoma mansoni [2] and 
Schistosoma japonicum [32]. With this approach we validated the sequences of peptides 
from eight previously characterized schistosome prohormone genes (Table 5.6) [2, 37]. 
Furthermore, we identified eight additional Schistosoma genes not previously annotated 
as peptide prohormones (Table 5.6). Among these newly annotated prohormones are 
schistosome genes that encode the peptide YIRFamide, a well-conserved flatworm 
peptide that has potent stimulatory effects on schistosome muscle fibers [36] that was not 
identified in previous bioinformatic efforts [2, 37]. Together, these data provide 
biochemical validation for roughly half of the predicted prohormones in Schistosoma and 
demonstrate the utility of using planarians to understand flatworm parasites. 
 
5.5 Conclusions and Future Directions 
Traditional studies of neuropeptides have relied on the biochemical purification of 
individual peptides possessing interesting biological activities [16]. However, the 
application of genomic and peptidomic technologies make possible the determination of 
an expanded collection of neuropeptide-encoding genes and their encoded peptides. Here, 
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we uncovered 51 novel prohormones in S. mediterranea by the intergration of 
bioinformatics and MS-based approaches. Our MS studies on both sexual and asexual 
animals characterized 142 peptides from 40 prohormones. Furthermore, our quantitative 
peptidomics studies suggested that like other organisms, the pc2 in S. mediterranea is 
required for enzymatic processing of peptide prohormones. These studies provide a 
global view of the planarian prohormones and peptides in S. mediterranea, and lay the 
groundwork for using S. mediterranea as an experimental model for studies aimed at 
understanding the diverse functions of metazoan bioactive peptides.  
The importance of this work also lies in the revealed similarity between S. 
mediterranea peptides and Schistosoma peptides via the comparative genomics. 
According to one estimate, schistosomiasis (infection by Schistosoma) can be directly 
attributed to as many as 280,000 deaths per year in sub-Saharan Africa alone [54]. 
Despite the medical and economic impact of schistosomiasis, only a single 
chemotherapeutic agent (praziquantel) is currently used in treatment of this disease [46]. 
By striving to better understand the role of peptide hormones in S. mediterranea, we may 
obtain some implications for studying neuropeptide signaling in parasitic flatworms, and 
hope to eventually find a way to control and treat flatworm parasites. 
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5.7 Figures and Tables 
 
 
 
Figure 5.1 Schematic representation of the methodology used for the identification and 
confirmation of planarian prohormones and their respective peptides. Figure adapted from [9] 
with permission. 
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Figure 5.2 Full sequence coverage of prohormones SPP-1B, SPP-3, SPP-4, NPP-18, and PPP-1 
by MS. Underlined sequences indicate peptides identified by MS/MS sequencing and the shaded 
sequence indicates a peptide detected by MS mass match. Signal peptides for each prohormone 
are italicized. Figure adapted from [9] with permission. 
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Figure 5.3 Typical LC-ESI-IT MS results using S. mediterranea. Left: a peptide (714.79, +2 
charge) was identified from the existing prohormone database via MS/MS. Right: another 
peptide (787.83, +2 charge) and its corresponding prohormone were discovered through the de 
novo sequencing of unassigned MS/MS spectra. 
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(A) (B)
 
Figure 5.4 MALDI-MS analysis of pc2 RNAi in sexual animals. (A) Comparison of peptide profiles for control and pc2 
(RNAi)-treated sexual animals 16 d after the initiation of RNAi treatment. MALDI-TOF MS spectra (limited to m/z 1150–1450) 
comparing control and pc2(RNAi) groups (n = 7 for each group); stars indicate peaks that were significantly different (p<0.05). (B) 
Characterized peptides and their respective prohormones that were detected at significantly different levels (p<0.05) following pc2 
RNAi. The pc2 RNAi/control column reports the ratio of peak intensities of pc2 RNAi relative to control. Figure adapted from [9] 
with permission. 
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Table 5.1 Abbreviations of gene names for S. mediterranea neuropeptide prohormones* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Genes previously predicted from the S. mediterranea genome [37]. Table adapted from [9] with permission. 
 
 
 
 
 
 
 
 
 
 
Gene Name  Abbreviation Gene Subfamily 
cerebral peptide prohormone-1 cpp-1 — 
gonadotropin releasing hormone like-1 grh-1 — 
insulin-like peptide-1 Ilp-1 — 
myomodulin prohormone-like-1,2 mpl-1*,2 — 
neuropeptide precursor-1-5,8,12,18,22 npp-1-5*,8*, 12*,18*,22* — 
neuropeptide y superfamily-1-11 npy-1* neuropeptide F 
 npy-2 neuropeptide F 
 npy-3 neuropeptide F 
 npy-4* neuropeptide F 
 npy-5 neuropeptide Y 
 npy-6 neuropeptide F 
 npy-7 neuropeptide Y 
 npy-8 neuropeptide F 
 npy-9* neuropeptide Y 
 npy-10 neuropeptide Y 
 npy-11 atypical neuropeptide Y 
pyrokinin prohormone like-1 ppl-1 — 
pedal peptide prohormone like-1,2 ppp-1,2 — 
secreted peptide prohormone-1-19 spp-1-19 — 
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       Table 5.2 Sequence information for S. mediterranea prohormone genes (listed alphabetically)* 
 
Gene Name:  Smed-1020HH-1 Abbreviation: Smed-1020HH-1 
Prohormone Sequence:  
MNLKIFFILLIGIFVTCVTSYLSDGTSLENFDDLESNSDYMKRYSYLKGGIRWKKPNYRNNRYLKGGIRWKRRNYL
KGGLRF 
Signal Sequence: MNLKIFFILLIGIFVTCVTS 
Predicted Peptide(s): YLSDGTSLENFDDLESNSDYMФ, YSYLKGGIRWФ, PNYRNNRYLKGGIRW, NYLKGGLRF
 
Gene Name:  Smed-1020HH-2 Abbreviation: Smed-1020HH-2 
Prohormone Sequence:  
MIMKTVIVFFISVLLYGLLSISEAVPRSAENLRTYDSLLEELNDYDPIYKRQSYLTGGIRYKKQVPGKRYLTGGIRY 
Signal Sequence: MIMKTVIVFFISVLLYGLLSISEA 
Predicted Peptide(s): VPRSAENLRTYDSLLEELNDYDPIY, QSYLTGGIRY, pQSYLTGGIRY, QVPamide, QVPG, 
YLTGGIRY 
 
Gene Name:  Smed-Cerebral Peptide Prohormone Like-1 Abbreviation: Smed-cpp-1 
Prohormone Sequence:  
MNFTNRPWTCGTLILILSITFCVGLEGEDDTFVTFQEILRNGKPDLLSDNQDNQKVISFYKSKRVPGWGKRSYQWI
KKTPGWGKRTYQWSKKTPGWG 
Signal Sequence: MNFTNRPWTCGTLILILSITFCVG 
Predicted Peptide(s): LEGEDDTFVTFQEILRNamide, LEGEDDTFVTFQEILRNG, PDLLSDNQDNQKVISFYKS, 
VPGWamide, VPGWG, SYQWI, TPGWamide (x2), TPGWG(x2), TYQWS 
 
Gene Name:  Smed-eye53-1 Abbreviation: Smed-eye53-1 
Prohormone Sequence:  
MNLVPILTILCSLCLWLPRNADSMSMQKKLSIPTYWDDIDTSKRNAKRLSVPTYFDDWESRKKRSSAGKRLSVPP
YWDEWESQRR 
Signal Sequence: MNLVPILTILCSLCLWLPRNADS 
Predicted Peptide(s): MSMQ, LSIPTYWDDIDTS, NA, LSVPTYFDDWESR, SSAamide, SSAG, 
LSVPPYWDEWESQ 
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Table 5.2 (cont.) 
Gene Name:  Smed-eye53-2 Abbreviation: Smed-eye53-2 
Prohormone Sequence:  
MIIALVSAVIIGLTQGEYRSSKNSGRNDWSLLKSSHIKRALVPDAWDDWEIKRSEHKKRAVVPDAWDDWEIKRAI 
Signal Sequence: MIIALVSAVIIGLTQG 
Predicted Peptide(s): EYRSSKNSGRNDWSLLKSSHI, ALVPDAWDDWEI, SEH, AVVPDAWDDWEIФ, AI 
 
Gene Name:  Smed-gonadotropin releasing hormone like  Abbreviation: Smed-grh-1 
Prohormone Sequence: 
MTKFVRFFIILFIFLQIVSEICPQSYHFSNDWLPGKRYHTGHQMFRLKKGFHYFRLKKPSNCIFDNYFKQDILKLAR
KHSGLCPSDLSFIEELQNIK 
Signal Sequence: MTKFVRFFIILFIFLQIVS or MTKFVRFFIILFIFLQIVSEICP 
Predicted Peptide(s): EICPQSYHFSNDWLPamide, EICPQSYHFSNDWLPG, YHTGHQMFRL, GFHYFRL, 
PSNCIFDNYFKQDILKLARKHSGLCPSDLSFIEELQNIK 
 
Gene Name: Smed-Insulin Like Prohormone-1 Abbreviation: Smed-ilp-1 
Prohormone Sequence:  
MLKMYFAFYLVVLYIQFYSGEIFKYELYNQSQADLERNLEVRFCQHRLLKAITTLCNNVNINYLRHFFANRTNIMHPI
YKYVIRPELLSMASIGRYYSPESINCNAYKKSLVDECCCKSCTMLNLFKYCPSDDEARSLKFIK 
Signal Sequence: MLKMYFAFYLVVLYIQFYSG 
Predicted Peptide(s): EIFKYELYNQSQADLERNLEVRFCQHRLLФ, 
 AITTLCNNVNINYLRHFFANRTNIMHPIYKYVIRPELLSMASIGRYYSPESINCNAYФ, 
SLVDECCCKSCTMLNLFKYCPSDDEARSL, FIK 
 
Gene Name:  Smed-Myomodulin Prohormone Like-1 Abbreviation: Smed-mpl-1 
Prohormone Sequence:  
MSKLTYFIFMIMLFIFVQTIDINSNQYEEDYDPNDDHELDKRAYRLMRMGKRAVRLMRMGKKAVRLMRLGKRSDM
A 
Signal Sequence: MSKLTYFIFMIMLFIFVQT 
Predicted Peptide(s): IDINSNQYEEDYDPNDDHELD, AYRLMRMamide, AYRLMRMG, AVRLMRMamide, 
AVRLMRMG, AVRLMRLamide, AVRLMRLG, SDMA 
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                    Table 5.2 (cont.) 
Gene Name:  Smed-Myomodulin Prohormone Like-2 Abbreviation: Smed-mpl-2 
Prohormone Sequence:  
MQYLFAAFIFMAYYIRCEDFNENIIYPELFEDSEQYNAIPWNKRAVRLMRLGKRIAPLKRAVKLMRLGKREE 
Signal Sequence: MQYLFAAFIFMAYYIRC 
Predicted Peptide(s): EDFNENIIYPELFEDSEQYNAIPWN, AVRLMRLamide, AVRLMRLG, IAPL, 
AVKLMRLamide, AVKLMRLG§, EE 
 
Gene Name:  Smed-Neuropeptide Precursor-1 Abbreviation: Smed-npp-1 
Prohormone Sequence:  
MKLEIRIVVVTVLLSAVLADYYNSDDSDSKKRSFVRLGKRASFVRLGRSGYEWQSPFVKKASFVRLGKKSRLDYE
PVDDYNKRASFVRLGRTYE 
Signal Sequence: MKLEIRIVVVTVLLSAVLA 
Predicted Peptide(s): DYYNSDDSDS, SFVRLamide, SFVRLG, ASFVRLamide (x3), ASFVRLG (x3), 
SGYEWQSPFV, SRLDYEPVDDYN, TYE 
 
Gene Name:  Smed-Neuropeptide Precursor-2 Abbreviation: Smed-npp-2 
Prohormone Sequence:  
MIFQFLLLLFVTTVWTDSDSDCDICEICEAGGLMDSTECCLSSVLYKICESKLEISRDKRRGLIGKRRGLIGKRRGLI
GKRRGLIGKRRGLIGKRRGLIGKRRGLIGKRQLLNSKQSIFQDEY 
Signal Sequence: MIFQFLLLLFVTTVWT 
Predicted Peptide(s): DSDSDCDICEICEAGGLMDSTECCLSSVLYKICESKLEISRD, RGLIamide or GLIamide 
(x7), RGLIG or GLIG (x7), QLLNSKQSIFQDEY, pQLLNSKQSIFQDEY 
 
Gene Name:  Smed-Neuropeptide Precursor-3 Abbreviation: Smed-npp-3 
Prohormone Sequence:  
MMAKQFPYFIINLSIVLCLCFYIQFADQMPDQYENRYELLDPISKHELNYQTGKRAILLTRYGKRGSRRYFLNNDDS
KRAIVLTRFG 
Signal Sequence: MMAKQFPYFIINLSIVLCLCFYIQFADQ 
Predicted Peptide(s): MPDQYENRYELLDPISKHELNYQTamide, MPDQYENRYELLDPISKHELNYQTG, 
AILLTRYamide, AILLTRYG, GS,YFLNNDDS, GSRRYFLNNDDS, AIVLTRFamide, AIVLTRFG 
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           Table 5.2 (cont.) 
Gene Name:  Smed-Neuropeptide Precursor-4 Abbreviation: Smed-npp-4 
Prohormone Sequence:  
MNSLSITIFVLSILVSWAQSEQKRSSVFRFGKRDQSIDQLTDDSAFSNVPVESTRRNYEQLLSPYPENDQDENKR
SVAFRFGKRRGVAFRFGKRGSVFRYGKRQSVFRYG 
Signal Sequence: MNSLSITIFVLSILVSWAQS 
Predicted Peptide(s): EQ, SSVFRFamide, SSVFRFG, DQSIDQLTDDSAFSNVPVEST, 
NYEQLLSPYPENDQDEN, SVAFRFamide, SVAFRFG, RGVAFRFamide, RGVAFRFG, GSVFRYamide, 
GSVFRYG, QSVFRYamide, QSVFRYG,  
 
Gene Name:  Smed-Neuropeptide Precursor-5 Abbreviation: Smed-npp-5 
Prohormone Sequence:  
MNLFLLIGVIIVGVQVTVDAENSDLIDALKKRPNWKDMPWGKRSAWRDMPWGKRSAWRDMPWGKRSAWRDM
PWGKRSAWRDMPWGKKSAWRDMPWGKRSDWKDISWEKKQGLHDLSLNNPFEKSLILNNSEFED 
Signal Sequence: MNLFLLIGVIIVGVQVTVDA 
Predicted Peptide(s): ENSDLIDAL, PNWKDMPWamide, PNWKDMPWG, SAWRDMPWamide(x5), 
SAWRDMPG(x5), SDWKDISWE, QGLHDLSLNNPFEKSLILNNSEFED 
 
Gene Name:  Smed-Neuropeptide Precursor-8 Abbreviation: Smed-npp-8 
Prohormone Sequence:  
MKLVFMLLFSLNILILSNRWADGMMQDYLDRKLFLASKRLADKKDPRFSDQVWHSGYGKRNYYNRFDGQAWYS
GYGKRNDAFDGQAWYSGYGR 
Signal Sequence: MKLVFMLLFSLNILILSNRWADG 
Predicted Peptide(s): MMQDYLDRKLFLAS, LAD, DPRFSDQVWHSGYamide, DPRFSDQVWHSGYG, 
NYYNRFDGQAWYSGYamide, NYYNRFDGQAWYSGYG, NDAFDGQAWYSGYamide, NDAFDGQAWYSGY 
 
Gene Name:  Smed-Neuropeptide Precursor-12 Abbreviation: Smed-npp-12 
Prohormone Sequence:  
MKLILLFILLLVCIVHSRYFQPQQDFPKSNIFQLPESEFENDDVIQKRNYFGKRNYFGKRNYFGKRNYFWKKKLFR
LKIQTIN 
Signal Sequence: MKLILLFILLLVCIVHS 
Predicted Peptide(s): RYFQPQQDFPKSNIFQLPESEFENDDVIQ, NYFamide(x3), NYFG(x3), NYFW, 
LFRLKIQTIN 
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           Table 5.2 (cont.) 
Gene Name:  Smed-Neuropeptide Precursor-18 Abbreviation: Smed-npp-18 
Prohormone Sequence: 
MELFSRTTVFFLIIFPIWMMSVILIEARNMDLDEYDSLLPKDKRGAEFFIRRVVGKRGAEFFIRRVVGKRNSDYLIQ 
Signal Sequence: MELFSRTTVFFLIIFPIWMMSVILIEA 
Predicted Peptide(s): RNMDLDEYDSLLPKD, GAEFFIRRVVamide (x2), GAEFFIRRVVG(x2), NSDYLIQ 
 
Gene Name:  Smed-Neuropeptide Precursor-22 Abbreviation: Smed-npp-22 
Prohormone Sequence:  
MKTLSLCLSIGFSLVLIASLPFVSSTTDDEVNENICQSLCHKSLSCLDECHDISESNDSMEKRAKYFRLGKRAKYFR
LGKRSFDSSNLEKRAKYFRLG 
Signal Sequence: MKTLSLCLSIGFSLVLIASLPFVSS 
Predicted Peptide(s): TTDDEVNENICQSLCHKSLSCLDECHDISESNDSME, AKYFRLamide(x3), 
AKYFRLG(x3), SFDSSNLE   
 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-1 Abbreviation: Smed-npy-1 
Prohormone Sequence:  
MTFIYGFLCLTLVNVICSQKSLFIEPPAKPEFFDDPELLRNYIKKLNEYFAIVGRPRFGKRFDRGFS 
Signal Sequence: MTFIYGFLCLTLVNVICS 
Predicted Peptide(s): QKSLFIEPPAKPEFFDDPELLRNYI, pEPPAKPEFFDDPELLRNYI, 
LNEYFAIVGRPRFamide§, LNEYFAIVGRPRFG, FDRGFS 
 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-2 Abbreviation: Smed-npy-2 
Prohormone Sequence:  
MNFPIISIVALLTVFNCFSAMEDDTKSLAELKNLLSDLNEEYLIAGRPRFGKRNMIFKRSANPLKWMTL 
Signal Sequence: MNFPIISIVALLTVFNCFS 
Predicted Peptide(s): AMEDDTKSLAELKNLLSDLNEEYLIAGRPRFamide,  
AMEDDTKSLAELKNLLSDLNEEYLIAGRPRFG, NMIF, SANPLKWMTL 
 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-3 Abbreviation: Smed-npy-3 
Prohormone Sequence: 
MSTKEFTFCFVMICALFCQIVQISANKDELDILFKKRNNNQLDDPDIQQYLQDLNNFYQFYGRPRFGKRQKFHRD 
Signal Sequence: MSTKEFTFCFVMICALFCQIVQISA 
Predicted Peptide(s): NKDELDILF, NNNQLDDPDIQQYLQDLNNFYQFYGRPRFamide,  
NNNQLDDPDIQQYLQDLNNFYQFYGRPRFG, QKFHRD, pQKFHRD 
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           Table 5.2 (cont.) 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-4  Abbreviation: Smed-npy-4 
Prohormone Sequence:  
MKFCCAPRLSVLFLAVFIFGISLTAKEVKRKVVYLKSRNHFRSDEDYVSYLRKVQKYIQLYGRPRFGKRQTNWYD
MKNYEGNENYDSYTF 
Signal Sequence: MKFCCAPRLSVLFLAVFIFGISLTA 
Predicted Peptide(s): KEV, VVYLKSRNHFRSDEDYVSYLRKVQKYIQLYGRPRFamide, 
VVYLKSRNHFRSDEDYVSYLRKVQKYIQLYGRPRFG, QTNWYDMKNYEGNENYDSYTF 
 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-5  Abbreviation: Smed-npy-5 
Prohormone Sequence:  
MLIGYNCKSGIILLMAVLGAMWLSGIQTDDRVDIRKSIFSSPEALRRYLLQMNEYLAIVARPRYGKRSLPIDMNRLQ
FDNYENYFK 
Signal Sequence: MLIGYNCKSGIILLMAVLGAMWLSGIQT 
Predicted Peptide(s): DDRVDIRKSIFSSPEAL, YLLQMNEYLAIVARPRYamideФ, YLLQMNEYLAIVARPRYGФ, 
SLPIDMNRLQFDNYENYF 
 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-6 Abbreviation: Smed-npy-6 
Prohormone Sequence: 
MYGFSHSALKIILILISISSLILSTFSSDPVIDFDLEKDKDLMKYMQDLNNYSQLYGRPRFGKRSLNSFQTIREFVRD
RRLW 
Signal Sequence: MYGFSHSALKIILILISISSL 
Predicted Peptide(s): ILSTFSSDPVIDFDLEKDKDLMKYMQDLNNYSQLYGRPRFamide, 
ILSTFSSDPVIDFDLEKDKDLMKYMQDLNNYSQLYGRPRFG, SLNSFQTIREFVRD, LW 
 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-7 Abbreviation: Smed-npy-7 
Prohormone Sequence:  
MFERIRNSIFLLFISLNWCEAQYPIFGKMLDSIPFKSRTPIAGIVNKMGQIRKLSEREIKLLVYLLNEHFAIYGRPRYG 
Signal Sequence: MFERIRNSIFLLFISLNWCEA 
Predicted Peptide(s): QYPIFGKMLDSIPFKSRTPIAGIVNKMGQIRKLSEREI§, LLVYLLNEHFAIYGRPRYamide, 
LLVYLLNEHFAIYGRPRYG 
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           Table 5.2 (cont.) 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-8 Abbreviation: Smed-npy-8 
Prohormone Sequence:  
MIINKCYFLVFILCFMSFIHLNTCNQKRPMFDSADAFRNYLRKLNNEYMIAGRPRFGKRRSDFEKELFYNLKSNL 
Signal Sequence: MIINKCYFLVFIL 
Predicted Peptide(s): NQ, PMFDSADAFRNYL, LNNEYMIAGRPRFamide, LNNEYMIAGRPRFG, 
RSDFEKELFYNL, RSDFEKELFYNLKSNL 
 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-9  Abbreviation: Smed-npy-9 
Prohormone Sequence:  
MYFLQKFFILSISLTLCVICFNRNVSGLTKQKYSLFSGPEDLRNYLRQLNEYIALSSRPRYGKRNEWTSISE 
Signal Sequence: MYFLQKFFILSISLTLCVICFNRNVSG 
Predicted Peptide(s): LTKQKYSLFSGPEDLRNYLRQLNEYIALSSRPRYamide, 
LTKQKYSLFSGPEDLRNYLRQLNEYIALSSRPRYG, NEWTSISE, pEWTSISE§ 
 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-10  Abbreviation: Smed-npy-10 
Prohormone Sequence:  
MNISRFLKVFVIFILFQNICTLSDYETSSFNQWYDKRDLKPLFNNAKQLLWYLQKLDKMYAIAGRPRYGKR 
Signal Sequence: MNISRFLKVFVIFILFQNICT 
Predicted Peptide(s): LSDYETSSFNQWYD, DLKPLFNNAKQLLWYLQKLDKMYAIAGRPRYamide, 
DLKPLFNNAKQLLWYLQKLDKMYAIAGRPRYG 
 
Gene Name:  Smed-Neuropeptide Y Prohormone Like-11 Abbreviation: Smed-npy-11 
Prohormone Sequence:  
MLIPCLLGALIFAIQDSHCYFIMPSNSMDPNKPPIPLNSHATSDEIKDYLHHLNLYFQIVSRPRLGKRQKYDFHDILN
QF 
Signal Sequence: MLIPCLLGALIFAIQDSHC 
Predicted Peptide(s): YFIMPSNSMDPNKPPIPLNSHATSDEIKDYLHHLNLYFQIVSRPRLamide, 
YFIMPSNSMDPNKPPIPLNSHATSDEIKDYLHHLNLYFQIVSRPRLG, QKYDFHDILNQF 
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           Table 5.2 (cont.) 
Gene Name: Smed-Pyrokinin Prohormone like-1 Abbreviation: Smed-ppl-1  
Prohormone Sequence:  
MKFSRICFIILVSLELFVVNEAVHMSDQLVFSLLVLIANHEINSKNFIYIPDDSFINEMDRAIDKKIFSPRMGKRYFSPR
MGKRYFSPRMGKRYFSPRMGKRYFSPRLGK 
Signal Sequence: MKFSRICFIILVSLELFVVNEA 
Predicted Peptide(s): VHMSDQLVFSLLVLIANHEINSKNFIYIPDDSFINEMDRAID, IFSPRMamide, IFSPRMG, 
YFSPRMamide (x3), YFSPRMG(x3), YFSPRLamide, YFSPRLG 
 
Gene Name: Smed-Pedal Peptide Prohormone Like-1 Abbreviation: Smed-ppp-1 
Prohormone Sequence:  
MKSTGLLILTFVLVSVEFGDFYRVSSSDLRRFKKYSYYDSIGSGLLKRGAYYDPIGGGLLKRSSYYDPIGGGLLKR
DSNYDPIGGGLLKRRSFYDPIGGGLLKRRSFYDPIGGGLLKRRSFYDPIGGGLLKKRFYNDPLGVALLKSRFDKD
SIN 
Signal Sequence: MKSTGLLILTFVLVSVEFG 
Predicted Peptide(s): DFYRVSSSDLRRF, YSYYDSIGSGLL, GAYYDPIGGGLL, SSYYDPIGGGLL, 
DSNYDPIGGGLL, RSFYDPIGGGLL (x3), RFYNDPLGVALLKSRFDKDSIN 
 
Gene Name:  Smed-Pedal Peptide Prohormone Like-2 Abbreviation: Smed-ppp-2 
Prohormone Sequence:  
MTVNGILISSMMITIILSTVDLSKSREHGEIKRFRYFDKIGSDLLKRSYFDKIGNDLLKRSYMDKIGSDLLKRRYFDKI
GSEMLKRSYMDKIGSDL 
Signal Sequence: MTVNGILISSMMITIILS 
Predicted Peptide(s): TVDLSKSREHGEI, FRYFDKIGSDLL, SYFDKIGNDLL, SYMDKIGSDLL, RYFDKIGSEML, 
SYMDKIGSDL 
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         Table 5.2 (cont.) 
Gene Name:  Smed-Secreted Peptide Prohomone-1 Abbreviation: Smed-spp-1 
Prohormone Sequence (two splice variants):  
SMED-SPP-1A 
MTMNKLTILFSLFLSVFVARSNASAFSSPGNSGAMILLTSGCLFMNTFAEDLGSLNADIDLDDSRLDKKAYWASRM
GKRAYWASRMGKKAYWASRMGK 
SMED-SPP-1B 
MILLTSGCLFMNTFAEDLGSLNADIDLDDSRLDKKAYWASRMGKRAYWASRMGKKAYWASRMGK 
Signal Sequence: MTMNKLTILFSLFLSVFVARSNA (SMED-SPP-1A) 
                               MILLTSGCLFMNTFA (SMED-SPP-1B) 
Predicted Peptide(s): SAFSSPGNSGAMILLTSGCLFMNTFAEDLGSLNADIDLDDSRLD, 
EDLGSLNADIDLDDSRLD, AYWASRMamide (x3), AYWASRMG (x3) 
 
Gene Name:  Smed-Secreted Peptide Prohomone-2 Abbreviation: Smed-spp-2 
Prohormone Sequence: 
MAIKILYSFLSILFCISVQGEFYQNFPADSNPCDELCEPQNLCDKLCSSYQNSDFEHEDAKRAVFLRLGRNIKRAPF
LRLGRSQQKKSKFLRLGK 
Signal Sequence: MAIKILYSFLSILFCISVQG 
Predicted Peptide(s): EFYQNFPADSNPCDELCEPQNLCDKLCSSYQNSDFEHEDA, AVFLRLamide, AVFLRLG, 
NI, APFLRLamide, APFLRLG, SQQ, SKFLRLamide, SKFLRLG 
 
Gene Name:  Smed-Secreted Peptide Prohomone-3 Abbreviation: Smed-spp-3 
Prohormone Sequence:  
MYYFKIILLISFICIQQEFIFSSVMDDLSKDETYLSKRRYSLINPRLGKRYLINPRLGKRFQIKDIENLD 
Signal Sequence: MYYFKIILLISFICIQQEFIFS 
Predicted Peptide(s): SVMDDLSKDETYLS, RYSLINPRLamide, RYSLINPRLG, YLINPRLamide, YLINPRLG, 
FQIKDIENLD 
 
Gene Name:  Smed-Secreted Peptide Prohomone-4 Abbreviation: Smed-spp-4 
Prohormone Sequence:  
MFYKFILLSVIMIFITKIEADYSSLNDDSELEDSYHRYPSSIKRGLRLMRLGKRNMNDEFQFRDLKKRGLRLMRLG 
Signal Sequence: MFYKFILLSVIMIFITKIEA 
Predicted Peptide(s): DYSSLNDDSELEDSYHRYPSSI, GLRLMRLamide (x2), GLRLMRLG (x2), 
NMNDEFQFRDL  
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         Table 5.2 (cont.) 
Gene Name:  Smed-Secreted Peptide Prohomone-5 Abbreviation: Smed-spp-5 
Prohormone Sequence:  
MKVLLFIVLCVVFVFALDDPEDSLNYYSNYSPAAERSELVSKRGLRILRMGKRNDLFRLLDKRGMRHMRLG 
Signal Sequence: MKVLLFIVLCVVFVFA 
Predicted Peptide(s): LDDPEDSLNYYSNYSPAAERSELVS, GLRILRMamide, GLRILRMG, NDLFRLLD, 
GMRHMRLamide, GMRHMRLG 
 
Gene Name:  Smed-Secreted Peptide Prohomone-6 Abbreviation: Smed-spp-6 
Prohormone Sequence:  
MIKIRILMSVLLFMAICLAAGLAEIDKRIPGIGFNRNFAIYKRMLEKRLIDPMTFGYGFSNLK 
Signal Sequence: MIKIRILMSVLLFMAICLAAGLA 
Predicted Peptide(s): EID, IPGIGFNRNFAIY, MLE, LIDPMTFGYGFSNL 
 
Gene Name:  Smed-Secreted Peptide Prohomone-7 Abbreviation: Smed-spp-7 
Prohormone Sequence:  
MKFIISLFVVLFLCVVMAMSEIDKRTVGFGFNRNLHLYKRMLEKRLIDPMTFGSGFANLK 
Signal Sequence: MKFIISLFVVLFLCVVMAMS 
Predicted Peptide(s): EID, TVGFGFNRNLHLY, MLE, LIDPMTFGSGFANL 
 
Gene Name:  Smed-Secreted Peptide Prohomone-8 Abbreviation: Smed-spp-8 
Prohormone Sequence: MKIIILLAIILAVCAFEALGEVEKRTMGFGFNRNMLLYKRMLEKRLIDPMTFGSGFANLR 
Signal Sequence: MKIIILLAIILAVCAFEALG 
Predicted Peptide(s): EVE, TMGFGFNRNMLLY, MLE, LIDPMTFGSGFANL 
 
Gene Name:  Smed-Secreted Peptide Prohomone-9 Abbreviation: Smed-spp-9 
Prohormone Sequence:  
MNSLIILLIVALVCLANVCCGVQKRSLPYNPEYELYKRFVEKRLIDPLTFGSGFSNL 
Signal Sequence: MNSLIILLIVALVC 
Predicted Peptide(s): LANVCCGVQ§, SLPYNPEYELY, FVE, LIDPLTFGSGFSNL 
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         Table 5.2 (cont.) 
Gene Name:  Smed-Secreted Peptide Prohomone-10 Abbreviation: Smed-spp-10 
Prohormone Sequence:  
MNFQSKIIIMIMCHFVITVFNEPLSKYYPDNNEDLSATIKRGAEFFLQRVEGKRGAEFFLRRVVGKRSTKPIDPNQY
PLVYGE 
Signal Sequence: MNFQSKIIIMIMCHFVITVFN 
Predicted Peptide(s): EPLSKYYPDNNEDLSATI, GAEFFLQRVEamide, GAEFFLQRVEG, GAEFFLRRVVamide, 
GAEFFLRRVVG, STKPIDPNQYPLVYGE 
 
Gene Name:  Smed-Secreted Peptide Prohomone-11 Abbreviation: Smed-spp-11 
Prohormone Sequence: 
MKLLFVAALFLVIMDVYAIQEKRYIRFGKRHQQLFPNKRYIRFGKREYIPLDKRNDLLDSEFLNDMNENLEKRYIRF
GR 
Signal Sequence: MKLLFVAALFLVIMDVYA 
Predicted Peptide(s): IQE, YIRFamide (x3), YIRFG (x3), HQQLFPN, EYIPLD, NDLLDSEFLNDMNENLE 
 
Gene Name:  Smed-Secreted Peptide Prohomone-12 Abbreviation: Smed-spp-12 
Prohormone Sequence: 
MQLLLILMLTYTFYSVHEATPAMRSDKLDREDWYGPFKRNYMDFFGLNGDMQRFKKQQFFRNHRPEIEWN 
Signal Sequence: MQLLLILMLTYTFYSVH 
Predicted Peptide(s): EATPAMRSD§, LDREDWYGPF, NYMDFFGLNGDMQRF, QQFFRNHRPEIEWN, 
pQQFFRNHRPEIEWN. 
 
Gene Name:  Smed-Secreted Peptide Prohomone-13 Abbreviation: Smed-spp-13 
Prohormone Sequence:  
MKFTIYTVLTATLWIFLVQTEEAEIPQKDFLQNYDLIPNYEQRIEDSWRDPDRIRLMKKFRGLLGKRVHAKRFRGLL
G 
Signal Sequence: MKFTIYTVLTATLWIFLVQTEEA 
Predicted Peptide(s): EIPQKDFLQNYDLIPNYEQRIEDSWRDPDRIRLM, FRGLLamide(x2), FRGLLG(x2), VHA 
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         Table 5.2 (cont.) 
Gene Name:  Smed-Secreted Peptide Prohomone-14 Abbreviation: Smed-spp-14 
Prohormone Sequence: 
MKLTYTLSIIYFVTFTLCNSYDYDTKISNKRPYNGKRNGLDIDDLFMGKRTYLGKRTYLGKRTYLGKRLDHSISRLL
PQAFANTKYQLYRNQ 
Signal Sequence: MKLTYTLSIIYFVTFTLC 
Predicted Peptide(s): NSYDYDTKISN, PYNamide, PYNG, NGLDIDDLFMamide, NGLDIDDLFMG, TYLamide 
(x3), TYLG(x3), LDHSISRLLPQAFANTKYQLYRNQ 
 
Gene Name:  Smed-Secreted Peptide Prohomone-15 Abbreviation: Smed-spp-15 
Prohormone Sequence:  
MQFRFSKMTHVTLLITVGLFHVISGYPQTYELNQSDRGYYPILFDKRFDPIQFGKRFDPIQFGKRFDPIQFGKRFD
PIQFGKRFDPIQFGKRFDPIQFGKRFDPIQFGKKFDPIQFGKRFDPIMFGR 
Signal Sequence: MQFRFSKMTHVTLLITVGLFHVISG 
Predicted Peptide(s): YPQTYELNQSDRGYYPILFD, FDPIQFamide (x8), FDPIQFG (x8), FDPIMFamide§ , 
FDPIMFG 
 
Gene Name:  Smed-Secreted Peptide Prohomone-16 Abbreviation: Smed-spp-16 
Prohormone Sequence:  
MKIYILCLSLFFLQQLSVTRSFPSSNEIYKRQFDPIMYGKLRQFYRRSSKIGKGQFDPTMYEKSIFAKRQFDPIMYK
RQSNPYFLSDIRSIKRQFDPIMY 
Signal Sequence: MKIYILCLSLFFLQQLSVTRS 
Predicted Peptide(s): FPSSNEIY, QFDPIMYGKLRQFY, pQFDPIMYGKLRQFY, QFDPIMYamide§, SS, 
IGKGQFDPTMYEKSIFA, QFDPIMY(x2), pQFDPIMY(x2), QSNPYFLSDIRSI, pQSNPYFLSDIRSI 
 
Gene Name:  Smed-Secreted Peptide Prohomone-17 Abbreviation: Smed-spp-17 
Prohormone Sequence:  
MNKVIVLLLFLFIAFSSETPFKRYIQDPDENDTLRDFYLQNRMENSKSKKIIDPMTYGTGFSNL 
Signal Sequence: MNKVIVLLLFLFIAFS 
Predicted Peptide(s): SETPF, YIQDPDENDTLRDFYLQNRMENSKS, IIDPMTYGTGFSNL 
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         Table 5.2 (cont.) 
Gene Name:  Smed-Secreted Peptide Prohomone-18 Abbreviation: Smed-spp-18 
Prohormone Sequence:  
MKSGALTVVGFCLISYCMSAIPEDYEKRGYHFFRLKKSGDCVIPDVMKAMIETKIQNHEQLCAADKKFIEMISSV 
Signal Sequence: MKSGALTVVGFCLISYCMS 
Predicted Peptide(s): AIPEDYE, GYHFFRL, SGDCVIPDVMKAMIETKIQNHEQLCAAD, FIEMISSV 
 
Gene Name:  Smed-Secreted Peptide Prohomone-19 Abbreviation: Smed-spp-19 
Prohormone Sequence: 
MNGTVILCTLIVLLASFPSDGSDDLIVKRKHIGHQIFRLKRGYHFFRLRKDEKCLIPGELKSAIKNDLESGSNLCGSD
KSFLAELASLL 
Signal Sequence: MNGTVILCTLIVLLASFPSDG 
Predicted Peptide(s): SDDLIV, KHIGHQIFRL, GYHFFRL, 
DEKCLIPGELKSAIKNDLESGSNLCGSDKSFLAELASLL 
*Peptides confirmed by MS/MS sequencing are colored in red and peptides detected by mass match only are shaded. Peptides marked with § were 
identified with lower confidence, and peptides labeled with Ф are tentative, because their corresponding prohormone identification do not meet the 
criteria as described in experimental section. *Table adapted from [9] with permission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 145
Table 5.3 Summary of MS analysis from sexual and asexual Schmidtea mediterranea* 
   Number of Peptides in Sexual animals Number of Peptides in Asexual animals 
Gene  
Name 
Sequenced 
 Peptides 
Mass Match  
Peptides Total 
Sequenced  
Peptides 
Mass Match  
Peptides Total 
1020HH-1Ф N/A N/A N/A 2 N/A 2 
1020HH-2 3 N/A 3 4 N/A 4 
eye53-1 2 N/A 2 2 N/A 2 
eye53-2Ф 1 N/A 1 N/A N/A N/A 
ilp-1Ф 2 1 3 N/A N/A N/A 
mpl-1 1 1 2 3 2 4 
mpl-2 1 N/A 1 3 1 3 
npp-1 2 1 2 3 1 3 
npp-2 N/A N/A N/A 1 N/A 1 
npp-3 2 1 2 3 1 4 
npp-4 2 4 4 3 2 5 
npp-5 2 2 4 N/A N/A N/A 
npp-18 6 1 6 6 N/A 6 
npp-22 1 2 2 2 3 3 
npy-1 N/A N/A N/A 3 1 4 
npy-3 N/A N/A N/A 1 1 2 
npy-5Ф N/A N/A N/A 2 N/A 2 
npy-6 N/A N/A N/A 3 N/A 3 
npy-7 N/A N/A N/A 2 1 3 
npy-9 2 N/A 2 N/A N/A N/A 
npy-10 N/A N/A N/A 2 1 3 
ppp-1 5 4 6 7 2 7 
ppp-2 4 2 4 3 2 3 
spp-1 1 2 2 2 2 3 
spp-3 5 N/A 5 5 1 5 
spp-4 4 1 4 4 3 4 
spp-5 4 1 4 3 N/A 3 
spp-6 4 1 4 3 2 3 
spp-7 2 2 2 2 1 2 
spp-8 2 2 2 2 1 2 
spp-9 3 1 3 4 2 4 
spp-10 3 1 4 3 N/A 3 
spp-11 2 2 3 2 2 3 
spp-12 2 2 3 1 1 1 
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               Table 5.3 (cont.) 
   Number of Peptides in Sexual animals Number of Peptides in Asexual animals 
Gene  
Name 
Sequenced 
 Peptides 
Mass Match  
Peptides Total 
Sequenced  
Peptides 
Mass Match  
Peptides Total 
spp-13 N/A N/A N/A 1 1 1 
spp-15 2 3 3 1 2 3 
spp-16 5 2 5 6 3 7 
spp-17 1 N/A 1 1 N/A 1 
spp-18 1 1 1 1 1 1 
spp-19 1 1 1 3 1 3 
Four prohormones labeled with Ф are tentative and not completely validated, since they do not meet the criteria for prohormone identification as 
described in experimental section. *Table adapted from [9] with permission. 
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Table 5.4 Peptides Characterized by MS from Sexual Schmidtea mediterranea* 
Prohormone  Peptide Sequence Obs.  Mass (Da) 
Cal. 
Mass (Da) 
Error 
(ppm) Score 
ESI-IT
MS/MS 
MALDI-
TOF-MS 
1020HH-2 [52-61] KR.pQSYLTGGIRY.KK 1139.57 1139.56 8.8 98 X  
1020HH-2 [52-61] KR.QSYLTGGIRY.KK 1156.61 1156.59 17.3 99 X  
1020HH-2 [70-77] KR.YLTGGIRY.# 941.51 941.5 10.6 99 X  
EYE53-1 [30-42] KK.LSIPTYWDDIDTS.KR 1524.71 1524.7 6.6 98 X  
EYE53-1 [49-60] KR.LSVPTYFDDWES.RKKR 1457.54 1457.64 -68.6 99 X  
EYE53-2Ф [60-71] KKR.AVVPDAWDDWEI.KR 1415.71 1414.64 756.4 43 X
ILP-1Ф [21-49] *.EIFKYELYNQSQADLERNLEVRFCQHRLL.K 3654.23 3653.85 104 X
ILP-1Ф [43-48] R.FCQHRL.LK 802.47 802.39 99.7 25 X
ILP-1Ф [97-107] RY.YSPESINCNAY.KK 1259.1 1259.51 -325.5 28 X
MPL-1 [43-49] KR.AYRLMRMa.GKR 938.45 938.5 -53.3   X 
MPL-1 [63-69] KK.AVRLMRLa.GKR 856.58 856.54 46.7 53 X  
MPL-2 [45-51] KK.AVRLMRLa.GKR 856.58 856.54 46.7 53 X  
NPP-1 [70-81] KK.SRLDYEPVDDYN.KR 1484.62 1484.64 -13.5 98 X X 
NPP-1 [84-93] KR.ASFVRLGRTY.E# § 1168.75 1168.64 94.1 28 X  
NPP-3 [56-62] KR.AILLTRYa.GKR 847.58 847.53 59 98 X  
NPP-3 [80-86] KR.AIVLTRFa.G# 817.8 817.52 342.5 95 X X 
NPP-4 [25-30] KR.SSVFRFa.GKR 740.46 740.4 81 35 X X 
NPP-4 [25-31] KR.SSVFRFG.KR 798.28 798.41 -162.8   X 
NPP-4 [85-91] KR.RGVAFRFa.GKR 850.61 850.49 141.1 74 X X 
NPP-4 [104-109] KR.QSVFRYa.G# 797.31 797.43 -150.5   X 
NPP-5 [21-29] *.ENSDLIDAL.KKR 988.38 988.48 -101.2 X
NPP-5 [33-40] KKR.PNWKDMPWa.GKR 1071.59 1071.5 84 52 X
NPP-5 [44-51] (x5) KR.SAWRDMPWa.GKR 1046.46 1046.48 -19.1 87 X
NPP-5 [110-134] KK.QGLHDLSLNNPFEKSLILNNSEFED.# 2873.64 2874.11 -163.5 X
NPP-18 [28-42] *.RNMDLDEYDSLLPKD.KR 1822.85 1822.84 5.5 99 X X 
NPP-18 [29-42] *R.NMDLDEYDSLLPKD.KR 1666.65 1666.74 -54 97 X  
NPP-18 [34-42] D.EYDSLLPKD.KR 1078.59 1078.52 64.9 51 X  
NPP-18 [45-54](x2) KR.GAEFFIRRVVa.GKR 1191.68 1191.69 -8.4 98 X  
NPP-18 [45-55](x2) KR.GAEFFIRRVVG.KR 1249.66 1249.69 24 35 X  
NPP-18 [71-77] KR.NSDYLIQ.# 851.27 851.4 152.7 59 X  
NPP-22 [64-69](x3) KR.AKYFRLa.GKR 795.45 795.48 -37.7 88 X X 
NPP-22 [64-70](x3) KR.AKYFRLG.KR 853.32 853.49 -199.2   X 
NPY-9 [33-40] K.YSLFSGPE.DLR 898.44 898.41 33.4 51 X
NPY-9 [66-72] KRN.pEWTSISE.# § 832.56 832.36 240.3 27 X
PPP-1 [35-46] KK.YSYYDSIGSGLL.KR 1336.36 1336.62 -194.5 37 X  
PPP-1 [49-60] KR.GAYYDPIGGGLL.KR 1194.66 1194.59 58.6 99 X X 
PPP-1 [63-74] KR.SSYYDPIGGGLL.KR 1240.71 1240.6 88.7 88 X  
PPP-1 [77-88] KR.DSNYDPIGGGLL.KRR 1219.66 1219.57 73.8 99 X X 
PPP-1 [91-102](x3) KR.RSFYDPIGGGLL.KRR 1293.66 1293.67 -7.7 99 X X 
PPP-1 [133-154] KK.RFYNDPLGVALLKSRFDKDSIN.# 2568.53 2568.92 -151.8   X 
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       Table 5.4 (cont.) 
Prohormone  Peptide Sequence Obs.  Mass (Da) 
Cal. 
Mass (Da) 
Error 
(ppm) Score 
ESI-IT
MS/MS 
MALDI-
TOF-MS 
PPP-2 [34-45] KR.FRYFDKIGSDLL.KR 1472.74 1472.77 -20.4 97 X X 
PPP-2 [48-58] KR.SYFDKIGNDLL.KR 1283.61 1283.64 -23.4 98 X X 
PPP-2 [61-71] KR.SYMDKIGSDLL.KRR 1240.62 1240.6 16.1 99 X  
PPP-2 [74-84] KR.RYFDKIGSEML.KR 1357.72 1357.67 36.8 98 X  
SPP-1  A B 
[70-76](x3) KK.AYWASRMa.GKR 882.47 882.42 56.7 99 X X [36-42](x3) 
SPP-1  A B 
[70-77](x3) KK.AYWASRMG.KR 940.41 940.43 -21.3   X [36-43](x3) 
SPP-3 [23-36] *.SVMDDLSKDETYLS.KRR 1601.72 1601.71 6.2 80 X  
SPP-3 [39-47] KR.RYSLINPRLa.GKR 1129.64 1129.67 -26.6 98 X  
SPP-3 [51-57] KR.YLINPRLa.GKR 886.57 886.54 33.8 93 X  
SPP-3 [51-58] KR.YLINPRLG.KR 944.54 944.54 0 95 X  
SPP-3 [61-70] KR.FQIKDIENLD.# 1233.83 1233.62 170.2 99 X  
SPP-4 [45-51](x2) KR.GLRLMRLa.GKR 856.54 856.54 0 46 X  
SPP-4 [45-52](x2) KR.GLRLMRLG.KR§ 914.39 914.55 -174.9 22 X  
SPP-4 [56-65] KRN.MNDEFQFRDL.KKR 1312.75 1312.59 121.9 42 X  
SPP-4 [55-65] KR.NMNDEFQFRDL.KKR 1427.6 1427.61 -7 99 X X 
SPP-5 [44-50] KR.GLRILRMa.KR 856.54 856.54 0 59 X  
SPP-5 [44-51] KR.GLRILRMG.KR 915.2 915.17 32.8 40 X  
SPP-5 [54-61] KR.NDLFRLLD.KR 1004.5 1004.53 -29.9 93 X X 
SPP-5 [56-61] KRND.LFRLLD.KR § 775.48 775.46 25.8 25 X  
SPP-6 [29-39] KR.IPGIGFNRNFA.IYKR 1204.64 1204.64 0 68 X  
SPP-6 [29-41] KR.IPGIGFNRNFAIY.KR 1480.8 1480.78 13.5 99 X X 
SPP-6 [49-62] KR.LIDPMTFGYGFSNL.K# 1573.72 1573.75 -19.1 99 X  
SPP-6 [52-62] KRLID.PMTFGYGFSNL.K# 1232.57 1232.55 16.2 96 X  
SPP-7 [26-38] KR.TVGFGFNRNLHLY.KR 1536.74 1536.78 -26 96 X X 
SPP-7  [46-59] KR.LIDPMTFGSGFANL.K# 1481.68 1481.72 -27 99 X X 
SPP-8 [26-38] KR.TMGFGFNRNMLLY.KR 1562.69 1562.74 -32 99 X X 
SPP-8 [46-59] KR.LIDPMTFGSGFANL.R# 1481.68 1481.72 -27 99 X X 
SPP-9 [15-23] *.LANVCCGVQ.KR § 905.3 905.41 -121.5 44 X  
SPP-9 [26-36] KR.SLPYNPEYELY.KR 1386.66 1386.63 21.6 82 X  
SPP-9 [44-57] KR.LIDPLTFGSGFSNL.# 1479.87 1479.76 74.3 99 X X 
SPP-10 [42-51] KR.GAEFFLQRVEa.GKR 1193.52 1193.62 -83.8 94 X  
SPP-10 [55-64] KR.GAEFFLRRVVa.GKR 1191.68 1191.69 -8.4 98 X  
SPP-10 [55-65] KR.GAEFFLRRVVG.KR 1249.77 1249.69 64 37 X  
SPP-10 [68-83] KR.STKPIDPNQYPLVYGE.# -1 1819.9 -65.9   X 
SPP-11 [24-28] KR.YIRFG.KR 654.23 654.35 -183.4   X 
SPP-11 [31-37] KR.HQQLFPN.KR 882.32 882.43 -124.7 74 X X 
SPP-11 [47-52] KR.EYIPLD.KR 748.22 748.36 -187.1 91 X  
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      Table 5.4 (cont.) 
Prohormone  Peptide Sequence Obs.  Mass (Da) 
Cal. 
Mass (Da) 
Error 
(ppm) Score 
ESI-IT
MS/MS 
MALDI-
TOF-MS 
SPP-12 [18-26] *.EATPAMRSD.K § 976.55 976.43 122.9 36 X  
SPP-12 [40-54] KR.NYMDFFGLNGDMQRF.KK 1853.72 1853.79 -37.8 99 X X 
SPP-12 [57-70] KK.pQQFFRNHRPEIEWN.# 1882.52 1882.89 -196.5   X 
SPP-15 [48-53](x8) KR.FDPIQFa.GKR -1 764.37 -157   X 
SPP-15 [48-54](x8) KR.FDPIQFG.KR 822.36 822.39 -36.5 82 X X 
SPP-15 [120-125] KR.FDPIMFa.GR# § 767.33 767.37 -52.1 25 X X 
SPP-16 [32-43] KR.pQFDPIMYGKLRQ.FYRR 1477.45 1477.74 -196.2 64 X  
SPP-16 [32-45] KR.pQFDPIMYGKLRQFY.RR 1787.59 1787.87 -156.6 94 X  
SPP-16 [70-76](x2) KR.QFDPIMY.KR 912.24 912.41 -186.3 69 X X 
SPP-16 [79-91] KR.pQSNPYFLSDIRSI.KR 1521.69 1521.75 -39.4 99 X X 
SPP-16 [79-91] KR.QSNPYFLSDIRSI.KR 1538.84 1538.77 45.5 99 X  
SPP-17 [51-64] KK.IIDPMTYGTGFSNL.# 1527.72 1527.73 -6.5 99 X  
SPP-18 [29-35] KR.GYHFFRL.KK 938.52 938.48 42.6 98 X X 
SPP-19 [42-48] KR.GYHFFRL.RK 938.52 938.48 42.6 98 X X 
a Period (.) indicates a cleavage site. Asterisk (*) indicates the presence of signal peptide before the sequence. Pound (#) indicates the end of a precursor 
sequence. (x number) indicates the number of repeated sequences in this prohormone. “X” indicates the analytical platform used to identify the peptide. 
Putative PTMs include N-terminal pyroglutamination (“p”) and C-terminal amidation (“a”). Bold type indicates prohormone precursors characterized 
only in sexual animals by mass spectrometry. Underlined peptides are only detected in sexual animals, while the peptides in italic are identified as 
different forms (such as modified by PTM, etc.) compared to the ones in asexual animals. In addition, peptides detected with lower confidence are 
marked as §. Two prohormones labeled with Ф are tentative and not confirmed, since they do not meet the criteria for prohormone identification as 
described in experimental section. *Table adapted from [9] with permission. 
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Table 5.5 Peptides Characterized by MS from Asexual Schmidtea mediterranea* 
Prohormone  Peptide Sequence Obs.  Mass (Da) 
Cal. 
Mass (Da) 
Error 
(ppm) Score 
ESI-IT
MS/MS 
MALDI
TOF-MS 
1020HH-1Ф [29-41] L.ENFDDLESNSDYM.KR 1576.44 1577.58 -722.6 51 X
1020HH-1Ф [44-53] KR.YSYLKGGIRW.KK 1240.48 1241.66 -950.3 60 X
1020HH-2 [52-61] KR.pQSYLTGGIRY.KK 1139.57 1139.56 8.8 97 X  
1020HH-2 [52-61] KR.QSYLTGGIRY.KK 1156.51 1156.59 -69.2 96 X  
1020HH-2 [53-61] KRQ.SYLTGGIRY.KK 1028.52 1028.53 -9.7 99 X  
1020HH-2 [70-77] KR.YLTGGIRY.# 941.49 941.5 -10.6 99 X  
EYE53-1Ф [30-42] KK.LSIPTYWDDIDTS.KR 1525.45 1524.7 491.9 93 X  
EYE53-1Ф [49-61] KR.LSVPTYFDDWESR.KKR 1613.09 1613.74 -402.8 23 X  
MPL-1  [43-49] KR.AYRLMRMa.GKR 938.52 938.5 21.3   X 
MPL-1 [45-51] KR.AVRLMRLa.GKR 856.53 856.54 -11.7 87 X X 
MPL-1 [45-52] KR.AVRLMRLG.KR 914.54 914.55 -10.9 51 X  
MPL-1  [53-60] KR.AVRLMRMG.KK 932.75 932.51 257.4 84 X  
MPL-2 [45-51] KR.AVRLMRLa.GKR 856.53 856.54 -11.7 87 X X 
MPL-2 [45-52] KR.AVRLMRLG.KR 914.54 914.55 -10.9 51 X  
MPL-2 [61-68] KR.AVKLMRLG.KR § 886.28 886.54 -293.3 35 X  
NPP-1 [41-46](x3) KR.ASFVRLa.GR 690.39 690.418 -40.6 61 X  
NPP-1 [41-47](x3) KR.ASFVRLG.R 748.38 748.42 -53.4 91 X  
NPP-1 [70-81] KK.SRLDYEPVDDYN.KR 1484.64 1484.64 0 99 X X 
NPP-2 [110-123] KR.pQLLNSKQSIFQDEY.# 1695.09 1694.82 159.3 94 X
NPP-3 [56-62] KR.AILLTRYa.GKR 847.44 847.51 -82.6 94 X  
NPP-3 [56-63] KR.AILLTRYG.KR 905.6 905.53 77.3 99 X  
NPP-3 [66-77] KR.GSRRYFLNNDDS.KR 1442.67 1442.66 6.9   X 
NPP-3 [70-77] RR.YFLNNDDS.KR 986.72 986.4 324.4 58 X  
NPP-4 [25-30] KR.SSVFRFG.KR 798.33 798.4 -87.7 44 X  
NPP-4 [85-91] KR.RGVAFRFa.GKR 850.47 850.49 -23.5 99 X  
NPP-4 [85-92] KR.RGVAFRFG.KR 908.45 908.5 -55 99 X  
NPP-4 [104-109] KR.QSVFRYa.G# 797.44 797.43 12.5   X 
NPP-4 [104-110] KR.QSVFRYG.# 855.47 855.43 46.8   X 
NPP-18 [28-42] *.RNMDLDEYDSLLPKD.KR 1822.8 1822.84 -21.9 99 X  
NPP-18 [29-42] *R.NMDLDEYDSLLPKD.KR 1666.65 1666.74 -54 99 X  
NPP-18 [30-40] *RN.MDLDEYDSLLP.KDKR § 1309.22 1309.57 -267.3 41 X  
NPP-18 [45-54](x2) KR.GAEFFIRRVVa.GKR 1191.75 1191.69 50.3 87 X  
NPP-18 [45-55](x2) KR.GAEFFIRRVVG.KR 1249.71 1249.69 16 93 X  
NPP-18 [71-77] KR.NSDYLIQ.# 851.26 851.4 -164.4 71 X  
NPP-22 [26-61] *.TTDDEVNENICQSLCHKSLSCLDECHD ISESNDSME.KR 4044.74 4045.29 -136   X 
NPP-22 [64-69](x3) KR.AKYFRLa.GKR 795.46 795.48 -25.1 91 X X 
NPP-22 [64-70](x3) KR.AKYFRLG.KR 853.59 853.48 128.9 83 X X 
NPY-1 [25-37] I.pEPPAKPEFFDDPE.LLR 1498.65 1498.67 -13.3 51 X
NPY-1 [46-59] KK.LNEYFAIVGRPRFG.KR 1638.11 1637.87 146.5 X
NPY-1 [48-57] KKLN.EYFAIVGRPR.FGKR § 1206.94 1206.65 240.3 38 X
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     Table 5.5 (cont.) 
Prohormone  Peptide Sequence Obs.  Mass (Da) 
Cal. 
Mass (Da) 
Error 
(ppm) Score 
ESI-IT
MS/MS 
MALDI
TOF-MS 
NPY-1 [48-60] KKLN.EYFAIVGRPRFGK.R 1538.75 1538.84 -58.5 47 X
NPY-3 [26-34] *.NKDELDILF.KKR 1105.55 1105.57 -18.1 99 X
NPY-3 [70-75] KR.pQKFHRD.# 812.44 812.4 49.2 X
NPY-5Ф [49-62] RRY.LLQMNEYLAIVARP.RYGKR 1629.69 1629.89 -122.7 37 X
NPY-5Ф [56-65] RRYLLQMNEY.LAIVARPRYG.KR 1114.54 1114.66 -107.7 45 X
NPY-6 [22-39] *.ILSTFSSDPVIDFDLEKD.K § 2040.73 2039.99 362.7 45 X
NPY-6 [22-40] *.ILSTFSSDPVIDFDLEKDK.D 2168.1 2168.09 4.6 65 X
NPY-6 [65-78] KR.SLNSFQTIREFVRD.RR 1710.9 1710.87 17.5 48 X
NYP-7 [37-46] K.SRTPIAGIVN.K § 1026.23 1026.58 -340.9 30 X
NYP-7 [39-51] R.TPIAGIVNKMGQI.RK 1340.57 1340.75 -134.3 X
NYP-7 [63-79] L.VYLLNEHFAIYGRPRYG.# 2067.1 2067.07 14.5 55 X
NPY-10 [38-64] KR.DLKPLFNNAKQLLWYLQKLDKMYAIAG.R 3195.79 3195.81 -6.3 X
NPY-10 [59-64] K.MYAIAG.R 624.29 624.29 0 52 X
NPY-10 [61-68] KMY.AIAGRPRYa.GKR § 902.23 902.05 199.5 33 X
PPP-1 [22-32] *DF.YRVSSSDLRRF.KK 1384.66 1384.72 -43.4 66 X  
PPP-1 [35-46] KK.YSYYDSIGSGLL.KR 1336.63 1336.62 7.5 93 X  
PPP-1 [49-60] KR.GAYYDPIGGGLL.KR 1194.5 1194.59 -75.3 99 X  
PPP-1 [50-60] KRG.AYYDPIGGGLL.KR 1137.41 1137.57 -140.7 54 X  
PPP-1 [63-74] KR.SSYYDPIGGGLL.KR 1240.61 1240.6 8.1 93 X X 
PPP-1 [77-88] KR.DSNYDPIGGGLL.KRR 1219.59 1219.57 16.4 68 X  
PPP-1 [91-102](x3) KR.RSFYDPIGGGLL.KRR 1293.68 1293.67 7.7 94 X X 
PPP-2 [34-45] KR.FRYFDKIGSDLL.KR 1472.73 1472.77 -27.2 93 X X 
PPP-2 [48-58] KR.SYFDKIGNDLL.KR 1283.6 1283.64 -31.2 99 X  
PPP-2 [61-71] KR.SYMDKIGSDLL.KRR 1240.61 1240.6 8.1 99 X X 
SPP-1 A [50-67] A.EDLGSLNADIDLDDSRLD.KK 1974.36 1974.9 -273.4 85 X  B [16-33] *.EDLGSLNADIDLDDSRLD.KK 
SPP-1 A [70-76](x3) KK.AYWASRMa.GKR 882.31 882.42 -124.7 85 X X B [36-42](x3) 
SPP-1  A [70-77](x3) KK.AYWASRMG.KR 940.48 940.43 53.2   X B [36-43](x3) 
SPP-3 [39-47] KR.RYSLINPRLa.GKR 1129.71 1129.67 35.4 77 X X 
SPP-3 [39-48] KR.RYSLINPRLG.KR 1187.67 1187.68 -8.4 81 X  
SPP-3 [51-57] KR.YLINPRLa.GKR 886.45 886.54 -101.5 99 X  
SPP-3 [51-58] KR.YLINPRLG.KR 944.48 944.54 -63.5 99 X  
SPP-3 [61-70] KR.FQIKDIENLD.# 1233.56 1233.62 -48.6 98 X  
SPP-4 [21-42] *.DYSSLNDDSELEDSYHRYPSSI.KR 2591.1 2591.09 3.9 89 X X 
SPP-4 [45-51](x2) KR.GLRLMRLa.GKR 856.53 856.54 -11.7 57 X X 
SPP-4 [45-52](x2) KR.GLRLMRLG.KR 914.54 914.55 -10.9 46 X  
SPP-4 [55-65] KR.NMNDEFQFRDL.KKR 1427.66 1427.61 35 99 X X 
SPP-5 [44-50] KR.GLRILRMa.GKR 856.54 856.53 11.7 73 X  
SPP-5 [44-51] KR.GLRILRMG.KR 914.55 914.55 0 70 X  
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    Table 5.5 (cont.) 
Prohormone  Peptide Sequence Obs.  Mass (Da) 
Cal. 
Mass (Da) 
Error 
(ppm) Score 
ESI-IT
MS/MS 
MALDI
TOF-MS 
SPP-5 [54-61] KR.NDLFRLLD.KR 1004.5 1004.53 -29.9 99 X  
SPP-6 [29-39] KR.IPGIGFNRNFA.IYKR 1204.61 1204.64 -24.9 90 X  
SPP-6 [29-41] KR.IPGIGFNRNFAIY.KR 1480.73 1480.78 -33.8 91 X X 
SPP-6 [49-62] KR.LIDPMTFGYGFSNL.K# 1573.7 1573.75 -31.8 98 X X 
SPP-7 [26-38] KR.TVGFGFNRNLHLY.KR 1536.7 1536.78 -52.1 99 X X 
SPP-7 [46-59] KR.LIDPMTFGSGFANL.K# 1481.67 1481.72 -33.7 99 X  
SPP-8 [26-38] KR.TMGFGFNRNMLLY.KR 1562.6 1562.74 -89.6 81 X X 
SPP-8 [46-59] KR.LIDPMTFGSGFANL.R# 1481.67 1481.72 -33.7 99 X  
SPP-9  [18-22] *LAN.VCCGV.QKR 479.22 479.19 62.6 59 X  
SPP-9 [18-23] *LAN.VCCGVQ.KR 607.21 607.25 -65.9 42 X X 
SPP-9 [26-36] KR.SLPYNPEYELY.KR 1386.61 1386.63 -14.4 96 X  
SPP-9 [44-57] KR.LIDPLTFGSGFSNL.# 1479.62 1479.76 -94.6 99 X X 
SPP-10 [55-64] KR.GAEFFLRRVVa.GKR 1191.61 1191.69 -67.1 70 X  
SPP-10 [55-65] KR.GAEFFLRRVVG.KR 1249.65 1249.69 -32 93 X  
SPP-10 [69-78] KRS.TKPIDPNQYP.LVYGE#  1171.02 1171.59 -486.5 66 X  
SPP-11 [24-28] KR.YIRFG.KR 654.46 654.35 168.1   X 
SPP-11 [31-37] KR.HQQLFPN.KR 882.34 882.43 -102 85 X X 
SPP-11 [55-71] KR.NDLLDSEFLNDMNENLE.KR 2023.97 2023.87 49.4 99 X  
SPP-12 [40-54] KR.NYMDFFGLNGDMQRF.KK 1853.61 1853.79 -97.1 99 X X 
SPP-13 [60-64](x2) KK.FRGLLa.GKR 603.45 603.37 132.6 84 X X
SPP-15 [48-53](x8) KR.FDPIQFa.GKR 764.35 764.39 -52.3 62 X  
SPP-15 [48-54](x8) KR.FDPIQFG.KR 822.42 822.4 24.3   X 
SPP-15 [120-125] KR.FDPIMFa.GR# 767.4 767.37 39.1   X 
SPP-16 [32-45] KR.pQFDPIMYGKLRQFY.RR 1787.69 1787.87 -100.7 89 X  
SPP-16 [33-38] KRQ.FDPIMYa.GK § 783.32 783.35 -38.3 27 X  
SPP-16 [70-76] KR.pQFDPIMY.KR 895.23 895.38 -167.5 84 X  
SPP-16 [70-76] KR.QFDPIMY.KR 912.49 912.41 87.7   X 
SPP-16 [79-91] KR.pQSNPYFLSDIRSI.KR 1521.67 1521.75 -52.6 99 X X 
SPP-16 [79-91] KR.QSNPYFLSDIRSI.KR 1538.7 1538.7 0 83 X X 
SPP-16 [80-91] KRQ.SNPYFLSDIRSI.KR 1410.55 1410.71 -113.4 98 X  
SPP-17 [51-64] KK.IIDPMTYGTGFSNL.# 1527.6174 1527.73 -73.7 72 X  
SPP -18 [29-35] KR.GYHFFRL.KK 938.45 938.48 -32 96 X X 
SPP -19 [30-39] KR.KHIGHQIFRL.KR 1247.77 1247.73 32.1 73 X  
SPP -19 [34-39] G.HQIFRL.KR 812.39 812.47 -98.5 30 X  
SPP -19 [42-48] KR.GYHFFRL.RK 938.45 938.48 -32 96 X X 
a Period (.) indicates a cleavage site. Asterik (*) indicates the presence of signal peptide before the sequence. Pound (#) indicates the end of a precursor sequence. (x 
number) indicates the number of repeated sequences in this prohormone. “X” indicates the instrument used to identify the peptide. Putative PTMs include N-terminal 
pyroglutamination (“p”) and C-terminal amidation (“a”). Bold type indicates prohormone precursors characterized only in asexual animals by mass spectrometry. 
Underlined peptides are only detected in asexual animals, while the peptides in italic are identified as different forms (such as modified by PTM, etc.) compared to the 
ones in sexual animals. In addition, peptides detected with lower confidence are marked as §. Three prohormones labeled with Ф are tentative and not confirmed, since 
they do not meet the criteria for prohormone identification as described in experimental section. *Table adapted from [9] with permission.
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Table 5.6 Peptides detected in S. mediterranea that are conserved in Schistosoma* 
Schistosoma Gene(s)a S. mediterranea  
Gene 
Predicted  
Schistosoma  
Peptidec 
MS-Confirmed  
S. mediterranea  
Peptidec 
Sma-npp-23/Sja-npp-23 spp-11 YIRFG YIRFG 
Sma-npp-26 spp-15 EHFDPIIY FDPIMFa 
  SYFDPILF FDPIQFa 
  SYFDPIIY FDPIQFG 
  TLFNPILF  
  NFDPILF  
Sja-npp-26 spp-15 SYFDPIAF FDPIMFa 
  TYFDPIAF FDPIQFa 
  NFDRILF FDPIQFG 
  NFDPILF  
  SYFDPIAF  
  EYFDPIIY  
Sma-npp-27/Sja-npp-27 1020HH-2 VPPYITGGIRY QSYLTGGIRY 
   YLTGGIRY 
Sma-npp-28/Sja-npp-28 spp-18, -19 AYHFFRL GYHFFRL 
Sj-npp-1b/Sm-npp-1b npp-1 AFVRLa ASFVRLa 
  GFVRLa  
  GFVRIa  
Sm-npp-5b/Sj-npp-5b npp-5 AAYMDLPWa PNWKDMPWa 
  AAYIDLPWa SAWRDMPWa 
Sm-npp-6b/Sj-npp-6b mpl-1, -2 AVRLMRLa AVRLMRLa 
Sj-npp-14b/Sm-npp-14b spp-4 GLRNMRMa GLRLMRLa 
a Prefixes Sma and Sja are for genes from S. mansoni and S. japonicum, respectively. b Prohormone genes 
described previously [37]. c Identical residues are shown in bold; similar residues are underlined. Lower 
case “a” indicates C-terminal amidation.  All peptides except YIRFG were confirmed by tandem MS 
sequencing.*Table adapted from [9] with permission. 
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CHAPTER 6 
NEUROPEPTIDOMICS OF COMB JELLY 
 
6.1 Notes and Acknowledgements 
This project is in collaboration with the Moroz group at the University of Florida. 
This chapter presents the data on a comprehensive analysis of peptides in ctenophore. 
I am responsible for the MS studies. I would like to acknowledge Andrea Kohn and 
Leonid Moroz for providing the animals, performing genome sequencing and 
compiling the prohormone/protein database, which are the foundation for our 
peptidomics studies. I would like to thank Jonathan V. Sweedler and Leonid Moroz 
for initiating the collaboration and provide guidance and insightful suggestions. This 
project was supported by the National Institute on Drug Abuse under Award No. 
P30DA018310. The content is solely the responsibility of the authors and does not 
necessarily represent the official views of NIDA or the National Institutes of Health. 
 
6.2 Introduction 
Ctenophore, known as comb jelly, is a non-bilaterian animal living mostly in the 
open ocean, and its body plan is illustrated in Figure 6.1. It has sensory receptors, 
nerve cells and synapses as bilaterians, and is one of the earliest animals with nervous 
and mesoderm-derived muscular systems. Pleurobrachia pileus, the sea gooseberry, is 
one of the most common ctenophore species. The understanding of this basal metazoa 
and its nervous system will help solve the controversy on the origins and early 
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evolution of animals [8]. However, ctenophore has not been much investigated, and 
limited information is available regarding its nervous system and related 
neuropeptides. A recent investigation of ctenophore neural network by 
immunofluorescence distinguished two nerve nets, a mesogleal nerve net and a more 
compact nerve net [5]. They also indicated the presence of FMRFamide, vasopressin, 
as well as other proteins like actin and tubulin, in the aboral neurosensory complex 
[5].  
To characterize the sequences of these peptides and provide a more 
comprehensive and global view of the peptides in Pleurobrachia, we integrated 
bioinformatics and LC-MS approaches to identify peptides on a genome-wide scale. 
As a result, an in-house database containing 58 putative prohormones/proteins was 
collected. Based on this, 62 peptides were detected, with 12 from putative 
prohormones and 50 from putative proteins. On-going work is to compile a more 
complete database with the sequence of each prohormone confirmed experimentally, 
and thus characterize more peptides by MS.  
 
6.3 Experimental 
6.3.1 Animals  
Both adult and larval Pleurobrachia pileus were captured and provided by the 
Moroz group. Some adult animals were dissected into regions including 
oral-aboral/brain, mouth, tentacle, and combs. Whole animals (adult or larval) or 
dissected regions were frozen and then sent to us.  
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6.3.2 Chemicals 
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless 
otherwise stated. The peptide standards for Matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) calibration were from Bruker 
Daltonics (Billerica, MA). 
6.3.3 Extraction of Peptides 
Either whole animals (adult or larval) or dissected regions were mechanically and 
thoroughly homogenized in several milliliters of acidified acetone (40:6:1 
acetone/water/HCl). The homogenate was then sonicated, vortexed and centrifuged, 
and the supernatant was collected, which was followed by the removal of the organic 
solvent in a SpeedVac concentrator (Thermo Scientific, San Jose, CA). To get rid of 
large proteins, the supernatant was filtered through a Microcon centrifugal filter with 
a 10 kDa cutoff (Millipore, Billerica, MA). Its peptide profiling was obtained by 
mixing 0.5 µL sample and 0.5 µL DHB (2,5-dihydroxybenzoic acid) on MALDI-TOF 
MS target for MS analysis.  
6.3.4 Peptide Separation and Measurement 
To reduce the sample complexity, peptide extracts went through a first stage 
microbore HPLC system Magic 2000 (Michrom BioResources, Inc., Aubum, CA). It 
was equipped with a C18 reverse phase column (Dionex, 1,000 µm i.d., particle size 3 
µm, and pore size 100 Å). The solvent gradient was created by mixing mobile phases 
A (95% water and 5% acetonitrile (ACN), 0.1% formic acid (FA) and 0.01% 
trifluoroacetic acid (TFA), and B (95% ACN, 5% water, 0.1% FA, and 0.01% TFA) 
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at a 20 µL/min flow rate over a 70 min run: 5%–10% B in 20 min, 10%–50% B in 
next 30 min, 50%–80% B in next 10 min, isocratic 80% B for 5 min, 80%–5% B in 4 
min. Each fraction was manually collected and examined by MALDI-TOF MS 
(UltrafleXtreme, Bruker Daltonics, Bremen, Germany) before the second stage 
LC-MS analysis. 
A capillary HPLC system (Waters, Milford, MA), equipped with a C18 reverse 
phase column (Dionex, 300 µm i.d., particle size 3 µm, and pore size 100 Å), was 
coupled to a HCT Ultra ion-trap mass spectrometer via an electrospray ionization 
source (ESI) (Bruker Daltonics, Bremen, Germany). The solvents were mobile phase 
A (95% water and 5% methanol and 0.1% formic acid (FA)), and B (95% methanol, 
5% water, and 0.1% FA), with the gradient optimized individually for each fraction. 
The peptide detection and sequencing by MS and MS/MS were controlled by the 
Esquire software (Bruker Daltonics, Bremen, Germany) in a data-dependent manner. 
Three precursor ions with the highest intensities per MS spectra were selected for 
tandem MS, with a preferred charge state set to +2 and a dynamic exclusion of 
previously fragmented precursor ions limited to 2 spectra per minute. The scan m/z 
ranges for MS and MS/MS were 300–2000 and 50–3,000, respectively. 
6.3.5 Peptide Identification and De Novo Sequencing 
The MS/MS spectra were converted to the .mgf file format (Mascot generic file) 
and searched against a tentative in-house ctenophore prohormone/protein database 
using the PEAKS Studio 4.5 software (Bioinformatics Solutions, Inc., Waterloo, CA). 
The following search parameters were applied: cleavage sites, variable 
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Post-Translational Modifications (PTMs) (including N-terminal pyro-Glu and 
pyro-Gln, C-terminal amidation, and disulfide bond) with the maximum number of 
PTMs on a single peptide set to four, mass tolerance 0.3 Da for the precursor ion and 
0.5 Da for fragments. The criteria for peptide assignments were described earlier [1].  
Considering the incompletion of our database, MS/MS spectra with high qualities 
sometimes were not able to be assigned. In these cases, de novo sequencing of these 
unassigned tandem MS spectra was performed both manually and automatically (by 
PEAKS 4.5 software) to generate sequence tags, which were then searched against the 
ctenophore genome database for novel prohormones.  
 
6.4 Preliminary Results 
6.4.1 Compilation of a Tentative Database 
We compiled an in-house database with a total of 58 putative Pleurobrachia 
prohormones/proteins through three major approaches. First, we analyzed the 
Pleurobrachia genome database (unpublished) for sequences with the characteristics 
including multiple dibasic cleavage sites, repeating sequences and a signal sequence. 
Second, we performed similarity searches with collections of peptides or 
prohormones from invertebrate species, mainly Aplysia californica. Third, we 
conducted de novo sequencing of MS/MS spectra for unassigned peptide peaks, and 
obtained hundreds of sequence tags as queries to search against genome database. 
Four representative de novo results were shown in Figure 6.2, with molecular masses 
1747, 1295.2, 1191.6 and 853.6 Da respectively. They were considered as promising 
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tags due to the consistency between automatic and manual results. These approaches 
lead to the discovery of a number of putative prohormones or proteins to refine our 
database. However, many of the precursors only have partial sequences, and work is 
still on-going to improve the database and confirm their sequences biologically. 
6.4.2 Peptide Identification  
We performed peptide extraction of Pleurobrachia, followed by LC-MS for 
peptide identification. There are three types of samples we employed. First are the 
whole adult animals for global analysis. Since peptides are oftentimes differentially 
expressed in tissues, the adult animals were dissected into oral-aboral/brain, mouth, 
tentacle, and comb regions for individual extraction and analysis. In this way, 
peptides present at high local abundances but low global levels are more likely to be 
identified. In addition, some neuropeptides may only appear during certain 
developmental stages, and thus the larval animals were collected and extracted for MS 
studies as well. By utilizing a 2D LC-MS approach and searching against our current 
database, we were able to identify a number of putative peptides in Pleurobrachia.  
6.4.2.1 The Identification of peptides from putative prohormones 
In total, 12 peptides from 4 putative prohormones were characterized (Table 6.1), 
and four of them have been post-translationally modified via either pyroglutamate 
formation or amidation. The identification of several peptides only in dissected 
regions (e.g. oral-aboral/brain, mouth, tentacle, and combs) justified the necessity to 
investigate different regions of Pleurobrachia separately. One of the identified 
prohormone is homologous to buccalin prohormone in Aplysia californica, which has 
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been implicated to play a modulatory role in feeding [7] and acetylcholine release [4]. 
Another has a sequence similarity to CP1/APGWamide prohormone in Aplysia, and 
APGWamide from this precursor has been suggested to be a conserved factor in 
regulating male reproduction in Aplysia and other gastropods [2, 3]. The biological 
confirmation of the presence and the sequences of these prohormones is required for a 
more conclusive answer. 
6.4.2.2 The Identification of peptides from putative structural proteins 
Interestingly, 50 peptides were identified with high confidence from a number of 
putative proteins, such as tubulin, and actin (Table 6.2). All of them were from the 
extraction of whole adult or larval animals, which suggested their overall high 
abundance in Pleurobrachia. Tubulin and actin are both structural proteins: tubulin is 
required to assemble microtubules, which are essential for maintaining cell structure, 
intracellular transport and other cellular processes; actin has been suggested to 
participate in many cellular processes, such as cell motility, division and shape, and 
muscle contraction. These results are consistent with the recent immunofluorescence 
studies that showed the presence of a tangential bundle of actin-rich fibers, as well as 
tubulins [5]. The identification and understanding these structural proteins may help 
uncover the underlying mechanisms of its locomotion through comb rows, as well as 
the cell cycles and divisions in Pleurobrachia. 
6.4.3 De novo sequencing 
At the initial stage of peptide discovery in Pleurobrachia, de novo sequencing 
approach is essential due to the lack of prohormone/protein database. We performed 
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de novo sequencing on the high qualities MS/MS spectra, which led to the collection 
of a number of putative prohormones and proteins. Table 6.3 provided a partial list of 
the de novo tags, and these 110 listed tags demonstrated a consistency between 
manual and automatic approaches. An improved prohormone/protein database will be 
obtained through a more thorough search against the genome database of 
Pleurobrachia using these promising tags.  
 
6.5 Conclusions and Future Directions 
Pleurobrachia, although it has been recognized a long time ago, has very limited 
information regarding its neuropeptides. We integrated bioinformatics and 
peptidomics approaches, which resulted in a compilation of 58 putative 
prohormones/proteins, and the characterization of 62 peptides from the whole and 
dissected adult, or larval ctenophores. While 50 of them were derived from putative 
structural proteins, 12 were from putative prohormones, homologous to their 
counterparts in Aplysia, such as CP1/APGWamide and buccalin. Our de novo 
sequencing efforts lead to numerous sequence tags to search against the 
Pleurobrachia genome database, which greatly facilitates the assembly of a more 
complete prohormone/protein database. These studies demonstrate an initial effort to 
provide a global view of the prohormones and peptides in Pleurobrachia, and more 
complete work will set a foundation for locating the correct position of Pleurobrachia 
in the evolution tree and understanding the early evolution of the nervous system. 
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6.7 Figures and Tables 
 
 
 
 
 
 
 
 
 
Figure 6.1 Schematic diagram of the ctenophore body plan. Image was adapted from 
[6] with permission from Development, The Company of Biologists Ltd. © 1997. 
DOI: dev.biologists.org/content/124/10/1999. 
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Figure 6.2 Manual de novo sequence tags from MS/MS spectra. A) AA(I/L)VVDNGSGM (m/z=874.5, +2 charge) matches to auto de novo tag 
VAA(I/L)VVDNGSGMVK. (B) FMVLDFWP (m/z= 648.6, +2 charge) matches to auto tag FMVLDFWPLEamide. (C) ATGGQYVP 
(m/z=596.8, +2 charge) matches to auto tag NEATGGQYVPR. (D) LMMGAG (m/z=427.8, +2 charge) matches to auto tag QLMMGAG.. 
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Table 6.1. Peptides from putative prohormones in ctenophore characterized by MS/MS * 
Prohormone Name Sequence 
Obs. 
Mass (Da) 
Cal. 
Mass (Da) 
Error 
(ppm) 
PEAKS 
Score 
Contig 165441 Buccalin precursor-like APGVGR R.AAVSPCIAPG.VGR 884.65 884.44 229 37 
Contig 165441 Buccalin precursor-like APGVGR R.AAVSPCTAPGVG.R 1028.75 1028.5 242 50 
Contig 165441 Buccalin precursor-like APGVGR RA.AVSPCTAPGVG.R 957.29 957.46 181 51 
Contig 165441 Buccalin precursor-like APGVGR A.GSPCTAPGVG.R 844.45 844.36 97 70 
Contig 81945 CNS APGWamide-like PGSGV RSH.DSSPD.R 519.38 519.17 410 86 
EST-partial 2 KAQA.LRDNSSLGYMAA.KK 1296.01 1296.61 469 37 
Genome-partial 5 KG.DAGLAGNPa.GR 712.41 712.35 77 36 
Genome-partial 5 KGD.SGVVVGPPGPPa.G 961.03 960.53 518 63 
Genome-partial 5 KG.pESGRPGGSGEPG.RR 1067.41 1067.46 54 55 
Genome-partial 5 RRG.EPGRAGNSGTPG.QR 1098.39 1098.51 109 53 
Genome-partial 5 RGD.KGDGGIPGTPGTPa.GDR 1151.57 1151.58 15 66 
Genome-partial 5 RE.MLVAPECLDDLV.PR 1317.35 1316.64 539 46 
a Period (.) indicates a cleavage site. Putative PTMs include N-terminal pyroglutamination (“p”) and C-terminal amidation (“a”).  
 
 
 
 
 
 
 
 
 
 166
Table 6.2 Peptides from putative structural proteins in ctenophore characterized by MS/MS * 
Prohormone Name Sequence Obs. Mass (Da) Cal. Mass (Da) Error (ppm) PEAKS Score 
Contig 114670 tubulin *.LEPGTMDSVRSGPFG.Q 1548.81 1548.72 52 99 
Contig 114670 tubulin R.AVLVDLEPGTMD.S 1258.81 1258.61 154 99 
Contig 114670 tubulin R.AVLVDLEPGTMDSVR.S 1601.33 1600.81 320 99 
Contig 114670 tubulin G.pQVFRPDNFVFG.Q 1308.17 1307.63 410 99 
Contig 114670 tubulin G.QVFRPDNFVFG.Q 1325.21 1324.66 415 99 
Contig 114670 tubulin L.ISKIREEYPDRIM.T 1649.35 1648.86 294 94 
Contig 114670 tubulin I.SKIREEYPDRIM.T 1535.77 1535.78 7 94 
Contig 114670 tubulin S.KIREEYPDRIM.T 1449.17 1448.74 291 99 
Contig 139617 Actin G.MGQKDSYVG.D 983.59 983.44 150 99 
Contig 139617 Actin G.DEAQSKRGILT.L 1216.91 1216.64 217 87 
Contig 152847 L.YRGDVVPKDVN.A 1261.27 1260.65 491 92 
Contig 152847 Y.RGDVVPKDVN.A 1097.89 1097.58 276 91 
Contig 152847 Y.RGDVVPKDVNAA.I 1239.95 1239.66 233 74 
Contig 152847 Y.RGDVVPKDVNAAIA.T 1424.03 1423.78 174 89 
Contig 152847 R.IHFPLV.T 724.69 724.43 367 96 
Contig 152847 G.KVGINYQPPTVVPGG.D 1525.11 1524.83 181 74 
Contig 152847 G.INYQPPTVVPGGDLA.K 1540.21 1539.79 268 82 
Contig 152847 G.INYQPPTVVPGGDLAK.V 1667.85 1667.89 26 64 
Contig 152847 G.EGMEEGEFSEAREDLA.A 1798.05 1797.74 172 97 
Contig 152847 A.RLDHK.F 667.33 667.37 50 63 
Contig 38071 L.TEAPLNPK.A 868.75 868.46 335 86 
Contig 38071 G.DEAQSKRGILT.L 1217.23 1216.64 480 85 
Contig 38071 G.MGQKDSYVGDEAQSKRGILT.L 2182.13 2182.07 26 99 
Contig 38071 V.KAGFAGDDAPR.A 1104.01 1103.54 426 99 
Contig 38071 K.AGFAGDDAPR.(A/S) 975.33 975.44 118 99 
Contig 38071 K.AGFAGDDAPRA.V 1046.73 1046.48 237 69 
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Table 6.2 (cont.) 
Prohormone Name Sequence Obs. Mass (Da) Cal. Mass (Da) Error (ppm) PEAKS Score 
Contig 38071 A.GFAGDDAPR.A 904.93 904.40 577 92 
Contig 38071 G.FAGDDAPR.A 847.61 847.37 277 99 
Contig 38071 G.DDAPRAVFPSIVG.R 1342.35 1342.69 255 70 
Transcriptome or Contig 08451 D.LEPGTMDSVR.S 1103.71 1103.53 161 99 
Transcriptome or Contig 08451 E.VISDEHGIDPT.G 1181.71 1181.56 126 89 
Transcriptome or Contig 08451 N.VYYNEATGGKYVPR.A 1616.15 1615.80 214 99 
Transcriptome or Contig 08451 Y.YNEATGGKYVPR.A 1353.21 1353.67 342 99 
Transcriptome or Contig 08451 Y.NEATGGKYVPR.A 1191.29 1190.60 572 99 
Transcriptome *.MREIVH.L 783.97 783.41 714 99 
Transcriptome *.MREIVHLQ.A 1024.73 1024.55 172 99 
Transcriptome N.EATGGKYVPR.A 1077.07 1076.56 468 82 
Transcriptome G.QVFRPDNFVFG.Q 1324.91 1324.66 188 95 
Transcriptome S.DEHGIDPTGTYHG.D 1397.89 1397.57 223 99 
Transcriptome D.LEPGTMDSVRSGPFG.Q 1548.89 1548.72 104 98 
Transcriptome G.SKFWEVISDEHGIDPT.G 1859.29 1858.87 221 77 
Transcriptome R.AVLVDLEPGTMDSVRSGPFG.Q 2046.45 2046.01 213 99 
Transcriptome Tubulin R.IHFPLVT.Y 825.47 825.48 3 99 
Transcriptome Tubulin Q.TNLVPYPR.I 959.17 958.52 670 99 
Transcriptome Tubulin Y.RGDVVPKDVN.A 1098.27 1097.58 622 99 
Transcriptome Tubulin S.AEKAYHEQLS.V 1175.21 1174.56 548 82 
Transcriptome Tubulin T.EFQTNLVPYPR.I 1362.73 1362.69 24 99 
Transcriptome Tubulin V.ISAEKAYHEQLS.V 1374.99 1374.68 224 99 
Transcriptome Tubulin N.VDLTEFQTNLVPYPR.I 1790.29 1790.92 354 92 
Transcriptome Tubulin T.YAPVISAEKAYHEQLS.V 1805.41 1804.90 280 97 
a Period (.) indicates a cleavage site. Asterisk (*) indicates the presence of signal peptide before the sequence. N-terminal pyroglutamination is indicated as 
(“p”).  
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Table 6.3 Sequence tags from MS/MS spectra in ctenophore that show consistent results between manual and automatic de novo sequencing * 
Manual de novo tag Auto de novo tags M/Z Z Obs. Mass (Da) 
SLE GPSLE 503.5 1 502.5 
FGL TPFGL 534.4 1 533.4 
LLV HDLLV 596 1 595 
PVLE LAPVLE 641.9 1 639.9 
WHPKNN WHPKNN 651.4 1 650.4 
PSLF APSLRLa 328.4 2 654.8 
GPLVV SMEGPLVV 657.1 1 656.1 
NECG NECGGGL 657.5 1 656.5 
SPAL DSPALLNa 728.6 1 726.6 
EEAVT VEEAVLV 379.3 2 756.6 
(A/V)VPL VDEVPLS 759.1 1 757.1 
VEEAVT VEEAVLV 379.7 2 757.4 
TEEAV TEEAVLV 382.8 2 763.6 
EEAVT EEAAENC 383.5 2 765 
EEPAC EEPACSMa 383.5 2 765 
QGRL PGQGRLF 388 2 774 
HLR EVHLRPG 404.1 2 806.2 
GTLLVP AGGPGTLLVPVM 808.8 1 807.8 
DGGPN DDGGPN 824.7 1 823.7 
QNRL PGQNRLF 416.5 2 831 
AGDDAD FAGDDPAR 424.7 2 847.4 
FDQL FGFDQL 427.2 2 852.4 
GFKDL FGFKDL 427.6 2 853.2 
LMMGAG QLMMGAG 427.8 2 853.6 
FDQL FGFDQL 427.9 2 853.8 
FGFQDL FGFQDLQa 428.6 2 855.2 
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Table 6.3 (cont.) 
Manual de novo tag Auto de novo tags M/Z Z Obs. Mass (Da) 
NETAT GNETAGAH 434.2 2 866.4 
ETAQ NETAQH 434.2 2 866.4 
GGPTVL GGPTVLR 436.5 2 871 
HGGL LHGGLRPM 440.6 2 879.2 
QVGLLR LGHGLLRD 441.1 2 880.2 
GHGLRL LGHGLRLD 441.1 2 880.2 
GHGLLG LGHGLLG 441.1 2 880.2 
NEAT PSNEATEHa 442.2 2 882.4 
FTHGGG PSTHGGGG 442.2 2 882.4 
AGTEAP GFAGTEAPR 453.5 2 905 
AGETAD FGAGETAPR 453.7 2 905.4 
CWEE CWEEFNHSCY 908.8 1 907.8 
EMPSA EMPSAY 455.4 2 908.8 
VHAL VHALR 478 2 954 
MVRN VNMVRNG 481 2 960 
VFGAGDDL DAAGAGDDAPR 488.3 2 974.6 
EGAGDDAP FQAGDDAPR 489.1 2 976.2 
QFAGDDAP QFAGDDAPR 489.1 2 976.2 
FLSSP FLSSPGAG 490.1 2 978.2 
FQDLK FGFQDLKQa 491.7 2 981.4 
FAGG NSPFAGGTFTa 499 2 996 
LPVD PVDSA 499.1 2 996.2 
LYPDGL NDYPDGLMV 513.2 2 1024.4 
MRELVHL MRELVHLQ 513.9 2 1025.8 
DELVHL,LELVH LELVHLQ 514 2 1026 
LYLQLG WKVLQLGPM 537 2 1072 
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Table 6.3 (cont.) 
Manual de novo tag Auto de novo tags M/Z Z Obs. Mass (Da) 
GECS NPSGECSHG 550.7 2 1099.4 
ENVEGG ENVLGG 550.8 2 1099.6 
GFAGDDAP HGGFAGDDAPR 553.1 2 1104.2 
PGTMDTC WGPGTMDTLK 553.2 2 1104.4 
HGELLQK SPGELLQKGV 570.2 2 1138.4 
PLTVMS HPLTSSGDLHS 576.2 2 1150.4 
LELAGNAA ELLELAGNAAR 579.6 2 1157.2 
APPEGVVA LLAPPEGVVAAH 587.7 2 1173.4 
VLLVYL LLVYLA 589.5 2 1177 
EDNSATGGKYVP SRATGGKYVPR 596.3 2 1190.6 
ATGGGAYVP ATGGGAYVPR 596.5 2 1191 
ATGGKYVP NEATGGKYVPR 596.8 2 1191.6 
ATNGAYVP ENATNGAYVPR 597 2 1192 
ATGGGAYVP DEATGGGAYVPR 597.1 2 1192.2 
LGLGNATLL LGLGNATLLT 602.8 2 1203.6 
WPVSALK LKGVSALK 617.9 2 1233.8 
LMKEDVE NMMKEDVELK 619.6 2 1237.2 
AVDLEH VLAVDLEHVKH 630.9 2 1259.8 
EHELPEG PWVHELPEGPV 631.9 2 1261.8 
LGGRN PVGLGGRN 634.7 2 1267.4 
QLGCY VFFSTGLGCYLA 639.7 2 1277.4 
HYAMGK HYAMGKYY 642.9 2 1283.8 
FMVLSP FMVLSPTYPL 648.6 2 1295.2 
DLRNP SYNLRNPT 660.5 2 1319 
NMQEDTTL MNMQEDTTLQL 663.1 2 1324.2 
YPDY QPYASYPDYPQ 665.3 2 1328.6 
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Table 6.3 (cont.) 
Manual de novo tag Auto de novo tags M/Z Z Obs. Mass (Da) 
FKLL MTFKLLGKVKWa 676.2 2 1350.4 
LDMNLN MTGVLDMNLN 677.4 2 1352.8 
EATGGQYV YNEATGGQYVRP 678.3 2 1354.6 
TNLV ETNLVPYPR 683 2 1364 
FNVLALF MPYRVLALFPR 684 2 1366 
HNNGTF LHNNNGTC 696.5 2 1391 
EHGIDPTGTY DEHGIDPTGTYHG 700.2 2 1398.4 
MPVGPVN VPVGPVPQNH 705.4 2 1408.8 
AVYELVFV PFVGLVFV 719.3 2 1436.6 
VELAGADSC VELAGFLVN 739.3 2 1476.6 
PPSPSD PPSGCFDSPD 752.3 2 1502.6 
DTLTEAPVL WPADTLTEAPVLSE 765.3 2 1528.6 
LRARE LRAREDE 766.5 2 1531 
PGTMDSVY PGTMDVSGVSG 775.6 2 1549.2 
DLEPGTMD LVCEPLDLEPGTMDRW 801.7 2 1601.4 
DLEPLL VDLEPLLRV 802.1 2 1602.2 
DLEPGV(EP/PE)V RVFVAYPLDLEPGVEPVCYa 802.2 2 1602.4 
NEATGGQYV ATNEATGGQYVPR 809.5 2 1617 
PEATGGKYV HAAYPEATGGKYVRP 809.6 2 1617.2 
TEEYVLN REEYVLNRMa 826 2 1650 
VQHGVAHQPK QHGVAHQPDHT 848.2 2 1694.4 
EAVED DEVFLEAVEP 852 2 1702 
AALVVDNGSGM VAALVVDNGSGMVK 874.1 2 1746.2 
VAALVVDLGSGNV FVKLAALVVDNGSGMKV 874.6 2 1747.2 
EVAALSTPLQ AALPTSLAALKVK 885.9 2 1769.8 
PEEVSFSEAMAT PEEVSFSEAMATPPS 900.7 2 1799.4 
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Table 6.3 (cont.) 
Manual de novo tag Auto de novo tags M/Z Z Obs. Mass (Da) 
VTPMVVQFKDDA PSNVQCACCSGQCFQFKDDAPR 902.6 2 1803.2 
YFVDEV NVLEPTVVDEVKW 930.9 2 1859.8 
MESPVPTV WEMESPVPTVCSAARRYa 990.9 2 1979.8 
PGTMDSVRP DLEPGTMDSVRSGPFG 1024.3 2 2046.6 
SFEPGTMDSV GSFEPGTMDSVRSGDW 1024.4 2 2046.8 
FEPGTMDSVH TLVYRRKGSFEPGTMDSVH 1024.7 3 3072.1 
* Putative C-terminal amidation is indicated as (“a”).  
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CHAPTER 7 
CHARACTERIZATION OF PEPTIDES  
IN ATRIAL GLAND AND CONNECTIVES FROM SEA HARE 
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7.2 Introduction 
The California sea hare, Aplysia californica, is a well-established physiological and 
neurochemical model for studying the neuronal network, behaviors, and learning and 
memory. Aplysia has ~20,000 large and easily accessible neurons within the central 
nervous system (Figure 7.1), with the diameters ranging from 5 μm to 500 μm. More 
importantly, it has a well-defined neuronal network (Figure 7.1), which provides great 
opportunities to associate animal behaviors to the activities of specific neurons or 
network activity. To have a better understanding of the organization and the functions 
of these defined neural circuits, the complement of signaling peptides and hormones 
that are present within neurons, ganglia and endocrine structures should be known.  
Neuropeptides are one of the most diverse messenger molecules in the nervous 
system, and exhibit diverse regulatory and behavioral functions [19, 53]. As described 
in chapter 1, they are expressed as protein precursors, which then undergo enzymatic 
cleavage at mono- or dibasic sites and post-translational modifications (PTM) to 
produce multiple bioactive peptides [13, 19, 20, 29]. Often, PTMs, such as 
N-pyroglutamyl formation and C-terminal amidation, modulate the activity of a 
peptide and/or its resistance to degradation [24]. Therefore, understanding 
neuropeptide function requires the information concerning the amino acid sequence 
and PTMs of the peptide. MS-based techniques provide a sensitive and rapid 
analytical platform for peptidomic studies, which can simultaneously detect multiple 
peptides in an organism, tissue or even cell [14, 21]. 
The Sweedler and Weiss groups, as well as some other groups, have been 
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characterizing the peptides for a decade, and uncovered more than one hundred 
peptides [1, 2, 5, 7-12, 15-17, 23, 27, 28, 30, 31, 33, 36, 38-42, 44-47, 50, 54, 55, 
57-59]. A great acceleration for peptidomics studies is the availability of the Aplysia 
genome database. The Aplysia genome is ~1.8 × 109 bp in size, which is distributed 
across 17 haploid chromosomes. Owing to the current genome sequencing project, the 
EST and the whole genome shotgun (WGS) libraries of Aplysia become available on 
the NCBI website, as well as a unique transcriptome library to search for transcripts in 
specific identified neurons [32]. Owing to our collaborations with the Moroz and 
Weiss groups, we were able to build up an in-house prohormone database. During the 
past two decades, a number of efforts have been made to characterize the peptides in 
Aplysia, including direct tissue and single-cell MALDI MS, and comprehensive 
peptidomics analysis by LC-MS [21, 28, 29, 49, 60]. In total, more than 450 peptides 
from approximately 50 prohormones have been characterized in Aplysia, which was 
summarized previously [21, 48, 49, 60].  
To complement previous studies, we continued to investigate another two regions 
of Aplysia that have not been fully studied, the connectives and the atrial gland. 
Among the numerous peptides identified, only a subset is transported between central 
nervous systems and periphery, and acts as cell-to-cell signaling molecules. To 
discover those peptides, the interganglionic connectives or nerves going to the 
periphery (collectively called connectives) could be cut and removed for investigation. 
A simple technique has been developed and the major ganglionic connectives were 
placed onto a sample plate for the direct measurement of peptides by MALDI MS 
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[28]. As a result, a number of peptides were identified by the mass-match approach. 
The question is whether there are other peptides present in Aplysia connectives. 
Another organ we are interested in is the atrial gland, an exocrine organ in the 
reproductive tract of Aplysia. It produces large amounts of egg-laying hormone (ELH) 
precursor-related peptides, as well as mollusk-derived growth factor (MDGF). Many 
of the peptides have been implicated in the Aplysia’s reproductive behavior and some 
have confirmed pheromonal activity [34-38]. Previous direct tissue analysis on the 
dense core vesicles of Aplysia atrial gland by MALDI MS, have identified 10 
different peptides from ELH and atrial gland (AG) related precursors based on 
mass-match [25, 48]. In addition, others have been characterizing peptides in AG 
using older approaches [26, 35-38, 47]. Similar question is asked here: are there other 
peptides present in Aplysia atrial gland?  
To obtain a better coverage of those signaling peptides, a comprehensive 
examination was performed here: we collected several animals for homogenization, 
reduced the sample complexity by a two-stage LC separation and employed both 
ESI-IT MS/MS and MALDI-TOF MS for peptide characterization. As a result, 44 
peptides from 21 prohormones were sequenced in Aplysia connectives, with 18 of 
them having PTMs. In addition, we have identified 24 peptides from an extract of 
whole atrial gland organs. Sixteen of them are novel, and twelve of them were 
post-translationally modified, which may be an indication of bioactivity [24].  
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7.3 Experimental 
7.3.1 Animals 
Aplysia were obtained from either the Aplysia Research Facility (Miami, FL), or 
Santa Barbara Marine Bio. (Santa Babara, CA). Before dissection, they were 
maintained in a tank of artificial seawater (ASW; Instant Ocean, Aquarium Systems, 
Mentor, OH, USA) at 14ºC. 
7.3.2 Chemicals 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless 
otherwise stated. The peptide standards for MALDI-TOF calibration were supplied by 
Bruker Daltonics (Billerica, MA). 
7.3.3 Sample Preparation.  
Atrial glands and connectives in A. californica were dissected from four animals 
after injection of 390 mM MgCl2 with an amount equal to half of animal’s body 
weight. The procedures are in accordance with animal use protocols approved by the 
UIUC IACUC and the UIUC guidelines on animal research. The atrial glands and 
connectives were combined separately, and then thoroughly homogenized and 
extracted using acidified acetone (40:6:1 acetone/water/12M HCl) and a plastic 
homogenizer. After vortexing and centrifugation at 14000 rpm (30×3.75g, Centrifuge 
5804R, Eppendorf, Westbury, NY, USA) for 15 mins, the supernatant was collected 
and the organic solvent was removed by evaporation in a SpeedVac concentrator 
(Thermo Scientific, San Jose, CA). 
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7.3.4 Microbore HPLC Separation  
The first stage chromatographic separation of the extracted peptides was 
performed on a microbore HPLC system (Magic 2002, Michrom BioResources, Inc., 
Aubum, CA) with a C18 reverse phase column (Vydac, 2,100 µm i.d., particle size 5 
µm, and pore size 300 Å, Hesperia, CA, USA) at 20 μl/min flow rate. The solvent 
gradient was generated by mixing solvent A (95% water and 5% acetonitrile (ACN) 
containing 0.1% FA and 0.01% TFA) and solvent B (aqueous 95% ACN containing 
0.1% FA and 0.01% TFA). The 70 min gradient for LC system had four steps: 10-50% 
solvent B in 20-50 min (linear); 50-80% solvent B in 50-60min (linear); 80% solvent 
B in 60-65 min (isocratic); 80-5% solvent B in 66-70 min (linear). All fractions were 
manually collected with a fraction collector (FC 203B, Gilson, Middletown, WI, 
USA), and concentrated using SpeedVac (Thermo Scientific, San Jose, CA) for 
further use.  
7.3.5 MALDI-TOF MS Analysis. 
With saturated 2,5-dihydroxy benzoic acid (DHB) as the matrix, each fraction 
was spotted onto a Bruker plate, which was then analyzed by a Bruker Ultraflex II 
mass spectromer (Bruker Daltonics, Bremen, Germany). Mass spectra consisted of 
10-15 acquisitions of 200 laser shots each. Peaks were assigned when a mass match 
within 200ppm was obtained. In several cases, the confidence was enhanced by the 
detection of several other related peptides from the same precursor.  
7.3.6 CapLC-ESI-IT MS Analysis  
The second stage chromatographic separation and mass spectrometric analysis of 
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all the fractions were conducted using a CapLC (Waters, Milford, MA) C18 
reverse-phase LC system (Dionex, 300 µm i.d., particle size 3 µm, and pore size 100 
Å) coupled with an HCT Ultra ion-trap mass spectrometer and an eletrospray 
ionization source (Bruker Daltonics, Bremen, Germany). The gradient range of each 
fraction was the same as that in the first LC separation, but the elution time in the 
second LC separation was set to be longer so that the peptides came out more slowly 
for better separation. Both MS and MS/MS were controlled by the Esquire software 
(Bruker Daltonics, Bremen, Germany). To make a balance between the signal 
intensity and number of analyzed peptides, three peptides, which have the highest 
intensity with consideration of their ion charge (preferably +2), were fragmented for 
each MS scan. Dynamic exclusion of previously fragmented precursor ions was set to 
be 2 spectra for a period of one minute. The scan ranges for MS and MS/MS were 
performed at m/z 300-1800 and 50-3000. 
7.3.7 Data Analysis  
Tandem MS data obtained from the ESI-MS/MS system were converted into .mgf 
file format (Mascot generic file). These spectra were automatically sequenced, and 
searched against an in-house Aplysia database of known precursors by PEAKS 4.5 
software (Bioinformatics Solutions, Inc., Waterloo, CA). Searching parameters were 
cleavage sites, PTMs including N-terminal pyro-Glu and pyro-Gln, C-terminal 
amidation, and disulfide bond. The peptide mass tolerance for MS/MS data was set to 
be 0.5 Da. The results were further confirmed by manual sequencing of these spectra, 
and the match of at least three consecutive amino acid fragment ions to a peptide 
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sequence confirmed its presence. MALDI MS data were mass-matched to the putative 
peptides predicted by NeuroPred prediction engine 
(http://neuroproteomics.scs.uiuc.edu/neuropred.html) [51] using an in-house database 
of known Aplysia prohormone precursors. More details and criteria were described in  
[3, 22].  
 
7.4 Results and Discussion 
7.4.1 Aplysia Atrial Gland 
7.4.1.1 Results 
By using an LC-MS-based approach, our peptidomic studies provide a complete 
profile of the peptides that are present in Aplysia atrial gland. We detected and 
characterized 24 peptides in total (Table 1), most of which are derived from known 
precursors in the atrial gland. MALDI-TOF MS identified 18 peptides, with four only 
detected by MALDI MS. Six additional peptides were identified in LC-ESI-IT 
MS/MS only. Thus, most of the peptide identities are confirmed by MS/MS 
sequencing. A representative MS/MS spectrum from LC-ESI-IT was demonstrated in 
Figure 7.2. 
Among the 24 peptides, eight peptides, including peptide A, peptide B, Califin A, 
Califin B, Califin C, A-NTP, B’-NTP, and C’/D’-NTP (Table 7.1), have been reported 
previously in Aplysia atrial gland [48]. The other sixteen peptides are novel (indicated 
in bold type in Table 7.1). While most of the novel peptides were processed from 
egg-laying hormone (ELH) or atrial gland (AG) related precursors. Three peptides 
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came from B3-5 precursor. The presence of multiple peptides processed from one 
precursor further confirms their existence in atrial gland.  
7.4.1.2 Discussion 
The great coverage of peptides and unambiguous peptide identification is achieved 
via the utilization of two-stage LC separation combined with two MS platforms 
(LC-ESI-IT MS/MS and MALDI-TOF MS). First, the two-stage LC separates the 
complex samples into simpler fractions, which reduces the interference from other 
peptides and facilitates better identification. Second, these two mass spectrometric 
approaches have different ionization mechanisms, so that they excel at characterizing 
different types of peptides and modifications. As shown in our results, some peptides 
were identified by only one of the MS approaches (Table 7.1). In addition, the broader 
coverage as compared to previous studies may partially result from the use of whole 
atrial gland organs instead of vesicles [48]. 
The detected peptides were produced from cleavage of prohormone precursors 
either intracellularly (enzymatic cleavage) or extracellularly (peptide degradation). 
Our results demonstrated that many peptides in atrial gland were enzymatically 
cleaved at conventional mono- or dibasic sites (Table 7.1). However, there are a 
number of peptides resulting from unexpected cleavages, such as ELH-related A, and 
B3-5 (Table 7.1). While it is possible that the degradation of peptides occurs during 
sample preparation, it is also likely that some peptides are generated by additional 
enzymatic cleavages. Further studies are required to address these possibilities.  
We identified three peptides from B3-5 precursor in atrial gland, which has not 
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been correctly identified in previous studies [36]. Very interestingly, disulfide bonds 
are present in B3-5 related peptides. Previous studies identified disulfide bonds for 
two members of the E. raikovi pheromone family, Er-1 and Er-2, so they suspected 
that this pattern is conserved throughout pheromones [52]. Cummins S.F. et al. 
proposed that a newly characterized peptide, Alb-1, which also contains multiple 
disulfide bonds, may serve as a pheromone in Aplysia [6]. In addition, behavioral 
studies demonstrated that the latency to mating between two nonlaying animals can be 
reduced by adding atrial gland homogenates into surrounding seawater [43]. 
Therefore, considering the presence of disulfide bond and its localization in atrial 
gland, it is possible that B3-5 related peptides are involved in the pheromone activity 
of Aplysia. Further investigation will aid the understanding of the potential functions 
of these peptides in atrial gland.  
PTMs play an important role in modifying the biological activity and life-time of 
neuropeptides. N-terminal pyro-Glu and pyro-Gln, C-terminal amidation, and 
disulfide bond formation are common PTMs in Aplysia [34]. Tandem MS is capable 
of characterizing such PTMs, which makes it ideal for neuropeptidomic studies. Here 
we detected 16 peptides with PTMs: besides disulfide bonds from B3-5 related 
peptides, several from ELH-related A, ELH-related B, and Atrial Gland B-B 
precursors with pyro-Glu at N-terminal; others from ELH-related A, and ELH-related 
B precursors with C-terminal amidation. Since we can not rule out the possibility that 
the identified PTMs may be artifacts generated during sample preparation, further 
biological verification is required. However, the peptides with these putative PTMs 
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are likely to be bioactive.  
7.4.2 Aplysia connectives 
7.4.2.1 Results 
Our peptidomic studies of Aplysia connectives by LC-ESI-IT MS/MS discovered 
44 peptides from a variety of prohormone precursors (Table 7.2), including Aplysia 
FRFa, Beta-thymosin, Buccalin, CP1/APGWamide, Egg-laying prohormone, Enterins 
precursor, Feeding circuit activating peptide precursor (FCAP), FMRFamide 
neuropeptide precursor, Insulin-like peptide precursor II, MIP-related peptides 
precursor, Orphan MM Precursor, Pedal peptide-1 precursor, proCCK, procerebrin, 
proCP2, proInsulin, proMyomodulin, R3-14, SCP precursor, Urotensin, and Whitnin 
precursor. For half of the precursors, multiple peptides processed from one precursor 
were detected, which is a stronger evidence for their presence. Compared to previous 
direct tissue analysis by MALDI-TOF MS [28], we characterized additional 34 
peptides from 11 prohormones in Aplysia connectives. Therefore, by collecting more 
samples and performing LC separation before MS/MS, a more complete picture of 
peptide complement in Aplysia connectives was achieved.  
7.4.2.2 Discussion 
We characterized peptides from 11 prohormones in the connectives, including 
Aplysia FRFa, beta-thymosin, enterins, FCAP, orphan MM, MIP, proCCK, 
procerebrin, proInsulin, Aplysia urotensin and Whitnin [4, 12, 16, 18, 27, 46, 54, 56]. 
Some of these prohormones have been demonstrated to participate in behavioral or 
physiological functions. For example, the enterin precursor has been previously 
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suggested to play a regulatory role in feeding behaviors of Aplysia. FCAP precursor 
has been indicated to initiate rhythmic feeding motor programs, and may also 
participate in inducing and maintaining food-induced arousal. MIP-related peptides 
may also play essential roles in the feeding, and possibly other systems, of Aplysia. 
More importantly, these peptides were identified in connectives, the major pipeline for 
peptide transportation and communication, and thus have a high tendency to be 
bioactive. Notably, 18 peptides were post-translationally modified, and thus are great 
candidates to be targeted for biological tests. Indeed, there are some peptides more 
easily detected in previous direct-tissue analysis [28], which may be due to some 
highly localized peptides with overall low abundance, and/or the difficulty in 
fragmenting certain peptides and generating high quality spectra by MS/MS. 
 
7.5 Conclusions and Future Directions 
Our MS-based approach identified many peptides from the Aplysia atrial gland and 
connectives, which not only provides a complement to the previous work on Aplysia 
peptides, but also provides a list of peptides with high potential to be bioactive. In 
addition, some of the peptides were post-translationally modified, which further 
increase their chances to be functional. For instance, the discovery of B3-5 related 
peptides in atrial gland and the presence of disulfide bonds imply their potential role 
as pheromones in Aplysia, as most other Aplysia pheromone share these 
characteristics Combined with a wealth of physiological studies on Aplysia, it is 
possible to link peptide to its function. More specifically, we could address questions 
 185
like, which neuropeptide modulates the Aplysia reproductive activity, and how it 
transports and signals within or without the neuronal network.  
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7.7 Figures and Tables 
 
 
 
 
 
Figure 7.1 Aplysia CNS with five major ganglia and connectives. These connective 
are named as: 1, cerebrobuccal; 2, cerebropleural; 3, cerebropedal; 4, pedalpleural; 5, 
pleuroabdominal; 6, superior labial nerve; 7, anterior tentacular nerve; 8, inferior 
labial nerve; 9, branchial nerve; 10, genital nerve; 11, pericardial nerve; 12, siphon 
nerve. Figure adapted from [28] with permission from Elsevier © 1998. 
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Figure 7.2 Representative MS/MS spectra from CID fragmentatioin of CapLC-ESI-IT 
MS/MS. Peptide pQFTSVLGKIFV (Theoretical Mass= 1237.70) is processed from 
atrial gland peptide B/califin B precursor of Aplysia. The fragment b and y ions are 
confidently assigned and labeled accordingly. 
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Table 7.1 Peptides and their precursors identified in Aplysia atrial gland a 
Precursor Peptide sequence 
Obs.  
Mass 
Theor. 
Mass 
Error 
(ppm) 
Score 
ESI-IT  
MS/MS 
MALDI- 
TOF MS 
Atrial Gland A-A [117-152, 156-173] 
R.ISINQDLKAITDMLLTEQIQARRRCLDALRQ 
RLLDLDSDVSLFNGDLLPNGRCS.#(Califin A) 
6140.69 6140.18 83   X 
ELH-related A [23-34], or Atrial Gland A-A,  
or Atrial Gland A-C 
*Q.STSVHGKIFVPN.R 1284.88 1284.67 163 98 X X 
ELH-related A [22-33], or Atrial Gland A-A,  
or Atrial Gland A-C 
*S.pQSTSVHGKIFVP.N 1281.71 1281.69 16 99 X   
ELH-related A [22-34], or Atrial Gland A-A,  
or Atrial Gland A-C 
*S.pQSTSVHGKIFVPN.R (A-NTP) 1395.76 1395.73 21 99 X X 
ELH-related A [36-69], or Atrial Gland A-A,  
Atrial Gland A-C 
R.AVKLSSDGNYPFDLSKEDGAQPYFMTPR 
LRFYPIa.G (peptide A) 
3920.83 3920.95 31 35 X X 
ELH-related A [96-112], or Atrial Gland A-A,  
Atrial Gland A-C, or ELH 
RKR.SVLTPSLSSLGESLESG.ISKR 1661.99 1661.83 96 86 X   
ELH-related A [96-114], or Atrial Gland A-A, 
Atrial Gland A-C, or ELH 
RKR.SVLTPSLSSLGESLESGIS.KR 1861.99 1861.94 27 99 X X 
ELH-related [Pro 25] B [22-30] *S.pQFTPVLGKIF.V 1131.78 1131.65 115 99 X   
ELH-related [Pro 25] B [22-31] *S.pQFTPVLGKIFV.T (C’/D’-NTP) 1230.93 1230.72 171 99 X X 
Atrial Gland B-B [22-30] *S.pQFTSVLGKIF.V 1121.88 1121.63 223 98 X X 
Atrial Gland B-B [22-31] *S.pQFTSVLGKIFV.T (B’-NTP) 1220.84 1220.7 115 99 X X 
Atrial Gland B-B [22-32] *S.pQFTSVLGKIFVT.N 1321.86 1321.74 91 74 X   
Atrial Gland B-B [22-33] *S.pQFTSVLGKIFVTN.R (B-NTP) 1436.03 1435.79 167 99 X X 
Atrial Gland B-B [117-152, 156-173] 
R.ISINQDLKAITDMLLTEQIQARQRCLAALRQR 
LLDLDSDVSLFNGDLLPNGRCS.# (Califin B) 
6067.61 6068.15 89   X 
ELH-related  [Pro 25] B [99-112],  
or Atrial Gland B-B  
L.TPSLLSLGESLESG.I 1388.85 1388.69 115 99 X   
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 Table 7.1 (cont.) 
Precursor Peptide sequence 
Obs.  
Mass 
Theor. 
Mass 
Error 
(ppm) 
Score 
ESI-IT  
MS/MS 
MALDI- 
TOF MS 
ELH-related [Pro 25] B [36-64],  
or Atrial Gland B-B  
R.AVKSSSYEKYPFDLSKEDGAQPYFMTPRL.R 3354.03 3355.75 513 85 X X 
ELH-related [Pro 25] B [36-69],  
or Atrial Gland B-B  
R.AVKSSSYEKYPFDLSKEDGAQPYFMTPRL 
RFYPIa.G (peptide B) 
4032.23 4031.58 161     X 
ELH-related A [62-69], or [Pro 25] B, 
or Atrial Gland A-A, or Atrial Gland A-C,  
Atrial Gland B-B 
T. PRLRFYPIa.G 1059.84 1059.62 208 59 X X 
ELH-related A [79-90], or [Pro 25] B, 
or Atrial Gland A-A, or Atrial Gland A-C,  
Atrial Gland B-B 
E.pQSEGQNPETKSH.S 1323.79 1323.59 151 88 X   
ELH-related A [79-92], or [Pro 25] B, 
 or Atrial Gland A-A, or Atrial Gland A-C,  
Atrial Gland B-B 
E.pQSEGQNPETKSHSW.R 1596.83 1596.67 100 99 X X 
ELH-related A [104-139, 143-160],  
or ELH-related B 
R.ISINQDLKAITDMLLTEQIQARRRCLAALRQR 
LLDLDSDVSLFNGDLLPNGRCS.# (Califin C) 
6096.26 6096.19 11   X 
B3-5 [63-72] E.(OxC)RFIT(OxC)VFWD.R 1286.56 1286.54 16 65 X X 
B3-5 [63-73] E.(OxC)RFIT(OxC)VFWDR.I 1442.83 1442.64 132 58 X X 
B3-5 [63-75] E.(OxC)RFIT(OxC)VFWDRID.R 1670.86 1670.75 66 81 X X 
a (.) indicates a cleavage site; (*) indicates the presence of signal peptide before the sequence; Pound (#) indicates the end of a precursor sequence; Obs. mass, 
observed monoisotopic mass; Theor. mass, theoretical monoisotopic mass; Bold type indicates peptides that are not previously identified. “X” indicates the 
instrument used to identify the peptide. The names of some peptides are shown in parentheses. Putative PTMs include N-terminal pyroglutamination (“p”), 
C-terminal amidation (“a”) and oxidation of cysteine (“Ox.”). Square bracket [ ] indicates the amino acid positions in the precursor, which span the sequence of 
identified peptide. Since there is similarity among the precursors, some identified peptides may come from either one of or all of the indicated precursors.  
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     Table 7.2 Peptides and their precursors in Aplysia connectives identified by LC-ESI-IT MS/MS a 
Precursor Peptide sequence Obs. Mass Theor. Mass 
Error  
(ppm) 
PEAKS 
Score 
Aplysia FRFa KR.GAGTLFRFa.GKR 866.48 866.47 12 99 
Aplysia FRFa KR.GVASGSGAFPLADDSDV.KR 1563.69 1563.69 0 99 
Beta-thymosin K.ETIDQEKQG.# 1046.44 1046.48 38 61 
Buccalin KR.GFDHYGFTGGLa.GKR 1168.64 1168.52 103 53 
Buccalin KR.SSSEQEEEDVRQVE.KR 1649.66 1649.69 18 99 
CP1/APGWamide KR.SSLNDEDLFADSDSAQELLDSVAAL.KR 2623.90 2624.19 111 99 
CP1/APGWamide KR.GQEIDVDEDGSEQE.KR 1548.65 1548.60 32 99 
Egg-laying prohormone Q.NPETESHS.RR 899.36 899.35 11 64 
Egg-Laying prohormone KR.SVLTPSLSSLGESLESGIS.KR 1861.86 1861.94 43 99 
Enterins precursor KR.VPGYSHSFVa.GKR 990.60 990.48 121 49 
Enterins precursor KR.TPGYSHSFVa.GKR 992.34 992.46 121 45 
Feeding circuit activating peptide precursor KR.ALDSLGGFQVHGW.KR 1385.68 1385.66 14 97 
FMRFamide neuropeptide precursor KR.FMRFa.GKR 598.55 598.29 435 50 
Insulin-like peptide precursor II KR.SASPELQASQN.KR 1130.58 1130.51 62 50 
MIP-related peptides precursor R.GSPRFFa.GKK 708.27 708.36 127 94 
Orphan MM Precursor *A.pQPESFSGSAVTDDSTSGAN.KR 1838.55 1838.74 103 97 
Orphan MM Precursor *AQP.pESFSGSAVTDDSTSGAN.KR 1612.58 1612.63 31 92 
Orphan MM Precursor KR.GGSLDALRSGHQVPML.R 1636.94 1636.83 67 24 
Orphan MM Precursor R.FSGSPRLQA.K 961.09 961.49 416 82 
Pedal peptide-1 precursor KR.PLDSVYGTHGMSGFA.KR 1537.78 1537.68 65 99 
Pedal peptide-1 precursor KR.PFDSISQGEGLSGFA.KR 1510.82 1510.68 93 99 
Pedal peptide-1 precursor KR.PLDSVYGTHGLSGFA.KR 1519.33 1519.72 257 99 
Pedal Peptide-1 precursor *LC.EETNDVTADSDSEEVE.AAKR 1767.60 1767.67 40 88 
Pedal Peptide-1 precursor *LC.pEETNDVTADSDSEEVEA.AKR 1820.60 1820.69 49 99 
Pedal peptide-1 precursor *LC.EETNDVTADSDSEEVEA.AKR 1838.64 1838.71 38 99 
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       Table 7.2 (cont.) 
Precursor Peptide sequence Obs. Mass Theor. Mass 
Error  
(ppm) 
PEAKS 
Score 
Pedal Peptide-1 precursor *LC.pEETNDVTADSDSEEVEAA.KR 1891.66 1891.72 32 99 
Pedal peptide-1 precursor *LC.EETNDVTADSDSEEVEAA.KR 1909.66 1909.74 42 99 
Pedal Peptide-1 precursor KR.SVDSDEEEAETQAE.E# 1537.58 1537.58 0 79 
Pedal peptide-1 precursor KR.SVDSDEEEAETQAEE.# 1666.64 1666.62 12 86 
proCCK KR.RFDSIASSSPFSGFa.GKR 1502.60 1502.70 67 53 
procerebrin KR.NGGTADALYNLPDLEKIa.GKR 1801.96 1801.91 28 99 
proCP2 R.SSERWAPKS.KR 1046.58 1046.50 76 87 
proInsulin KR.DTENVNDKLRGIL.LNKK 1485.82 1485.77 34 62 
proinsulin KR.DTENVNDKLRGILLN.KK 1712.90 1712.90 0 43 
proInsulin KR.DTENVNDKLRa.G 1201.66 1201.59 58 99 
proInsulin T.pENVNDKLRa.G 967.58 967.50 83 96 
proMyomodulin KR.PMSMLRLa.GKR 845.54 845.45 106 99 
R3-14 KR.EAEEPSAFMTRL.RR 1379.70 1379.63 51 95 
R3-14 KR.pEAEEPSAFMTRL.RR 1361.58 1361.61 22 99 
SCP precursor *DA.MNYLAFPRMa.GR 1140.42 1140.55 114 99 
SCP precursor R.ARPGYLAFPRMa.GR 1276.78 1276.68 78 99 
Urotensin *SA.MPLEDDNTDIDD.KR 1391.46 1391.53 50 63 
Urotensin KR.FKSPMQS.R 823.38 823.38 0 99 
Whitnin precursor *SS.LPASRTDDVLQEASGLALN.KR 1969.03 1969.00 15 66 
 (.) indicates a cleavage site; (*) indicates the presence of signal peptide before the sequence; Pound (#) indicates the end of a precursor sequence; Obs. mass, 
observed monoisotopic mass; Theor. mass, theoretical monoisotopic mass; Putative PTMs include N-terminal pyroglutamination (“p”) and C-terminal amidation 
(“a”). 
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CHAPTER 8 
DETERMINATION OF THE SEQUENCE AND PTMS OF 
ECTOPICALLY EXPRESSED INSULIN IN FLY BRAINS 
 
8.1 Notes and Acknowledgements 
This project is in collaboration with Paul Taghert and his group from the 
University of Washington in St Louis. This chapter presents the data on MS-based 
efforts to sequence insulin ectopically expressed in Drosophila heads. I am 
responsible for the MS studies from designing and performing experiments to data 
analysis and interpretation.  
 I would like to acknowledge the following people for their contributions: 
Dongkook Park and Paul H. Taghert from University of Washington in St Louis, and 
Elena V. Romanova, Peter M. Yau, Brian Imai, Sarah Dowd, and Jonathan V. 
Sweedler from University of Illinois at Urbana-Champaign. D. P. raised Drosophila 
expressing human insulin, dissected fly heads, conducted biological studies, and 
provided insightful background information for this project. E. V. R. greatly helped 
me with the maXis instrument. I would like to thank P. M. Y. and B. I. in the Protein 
Sciences Facility at University of Illinois for always maintaining the Waters Q-TOF 
MS in a good condition, and accommodating my plan of work. S. D. was involved in 
and helped with this project. I greatly acknowledge J. V. S. and P. H. T. for initiating 
the exciting collaboration and providing insightful suggestions and discussions. The 
project was supported by the National Institute on Drug Abuse under Award No. 
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P30DA018310. The content is solely the responsibility of the authors and does not 
necessarily represent the official views of NIDA or the National Institutes of Health. 
 
8.2 Introduction 
Compared to neurons primarily releasing classical neurotransmitters, peptidergic 
neurons have been shown to have enhanced capability to accumulate and/or release 
neuropeptides [9, 16]. In Drosophila, a specific basic helix-loop-helix (bHLH) 
transcriptional factor gene dimmed (DIMM), is restricted to peptidergic neurons [10, 
14], and promotes peptidergic neurosecretory properties. For example, although null 
dimm mutant cells survived, they failed to accumulate neuropeptides or have the 
associated processing enzymes [1, 7, 10]. The gain-of-function studies showed that 
the supplementation of ectopic DIMM to non-peptidergic neurons could overcome its 
inability in accumulating ectopic peptides, and in fostering the normal 
post-translational processing of an ectopic peptide with C-terminal amidation [8]. 
Here, we investigated whether another peptide of interest could be processed to its 
bioactive form, and produced at high levels upon the expression of DIMM in 
Drosophila. 
Nowadays, bioactive peptides as potential therapeutics are becoming important as 
attributed to their high target specificity, low toxicity and lower probability of side 
effects [18]. Human insulin is a well-known peptide drug that can treat diabetes. It 
plays a role as a peptide hormone to regulate carbohydrate and/or fat metabolism in 
the human body. Bioactive insulin is processed from the insulin precursor via a series 
of enzymatic processes, and contains two peptide chains-A and B-linked through 
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three inter/intrachain disulfide bonds [5]. A lack of adequate human insulin will result 
in some forms of diabetes, with type II diabetes mellitus as the most common 
metabolic disorder worldwide. According to the recent World Health Organization 
report (2011), diabetes-related deaths are doubling and thus the demand for insulin is 
increasing. However, the structural complexity of bioactive insulin adds some 
difficulties to produce insulin in high amounts. Here, we ectopically constructed the 
human insulin gene into Drosophila, and investigated whether the addition of DIMM 
facilitates the production and the proper processing of human insulin in Drosophila to 
its bioactive form. 
Mass spectrometry (MS) related technologies have been successfully implemented 
to characterize the sequence and PTMs of neuropeptides [3, 6, 12] including insects 
such as Drosophila [2, 8, 11, 15, 17]. Here, we extracted peptides from Drosophila 
heads, conducted disulfide bond reduction/alkylation, and developed LC-MS 
approaches to detect and sequence the insulin. These results demonstrate that the form 
of ectopic insulin in Drosophila is identical to that of human insulin, and thus a proper 
and complete enzymatic processing occurs to produce the bioactive form of human 
insulin. Therefore, the use of Drosophila as a method for producing correctly 
processed peptides appears feasible. 
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8.3 Experimental 
8.3.1 Animals  
The ectopic human insulin precursor and transgenetic lines were constructed in 
the Taghert group. Two gal4 lines, GMR-gal4 (II) and PHM-gal4 (III), were used to 
drive human insulin and dimm in the eye and in subsets of brain neurons. Transgenic 
UAS-human insulin lines (two independent lines, UH-2 and UH-27) were generated. 
To increase insulin production, they combined two gal4 and two UAS together (w; 
GMR-gal4, UAS-dimm; PHM-gal4, UAS-hINS) and maintained them at room 
temperature (~25oC). Drosophila heads were then dissected, frozen and sent to us for 
MS characterization. 
8.3.2 Chemicals 
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless 
otherwise stated.  
8.3.3 Sample preparation 
Drosophila heads (~60 mg) ectopically expressing human insulin were 
thoroughly homogenized in 4 ml acidified acetone (40 6 1 acetone/water/12M HCl, by 
volume) [13], followed by sonication, vortexing and centrifugation. The supernatant 
was collected and dried in a Savant Speed Vac concentrator (Thermo Fisher Scientific, 
Waltham, MA), which was then reconstituted in 15 μl solvent A (95% water/5% 
acetonitrile (ACN)/0.1% formic acid (FA)/0.01% Trifluoroacetic acid (TFA)). 3 μl of 
the homogenate was saved for intact insulin detection, while the remaining 12 μl went 
through disulfide bond reduction and alkylation before LC-MS analysis.  
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After adjusting the pH of fly head extract to basic with 1 M NH4HCO3, 8 μl of 
200 mM 1,4-Dithio-DL-threitol (DTT) in 100 mM NH4HCO3 was added to reduce 
disulfide bonds. The sample was then immersed in boiling water bath for 10 min, 
followed by vortexing, centrifugation, and incubation at the room temperature for an 
hour. Alkylation was performed by adding 6.4 μl of 1 M iodoacetamide in 100 mM 
NH4HCO3 into the reduced solution, and allowing one and a half hours for a complete 
reaction. The last step was to remove unreacted iodoacetamide by adding 32 μl of 
DTT into the solution [13]. Upon completion of the reaction, samples were desalted 
using PepClean C18 spin columns (Pierce, Rockford, IL) and its standard protocols, 
and the eluent was dried in a Savant Speed Vac concentrator (Thermo Fisher 
Scientific, Waltham, MA) and reconstituted in 8 μl solvent A. The sample was ready 
for LC-MS analysis. 
8.3.4 Peptide Separations and MS Measurements 
After reduction/alkylation procedures, the sample was fractionated using a 
UltiMate/Switchos/Famos capillary LC system (Dionex Co., Sunnyvale, CA) with a 
C18 reverse phase column (Dionex Acclaim, 300 µm i.d. х 15cm, particle size 3 µm, 
and pore size 100 Å) at a 7 µL/min flow rate over a 70 min run. A five-step linear 
solvent gradient was created by mixing solvent A and B as follows (modified from 
[4]): 4%–10% B in 10 min, 10%–50% B in next 40 min, 50%–90% B in next 3 min, 
isocratic 90% B for 4 min, 90%–4% B in 3 min, and isocratic 4% B for 10 min. 
Fractions were manually collected, and subjected to a second stage LC separation and 
MS studies. 
 202
To detect both intact and reduced insulin with high MS resolution and accuracy, 
we employed a maXis 4G™ quadrupole time-of-flight (Q-TOF) mass spectrometer 
with an electrospray ionization (ESI) source (Bruker Daltonics, Bremen, Germany). 
The Dionex UltiMate 3000 nanoLC system (Dionex Co., Sunnyvale, CA) was utilized 
before MS. It was equipped with a C18 reverse phase column (Dionex Acclaim, 75 
µm i.d. х 15 cm, particle size 3 µm, and pore size 100 Å), and used the same 
water/ACN solvent system with 0.1% FA and 0.01% TFA at a flow rate of 300 nl/min. 
Second stage separation parameters were optimized individually for each fraction, 
while the separation of non-reduced sample used the same gradient as described 
above. The scan mass-to-charge (m/z) ranges for MS were 300–2000, and the data 
were analyzed using the DataAnalysis software version 3.4 (Bruker Daltonics, 
Bremen, Germany). 
To further sequence peptide by tandem MS, a NanoAcquity Ultra Performance 
LC (UPLC) system connected to ESI-Q-TOF (Waters Premier, Milford, MA, 
USA).was utilized with a C18 reverse phase column (Waters Atlantis dC18, 75 μm i.d. 
х 15 cm, particle size 3 μm, and pore size 100 A). The solvent gradient over a 90 min 
run was generated by the same water/ACN solvent system with 0.1% FA at a flow rate 
of 400 nl/min, and was optimized for each individual fraction. MS/MS fragmentation 
of eluting peptides was controlled by MassLynx 4.1 software (Waters, Milford, MA, 
USA) in a data-dependent manner. The precursor ion selection for tandem MS was 
limited to four ions per MS scan sorted by intensity. Two peptides were included for 
fragmentation, m/z 1306.1±0.3 and 871.1±0.3 Da for +2 and +3 charged insulin chain 
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A, and 1181.6±0.3, 886.4±0.3 and 709.4±0.3 Da for +3, +4 and +5 charged insulin 
chain B. The scan m/z ranges for the MS and MS/MS were 200-2000 and 50-2000 Da, 
respectively. After MS/MS data collection and conversion to .pkl file format, the 
PEAKS Studio 5.2 software (Bioinformatics Solutions, Inc., Waterloo, CA) was 
performed for peptide identification, and the criteria for confident peptide 
assignments, including the PEAKS score, post-translational modification (PTM) 
match, mass error, and manual verification, were described previously [4]. 
 
8.4 Results and Discussion 
8.4.1 The Strategy 
We carefully prepared the samples and developed MS-based approaches to detect 
and sequence the insulin expressed in Drosophila heads. Figure 8.1 (the top) 
illustrates the intact human insulin and its three disulfide bonds (one intrachain and 
two interchains), which has an isotopic molecular weight (MW) 5803.66 Da. After 
reduction/alkylation, two alkylated peptides, insulin chain A and chain B, are 
generated with isotopic molecular weights 2610.19 and 3541.77 Da, respectively 
(Figure 8.1 the bottom). Two ESI-Q-TOF platforms were utilized for insulin detection 
and sequencing (UPLC-ESI-Q-TOF MS (Waters, Premier, Milford, MA, USA) and 
nanoLC-ESI-Q-TOF MS (Bruker maXis, Bremen, Germany)), and selected because 
of the insulin molecular weight and multiple charged residues. 
8.4.2 Insulin detection by maXis Q-TOF MS 
We extracted the peptides from insulin-expressing Drosophila heads, did one and 
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two-stage LC separation to reduce sample complexity, and analyzed the samples using 
maXis 4G™ ESI-Q-TOF MS. We observed intact insulin (+5 charge state) via the 
mass-match approach within ~200 ppm (Figure 8.2A). To verify the assignment of 
this peak, we reduced the disulfide bonds with 1,4-Dithio-DL-threitol (DTT), 
followed by alkylating the thiols with iodoacetamide. The masses of the expected 
insulin chain A (+2 charge state) and chain B (+5 and +4 charge states) were detected 
within ~200 ppm (Figure 8.2 B-D). In addition, the retention times of both intact and 
reduced insulin extracted from Drosophila are consistent with those of insulin 
standards.  
8.4.3 Insulin Sequencing by Waters Q-TOF MS/MS 
We confirmed the sequence of insulin via tandem MS by UPLC-ESI-Q-TOF MS 
(Waters Premier, Milford, MA). As shown in Figure 8.3, the alkylated chain B was 
sequenced with high confidence, producing sequence identical to human insulin chain 
B. The absence of positively charged residues makes it difficult to ionize chain A, so 
its intensity is much lower than that of chain B, although the amounts of chain A and 
B should be equal after reduction/alkylation. Also considering the limited amount of 
sample and the sample complexity, we did not find it practical to sequence chain A by 
tandem MS.  
 
8.5 Conclusions 
By integrating multiple strategies, including disulfide bond reduction/alkylation, 
and multiple LC-MS platforms and approaches, we unambiguously identify human 
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insulin ectopically expressed in Drosophila. We detected both intact insulin and 
insulin chain A and B after reduction/alkylation, and sequenced chain B. Together, 
these data confirm that the ectopic human insulin expressed in Drosophila heads is 
processed into the same peptide as human insulin. The quantification data from 
ELISA assays, which used antibody against only full-processed hINS, indicate that 
insulin was produced at high levels (~7ng/mg adult head) upon expression of DIMM 
(data not shown). Therefore, the expression of DIMM in Drosophila neurons 
promotes the production and accurate processing of the peptide drug, human insulin. 
This approach has the potential to serve as an alternative way to increase insulin 
production and meet the increasing demands. This same technology and the in vivo 
system provide an innovative and simple approach to produce a range of bioactive 
peptide as therapeutic drugs. 
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8.7 Figures 
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Figure 8.1 Sequence and PTMs of human insulin before (the top) and after (the 
bottom) reduction/alkylation. Human insulin is composed of chain A and B, and three 
disulfide bonds (connected by blue lines). “A” in circle indicates the reduced and 
alkylated cysteines by iodoacetamide. The positively charged amino acids are colored 
in red.  
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Figure 8.2 Mass spectra of insulin in Drosophila head extracts. (A) Intact insulin (z=5) 
before reduction/alkylation, which mass-matches the expected peptide. (B) Insulin 
chain A (z=2) after reduction/alkylation. (C, D) Insulin chain B (z=5 and 4) after 
reduction/alkylation. All peptide mass assignments are within ~200 ppm. 
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m/z
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R
R
 
 
Figure 8.3 Tandem MS spectrum of insulin chain B in Drosophila head extracts after reduction/alkylation (m/z 709.27, z=5). The precursor ion 
mass-matches the expected peptide within 112 ppm. The assignment of ions match expected fragments within 0.3 Da. R=CH2CONH2. 
 
 
 
 211
CHAPTER 9 
INVESTIGATION OF THE ALARIN PEPTIDE  
FROM HUMAN CELL LINE 
 
9.1 Notes and Acknowledgements 
This project is in collaboration with the Kofler group from the University 
Hospital Salzburg Paracelsus Medical University (Austria), and presents our work on 
developing sampling protocols and MS-based approaches to detect and sequence an 
alternatively spliced alarin peptide provided from a human cell line. I am responsible 
for the MS studies from experimental design to data analysis and interpretation.  
 I would like to acknowledge the following people for their work: Sarah Dowd, 
Yi Fan and Jonathan V. Sweedler from University of Illinois at Urbana-Champaign, 
and Barbara Holub and Barbara Kofler from the University Hospital Salzburg 
Paracelsus Medical University (Austria). I would like to thank S.D. for working with 
me throughout this project; she will continue to carry out these studies. I would like to 
acknowledge B. H. for culturing the human keratinocyte cell line and collecting the 
peptide for our MS investigation. I would like to thank Y.F. for her suggestions about 
sample preparation. I greatly acknowledge J.V.S. and B.K. for initiating the 
collaboration, and insightful suggestions and directions. The project was supported by 
the National Institute on Drug Abuse under Award No. P30DA018310. The content is 
solely the responsibility of the authors and does not necessarily represent the official 
views of NIDA or the National Institutes of Health. 
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9.2 Introduction 
Galanin-like peptide (GALP), a 60 amino acid peptide, belongs to the galanin 
peptide family (Figure 9.1), and has been identified in a variety of species, such as pig, 
rat, mouse, and human [5]. Its various physiological functions have been investigated, 
especially in regulation of body homeostasis [5]. Recently studies discovered a splice 
variant of GALP in human neuroblastic tumors, which misses exon 3 of GALP and 
thus causes a frame shift in the sequence (Figure 9.1) [9]. This putative 25 amino acid 
peptide was termed alarin, and its mRNA was later detected in the brain, thymus and 
skin of rodents [10]. Further investigations found that it not only acts as a vasoactive 
peptide and exhibits vasoconstrictor and anti-edema activity [10], but also stimulates 
food intake and regulates body weight in rats [11]. Since previous studies utilized a 
synthetic version of the peptide, it is important to know whether this peptide is 
endogenously produced, and if so, confirm the bioactive form.  
In this study, we examined two types of human keratinocyte cell lines (HaCaT): 
one was transfected with a vector encoding human prepro-alarin (A9), while the other 
was mock transfected as a control (TE19). After induced expression of alarin by 
doxycycline, the supernatant was collected for MS identification. A major challenge 
is the low abundance of alarin peptide in the media containing other substances that 
generate intense MS peaks. To overcome this challenge, we developed appropriate 
sampling protocols and MS-base approaches to isolate and sequence alarin [2, 3, 6]. 
Our preliminary results detected a putative alarin peak using MALDI-TOF MS, which 
requires further confirmation by MS/MS. 
 213
9.3 Experimental 
9.3.1 Human cell line and sample collection  
Two types of the human keratinocyte cell lines (HaCaT) were produced: one was 
mock transfected (named as TE19), and the other was transfected with a vector 
encoding human preproalarin (named as A9). The T-Rex TM system (Invitrogen, 
Carlsbad, CA) was integrated into A9, not TE19, to allow the expression of alarin 
through doxycyclin (+Dox) induction. The cell lines were washed 2-3 times with PBS, 
and cultured in serum-free and supplement-free Epilife keratinocyte growth medium 
(Invitrogen, Carlsbad, CA). TE19 cells were supplemented with Blasticidin, while A9 
cells with Blasticidin and Zeocin. After addition of 100 ng/ml doxycycline, the 
supernatants of TE19 and A9 cell lines, 10 ml each, were collected at 2, 8, 12, 24 
hours in serum-free and supplement-free Epilife Medium. The cell pellets were saved. 
9.3.2 Chemicals 
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO) unless 
otherwise stated. The peptide standards for matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS) calibration were supplied by 
Bruker Daltonics (Billerica, MA). Alarin standards were supplied by the Kofler group 
from University Hospital Salzburg Paracelsus Medical University. The sequence of 
alarin 1-25 is APAHRSSTFPKWVTKTERGRQPLRS [5], and the other alarin 
peptides are named accordingly. 
9.3.3 Sample preparation 
Supernatants from either A9 or TE19 cell lines were first concentrated in a Savant 
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Speed Vac concentrator (Thermo Fisher Scientific, Waltham, MA), which was then 
reconstituted in 10-15 μl solvent A (95% water/5% acetonitrile (ACN)/0.1% formic 
acid (FA)/0.01% Trifluoroacetic acid (TFA)). The excess salt not dissolved was 
removed. PepClean C18 spin columns (Pierce, Rockford, IL) were utilized to further 
remove salt and other substances from the supernatants. The standard desalting 
protocols removed the salt by washing with 95% aqueous solution 2~3 times. To 
isolate peptides from the abundant cell medium components, we modified the 
sampling procedures by adding 7~8 additional washing steps at 90/10 H2O/ACN, and 
collecting fractions with increasing organic content (H2O/ACN with 0.1% FA/0.01% 
TFA from 90/10 to 80/20 to 70/30 to 60/40 to 50/50 and 30/70). The eluents were 
evaporated in the Speed Vac concentrator (Thermo Fisher Scientific, Waltham, MA), 
and reconstituted in 5 μl solvent A for MS studies. 
9.3.4 MS and MS/MS measurement 
For MALDI-TOF MS analysis, 0.5 µL of each sample was spotted on a stainless 
steel MALDI plate and co-crystallized with 0.5 µL of concentrated DHB matrix 
(DHB: 2,5-dihydroxybenzoic acid, 50 mg/mL 50% acetone). MS spectra were 
acquired in positive ion mode and 500–10,000 m/z region using a Bruker 
ultrafleXtreme mass spectrometer (Bremen, Germany) with external calibration.  
To obtain the sequence information, a NanoAcquity Ultra Performance LC 
(UPLC) system connected to ESI-Q-TOF (Waters Premier, Milford, MA, USA) was 
implemented with a C18 reverse phase column (Waters Atlantis dC18, 75 μm i.d. х15 
cm, particle size 3 μm, and pore size 100 A). The solvent gradient was generated by 
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the water/ACN solvent system with 0.1% FA at a flow rate of 400 nl/min. MS/MS 
fragmentation was controlled by MassLynx 4.1 software (Waters, Milford, MA, USA) 
in a data-dependent manner, with the precursor ion selection set to three ions of the 
highest intensities per MS scan. The scan m/z ranges for the MS and MS/MS were 
400-2000 and 50-2000 Da, respectively. Detailed information was described in [7]. 
After the conversion of MS/MS data to .pkl file format, the PEAKS Studio 5.2 
software (Bioinformatics Solutions, Inc., Waterloo, CA) was employed for peptide 
identification, and for confident peptide assignments, the PEAKS score, 
post-translational modification (PTM) match, mass error, and manual verification, 
were considered as previously described [4]. 
 
9.4 Preliminary Results 
While our collaborators verified the expression of alarin using molecular 
approaches, their immunohistochemical studies suggested the peptide is at very low 
levels. Considering the expected low abundance of alarin peptide in the chemically 
complex culturing media, we used a three-step strategy to detect and sequence the 
alarin peptide from the releasates. First, using the synthesized peptide standards, 
appropriate instruments and conditions were validated for alarin identification. Once 
that was accomplished, the standards were spiked into the Epilife medium to optimize 
the sampling procedures. Finally, samples from human cell lines were investigated to 
confirm the presence and the sequence of the alarin peptide.  
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9.4.1 Selection of MS platforms 
The human alarin peptide is expected to contain up to 25 amino acids in its 
sequence, with the presence of multiple positively charged amino acids (e.g. K, R). 
Considering the size and the charges of alarin peptide, two MS platforms were 
selected: MALDI-TOF MS (Bruker ultrafleXtreme, Bremen, Germany), and 
UPLC-ESI-Q-TOF MS (Waters, Premier, Milford, MA). Their capabilities to detect 
and sequence alarin were validated by using alarin standards. MALDI-TOF MS was 
able to detect alarin 1-25 (Figure 9.2 A-B) and alarin 1-25 with C-terminal amidation 
at low fmol level (Figure 9.2 C-D), and thus was selected for initial MS screening. 
Notably, due to the presence of multiple positively charged amino acids in its 
sequence, alarin peptides were detected as both +1 and +2 charge states in 
MALDI-TOF MS, which could be utilized as an additional evidence to facilitate 
alarin detection. UPLC-ESI-Q-TOF MS/MS was used to sequence alarin peptide 
(Figure 9.3) when at picomole levels.  
9.4.2 Optimization of sampling protocols 
The supernatants were collected in Epilife medium, which is a typically complex 
mixture containing amino acids, vitamins, other organic/inorganic compounds, trace 
minerals (http://tools.invitrogen.com/content/sfs/manuals/EpiLifeMedium_man.pdf).  
A 0.5 μl media sample generated a number of intense MS peaks in MALDI-TOF MS. 
Since we are trying to identify alarin peptide from samples with a possible 
concentration 100-500 fmol/ml Epilife media, appropriate sampling protocols were 
optimized to purify the samples. Considering the properties of Epilife medium, we 
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employed PepClean C18 spin columns (Pierce, Rockford, IL) to remove most of the 
salt and other aqueous-soluble substances. To validate our approach, we spiked alarin 
standards (MW=2892.5 Da) into Epilife medium to generate a concentration of ~500 
fmol/ml, which mimics the biological environment. 
As we expected, the standard protocols for such spin columns did not produce 
desirable results (Figure 9.4A). Therefore, we modified the sampling procedures by 
adding 7~8 additional washing steps at 90/10 H2O/ACN, followed by collecting 
eluents with increasing organic content (H2O/ACN from 90/10 to 80/20 to 70/30 to 
60/40 to 50/50 and 30/70). As a result, the alarin peptides were mainly eluted in the 
80/20 and 70/30 H2O/ACN fractions. The MS intensity of alarin peptide was greatly 
boosted (at least 10 fold) due to the fewer interfering compounds from Epilife 
medium (Figure 9.4B). 
9.4.3 Investigation of biological samples 
Next, we applied the optimized sampling procedures to the supernatant of A9 
human cell line collected at 24 hrs after induced expression of alarin, which was then 
analyzed by MALDI-TOF MS. The choice of 24 hrs sample is as we expect it should 
contain the highest amount of alarin peptide. As shown in Figure 9.5, two interesting 
peaks, 2483.65 and 4966.19 Da (Average MW), were detected, which were not 
observed in the MS spectra of Epilife medium alone. Based on the isotopic 
distribution of these peaks, although not well-resolved, it is likely that the peak 
2483.65 Da is +2 charge, while 4966.19 Da is +1, both of which suggest a peptide 
with molecule weight ~ 4965.3 Da. Similar peaks were observed in the 2 and 8 hrs 
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samples as well (data not shown). These are consistent with the observation that our 
alarin standards indicated the coexistence of +1 and +2 charge states in MALDI-TOF 
MS.  
Since the observed mass is higher than that of our expected alarin peptide, we 
further explored it. First, this mass does not match the mass of the GALP peptide 
(sequence APAHRGRGGWTLNSAGYLLGPVLHLPQMGDQDGKRETALEILDL- 
WKAIDGLPYSHPPQPS with an average MW=6500.33). Previous studies found that 
PTMs such as hydroxyproline and disulfide bonds are common and play important 
roles in human keratinocytes [1, 8]. The pro-alarin sequence has two putative 
sequences that may explain these masses. One is alarin 3-23 (sequence: 
AHRSSTFPKWVTKTERGRQPL Average MW=2482.81), and the other is alarin 
2-22 (sequence: PAHRSSTFPKWVTKTERGRQ(hydroxyP), Average MW= 
2482.77). It is possible that alarin peptide exists as a dimer in biological systems, 
which doubles their molecular weight to ~4965.62 and 4965.54 Da respectively. If it 
is the case, the mass errors (64ppm, 48ppm) of the observed peptide are within the 
reasonable range for MALDI-TOF MS. Therefore, this observed peak pair (2483.65 
and 4966.19 Da) suggests the presence of an alarin peptide in an unexpected form. By 
collecting more samples, this peptide will be sequenced and confirmed by 
UPLC-ESI-Q-TOF MS/MS. Further studies are also required to confirm the absence 
of these peaks in the TE19 control samples.   
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9.5 Conclusions and Future Directions 
We developed a sampling approach to isolate the peptide of interest from the 
culturing medium, which enhanced the MS signal by at least 10 fold.  Applying this 
improved sample preparation and MALDI-TOF MS to the biological samples, we 
observed a putative alarin peak, which is larger than the predicted molecular weight of 
the alarin peptide. After examination, two possible origins have been proposed: alarin 
3-23 (two AHRSSTFPKWVTKTERGRQPL sequences form a dimer), and alarin 
2-22 (two PAHRSSTFPKWVTKTERGRQ(hydroxyP) sequences form a dimer). 
Current efforts aim to confirm this identification by tandem MS, thus involves 
additional and larger samples, and the use of ESI-Q-TOF MS/MS for sequencing 
purposes. In addition, the alarin peptide from human cell lines will be collected in 
PBS buffer, which only contains salts, instead of Epilife medium. This may simplify 
the sample preparation steps, and lead to an increased MS signal for more confident 
identification.  
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9.7 Figures 
 
 
 
Alarin 1-25 sequence: APAHRSSTFPKWVTKTERGRQPLRS 
Pro-alarin sequence: 
MAPPSVPLVLLLVLLLSLAETPASAPAHRSSTFPKWVTKTERGRQPLRS 
 
 
Figure 9.1 Schematics of GALP gene and its splice variant, ALARIN gene. The 
preproGALP is encoded by exons 2-6, with the mature GALP peptide by exons 2-5. 
The alternative splicing leads to the exclusion of exon 3 and thus a novel precursor 
(Pro-alarin), the proteolytic cleavage of which generates alarin (1-25) peptide. The 
signal peptide is in italic. Figure adapted from [5] with permission from Elsevier © 
2007.  
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Figure 9.2 MS and MS/MS spectra of alarin standards. (A-B) MALDI-TOF MS 
spectra of alarin 1-25, +1 (A) and +2 (B) charge states (MW=2892.5 Da). (C-D) 
MALDI-TOF MS spectra of alarin 1-25 with C-terminal amidation +1 (C) and +2 (D) 
charge states (MW=2891.6 Da).  
 
 
 
 
 
Figure 9.3 ESI-Q-TOF MS/MS spectra of alarin 1-25 (MW=2892.5 Da, +5 charge). 
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Figure 9.4 MALDI-TOF MS spectra of alarin 1-25 (MW=2892.5 Da) before (A) and 
after (B) optimizing sample protocols.  
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Figure 9.5 MALDI-TOF MS spectra of 24 hrs sample prepared by optimized 
protocols. Insert a and b are enlarged images of two peaks, m/z=2483.65 and 4966.19. 
 
 
 
 
